<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.soap.trials.v2.TrialResultsOutput xmlns:ns2="local" hits="10" offset="0" totalResults="6550"><Filters total="48"><Filter label="Trial Technologies" name="trialTechnologies" total="100"><FilterOption id="762" count="4189" label="Small molecule therapeutic"></FilterOption><FilterOption id="585" count="3353" label="Oral formulation"></FilterOption><FilterOption id="761" count="2518" label="Biological therapeutic"></FilterOption><FilterOption id="648" count="2508" label="Intravenous formulation"></FilterOption><FilterOption id="595" count="2398" label="Tablet formulation"></FilterOption><FilterOption id="740" count="2108" label="Infusion"></FilterOption><FilterOption id="746" count="1771" label="Solution"></FilterOption><FilterOption id="586" count="1555" label="Capsule formulation"></FilterOption><FilterOption id="751" count="1531" label="Film coating"></FilterOption><FilterOption id="573" count="1309" label="Immunoglobulin-G"></FilterOption><FilterOption id="647" count="1183" label="Subcutaneous formulation"></FilterOption><FilterOption id="85" count="1135" label="Protein recombinant"></FilterOption><FilterOption id="898" count="1134" label="Formulation powder"></FilterOption><FilterOption id="750" count="924" label="Freeze drying"></FilterOption><FilterOption id="169" count="833" label="Monoclonal antibody humanized"></FilterOption><FilterOption id="1263" count="688" label="Immuno-oncology"></FilterOption><FilterOption id="168" count="625" label="Monoclonal antibody human"></FilterOption><FilterOption id="594" count="491" label="Oral suspension formulation"></FilterOption><FilterOption id="1652" count="491" label="Prodrug"></FilterOption><FilterOption id="1647" count="450" label="Natural product"></FilterOption><FilterOption id="80" count="415" label="Peptide"></FilterOption><FilterOption id="805" count="392" label="Daily dosing"></FilterOption><FilterOption id="593" count="372" label="Oral liquid formulation"></FilterOption><FilterOption id="902" count="367" label="Orally disintegrating tablet"></FilterOption><FilterOption id="175" count="360" label="Drug combination"></FilterOption><FilterOption id="589" count="353" label="Sustained release formulation"></FilterOption><FilterOption id="651" count="281" label="Intramuscular formulation"></FilterOption><FilterOption id="766" count="252" label="Parenteral formulation unspecified"></FilterOption><FilterOption id="745" count="241" label="Suspension"></FilterOption><FilterOption id="180" count="218" label="Antibody fragment"></FilterOption><FilterOption id="743" count="214" label="Granule"></FilterOption><FilterOption id="894" count="205" label="Liquid formulation"></FilterOption><FilterOption id="166" count="201" label="Chimeric monoclonal antibody"></FilterOption><FilterOption id="348" count="170" label="PEGylated formulation"></FilterOption><FilterOption id="66" count="167" label="Antibiotic"></FilterOption><FilterOption id="84" count="165" label="Protein fusion"></FilterOption><FilterOption id="74" count="161" label="Glycoprotein"></FilterOption><FilterOption id="616" count="155" label="Inhalant formulation"></FilterOption><FilterOption id="128" count="137" label="Cell culture technique"></FilterOption><FilterOption id="90" count="133" label="Steroid"></FilterOption><FilterOption id="660" count="129" label="Oral sustained release formulation"></FilterOption><FilterOption id="112" count="126" label="DNA technology"></FilterOption><FilterOption id="596" count="125" label="Injectable formulation"></FilterOption><FilterOption id="667" count="125" label="Peptidomimetic"></FilterOption><FilterOption id="630" count="121" label="Stereochemistry"></FilterOption><FilterOption id="701" count="107" label="Nucleoside synthesis"></FilterOption><FilterOption id="649" count="106" label="Intraperitoneal formulation"></FilterOption><FilterOption id="680" count="104" label="Buccal formulation systemic"></FilterOption><FilterOption id="641" count="103" label="Controlled release formulation"></FilterOption><FilterOption id="852" count="99" label="Intravesical formulation"></FilterOption><FilterOption id="127" count="97" label="Cell culture"></FilterOption><FilterOption id="603" count="93" label="Systemic formulation unspecified"></FilterOption><FilterOption id="171" count="92" label="Monoclonal antibody conjugated"></FilterOption><FilterOption id="618" count="91" label="Powder formulation inhalant"></FilterOption><FilterOption id="723" count="90" label="Drug coating"></FilterOption><FilterOption id="599" count="89" label="Nanoparticle formulation injectable"></FilterOption><FilterOption id="207" count="88" label="Protein conjugated"></FilterOption><FilterOption id="742" count="85" label="Pellet"></FilterOption><FilterOption id="617" count="80" label="Aerosol formulation inhalant"></FilterOption><FilterOption id="620" count="75" label="Ophthalmic formulation"></FilterOption><FilterOption id="558" count="73" label="Transdermal formulation"></FilterOption><FilterOption id="590" count="72" label="Enteric coated formulation"></FilterOption><FilterOption id="611" count="68" label="Dermatological formulation"></FilterOption><FilterOption id="208" count="64" label="Protein conjugation"></FilterOption><FilterOption id="159" count="62" label="Oligosaccharide"></FilterOption><FilterOption id="1646" count="61" label="Injectable controlled release formulation"></FilterOption><FilterOption id="51" count="60" label="Monoclonal antibody"></FilterOption><FilterOption id="167" count="56" label="Monoclonal antibody murine"></FilterOption><FilterOption id="102" count="55" label="Nucleotide and derivatives"></FilterOption><FilterOption id="236" count="53" label="Macrolide"></FilterOption><FilterOption id="1164" count="51" label="Antibody drug conjugate"></FilterOption><FilterOption id="598" count="49" label="Liposome formulation injectable"></FilterOption><FilterOption id="662" count="49" label="Quick release formulation"></FilterOption><FilterOption id="559" count="48" label="Oral controlled release formulation"></FilterOption><FilterOption id="756" count="48" label="Pharmaceutical carrier"></FilterOption><FilterOption id="753" count="47" label="Microparticle formulation"></FilterOption><FilterOption id="661" count="46" label="Oral quick release formulation"></FilterOption><FilterOption id="776" count="41" label="Oral gel formulation"></FilterOption><FilterOption id="615" count="40" label="Aerosol formulation dermatological"></FilterOption><FilterOption id="807" count="38" label="Monthly dosing"></FilterOption><FilterOption id="62" count="38" label="Virus recombinant"></FilterOption><FilterOption id="347" count="37" label="Intratumoral formulation"></FilterOption><FilterOption id="569" count="35" label="Oligonucleotide antisense"></FilterOption><FilterOption id="170" count="34" label="Multivalent monoclonal antibody"></FilterOption><FilterOption id="1" count="33" label="Antibody"></FilterOption><FilterOption id="724" count="32" label="Radiolabeling"></FilterOption><FilterOption id="267" count="31" label="Multivalent antibody"></FilterOption><FilterOption id="103" count="31" label="Oligonucleotide"></FilterOption><FilterOption id="652" count="30" label="Intra-articular formulation"></FilterOption><FilterOption id="342" count="27" label="Receptor fusion"></FilterOption><FilterOption id="962" count="26" label="Biosimilar product"></FilterOption><FilterOption id="537" count="26" label="Chimeric antibody"></FilterOption><FilterOption id="901" count="26" label="Recombinant enzyme"></FilterOption><FilterOption id="806" count="26" label="Weekly dosing"></FilterOption><FilterOption id="654" count="25" label="Intrathecal formulation"></FilterOption><FilterOption id="582" count="24" label="Antibody polyclonal"></FilterOption><FilterOption id="731" count="24" label="Imaging"></FilterOption><FilterOption id="349" count="24" label="Lipid"></FilterOption><FilterOption id="111" count="23" label="Cloning technology"></FilterOption><FilterOption id="1669" count="23" label="Emulsion formulation"></FilterOption></Filter><Filter label="Indications" name="indications" total="100"><FilterOption id="3665" count="320" label="Metastatic non small cell lung cancer"></FilterOption><FilterOption id="3657" count="300" label="Metastatic breast cancer"></FilterOption><FilterOption id="3713" count="220" label="Advanced solid tumor"></FilterOption><FilterOption id="2399" count="201" label="Adenocarcinoma"></FilterOption><FilterOption id="837" count="178" label="Non-insulin dependent diabetes"></FilterOption><FilterOption id="159" count="172" label="HIV-1 infection"></FilterOption><FilterOption id="1069" count="171" label="Metastasis"></FilterOption><FilterOption id="3658" count="156" label="Metastatic colorectal cancer"></FilterOption><FilterOption id="307" count="144" label="Squamous cell carcinoma"></FilterOption><FilterOption id="1828" count="125" label="Multiple myeloma"></FilterOption><FilterOption id="49" count="122" label="Breast tumor"></FilterOption><FilterOption id="291" count="114" label="Rheumatoid arthritis"></FilterOption><FilterOption id="153" count="110" label="Hepatitis C virus infection"></FilterOption><FilterOption id="213" count="107" label="Multiple sclerosis"></FilterOption><FilterOption id="3246" count="104" label="Hormone refractory prostate cancer"></FilterOption><FilterOption id="14" count="101" label="Alzheimers disease"></FilterOption><FilterOption id="1185" count="101" label="Chronic obstructive pulmonary disease"></FilterOption><FilterOption id="3257" count="101" label="Stage IV melanoma"></FilterOption><FilterOption id="158" count="95" label="HIV infection"></FilterOption><FilterOption id="31" count="88" label="Asthma"></FilterOption><FilterOption id="3866" count="88" label="Metastatic ovary cancer"></FilterOption><FilterOption id="3666" count="85" label="Metastatic stomach cancer"></FilterOption><FilterOption id="1771" count="85" label="Transitional cell carcinoma"></FilterOption><FilterOption id="4250" count="84" label="Metastatic renal cell carcinoma"></FilterOption><FilterOption id="319" count="81" label="Non-Hodgkin lymphoma"></FilterOption><FilterOption id="1731" count="80" label="Acute myelogenous leukemia"></FilterOption><FilterOption id="3669" count="76" label="Metastatic pancreas cancer"></FilterOption><FilterOption id="3673" count="75" label="Metastatic head and neck cancer"></FilterOption><FilterOption id="1262" count="74" label="Non-small-cell lung cancer"></FilterOption><FilterOption id="1749" count="73" label="Diffuse large B-cell lymphoma"></FilterOption><FilterOption id="3083" count="72" label="Peritoneal tumor"></FilterOption><FilterOption id="84" count="71" label="Crohns disease"></FilterOption><FilterOption id="2243" count="70" label="Fallopian tube cancer"></FilterOption><FilterOption id="1745" count="70" label="Follicle center lymphoma"></FilterOption><FilterOption id="80" count="69" label="Coronary artery disease"></FilterOption><FilterOption id="1734" count="67" label="Chronic lymphocytic leukemia"></FilterOption><FilterOption id="3667" count="65" label="Metastatic esophageal cancer"></FilterOption><FilterOption id="1767" count="64" label="Hepatocellular carcinoma"></FilterOption><FilterOption id="255" count="60" label="Parkinsons disease"></FilterOption><FilterOption id="17" count="59" label="Anemia"></FilterOption><FilterOption id="55" count="59" label="Cardiac failure"></FilterOption><FilterOption id="1705" count="56" label="Endometrioid carcinoma"></FilterOption><FilterOption id="799" count="54" label="Ovary tumor"></FilterOption><FilterOption id="20" count="54" label="Pain"></FilterOption><FilterOption id="337" count="54" label="Ulcerative colitis"></FilterOption><FilterOption id="281" count="53" label="Psoriasis"></FilterOption><FilterOption id="1261" count="53" label="Small-cell lung cancer"></FilterOption><FilterOption id="2454" count="51" label="Glioblastoma"></FilterOption><FilterOption id="3466" count="51" label="Metastatic bladder cancer"></FilterOption><FilterOption id="224" count="50" label="Myocardial infarction"></FilterOption><FilterOption id="3676" count="49" label="Ischemic stroke"></FilterOption><FilterOption id="3256" count="48" label="Stage III melanoma"></FilterOption><FilterOption id="57" count="47" label="Cardiovascular disease"></FilterOption><FilterOption id="299" count="47" label="Schizophrenia"></FilterOption><FilterOption id="3664" count="46" label="Metastatic prostate cancer"></FilterOption><FilterOption id="1272" count="45" label="Myelodysplastic syndrome"></FilterOption><FilterOption id="1542" count="44" label="Atrial fibrillation"></FilterOption><FilterOption id="318" count="43" label="Systemic lupus erythematosus"></FilterOption><FilterOption id="836" count="39" label="Insulin dependent diabetes"></FilterOption><FilterOption id="552" count="38" label="Bleeding"></FilterOption><FilterOption id="203" count="38" label="Lymphoma"></FilterOption><FilterOption id="245" count="38" label="Osteoarthritis"></FilterOption><FilterOption id="3378" count="38" label="Soft tissue sarcoma"></FilterOption><FilterOption id="1128" count="37" label="Neuroendocrine tumor"></FilterOption><FilterOption id="3510" count="35" label="Pulmonary artery hypertension"></FilterOption><FilterOption id="427" count="35" label="Uterine cervix tumor"></FilterOption><FilterOption id="1728" count="34" label="Acute lymphoblastic leukemia"></FilterOption><FilterOption id="316" count="34" label="B-cell lymphoma"></FilterOption><FilterOption id="2380" count="34" label="Bladder cancer"></FilterOption><FilterOption id="1781" count="34" label="Psoriatic arthritis"></FilterOption><FilterOption id="238" count="32" label="Obesity"></FilterOption><FilterOption id="1765" count="31" label="Cholangiocarcinoma"></FilterOption><FilterOption id="119" count="31" label="Epilepsy"></FilterOption><FilterOption id="1080" count="31" label="Female infertility"></FilterOption><FilterOption id="1744" count="31" label="Mantle cell lymphoma"></FilterOption><FilterOption id="1735" count="30" label="Chronic myelocytic leukemia"></FilterOption><FilterOption id="989" count="30" label="Colorectal tumor"></FilterOption><FilterOption id="88" count="30" label="Cystic fibrosis"></FilterOption><FilterOption id="2989" count="30" label="Kidney transplant rejection"></FilterOption><FilterOption id="325" count="30" label="Thromboembolism"></FilterOption><FilterOption id="3258" count="29" label="Acute coronary syndrome"></FilterOption><FilterOption id="65" count="29" label="Stroke"></FilterOption><FilterOption id="1102" count="28" label="Atopic dermatitis"></FilterOption><FilterOption id="760" count="28" label="Brain tumor"></FilterOption><FilterOption id="1108" count="28" label="Glioma"></FilterOption><FilterOption id="623" count="28" label="Head and neck tumor"></FilterOption><FilterOption id="152" count="28" label="Hepatitis B virus infection"></FilterOption><FilterOption id="725" count="28" label="Solid tumor"></FilterOption><FilterOption id="3251" count="27" label="End stage renal disease"></FilterOption><FilterOption id="121" count="27" label="Factor VIII deficiency"></FilterOption><FilterOption id="178" count="27" label="Hypertension"></FilterOption><FilterOption id="70" count="27" label="Liver cirrhosis"></FilterOption><FilterOption id="793" count="27" label="Mouth tumor"></FilterOption><FilterOption id="3439" count="27" label="Partial seizure"></FilterOption><FilterOption id="4898" count="26" label="Major depressive disorder"></FilterOption><FilterOption id="3198" count="25" label="Larynx tumor"></FilterOption><FilterOption id="360" count="25" label="Pneumonia"></FilterOption><FilterOption id="276" count="25" label="Prostate tumor"></FilterOption><FilterOption id="574" count="24" label="Deep vein thrombosis"></FilterOption><FilterOption id="249" count="24" label="Pancreas tumor"></FilterOption></Filter><Filter label="Endpoint Index" name="trialEndpointIndex" total="100"><FilterOption id="8489" count="298" label="Lung tumor - Assessment of Progression Free Survival (PFS)"></FilterOption><FilterOption id="8481" count="262" label="Lung tumor - Assessment of Overall Survival (OS)"></FilterOption><FilterOption id="8998" count="256" label="Breast tumor - Assessment of adverse events"></FilterOption><FilterOption id="8719" count="245" label="Breast tumor - Assessment of Response Rates (RR) - Assessment of Overall/Objective Response Rate (ORR)"></FilterOption><FilterOption id="8713" count="235" label="Breast tumor - Assessment of Progression Free Survival (PFS)"></FilterOption><FilterOption id="8712" count="232" label="Breast tumor - Assessment of Overall Survival (OS)"></FilterOption><FilterOption id="8663" count="210" label="Lung tumor - Assessment of Pharmacokinetic/Pharmacodynamic Parameters"></FilterOption><FilterOption id="8505" count="201" label="Lung tumor - Assessment of Objective Response - Assessment of objective response rate(ORR)"></FilterOption><FilterOption id="8639" count="201" label="Lung tumor - Assessment of Safety and Tolerability"></FilterOption><FilterOption id="15312" count="198" label="Solid tumor - Assessment of Pharmacokinetic/Pharmacodynamic Parameters"></FilterOption><FilterOption id="15287" count="181" label="Solid tumor - Assessment of adverse events"></FilterOption><FilterOption id="8522" count="165" label="Lung tumor - Assessment of Response Rates (RR) - Assessment of duration of response"></FilterOption><FilterOption id="8738" count="162" label="Breast tumor - Assessment of Response Rates (RR) - Assessment of duration of tumor response"></FilterOption><FilterOption id="9153" count="162" label="Lung tumor - Imaging/Radiological Assessments - Assessment by Response Evaluation Criteria in Solid Tumors (RECIST) Criteria"></FilterOption><FilterOption id="8513" count="153" label="Lung tumor - Assessment of Response Rates (RR) - Assessment of Partial Response (PR)"></FilterOption><FilterOption id="9247" count="152" label="HIV infection - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events"></FilterOption><FilterOption id="8996" count="150" label="Breast tumor - Assessment of Safety and Tolerability"></FilterOption><FilterOption id="8514" count="148" label="Lung tumor - Assessment of Response Rates (RR) - Assessment of Complete Response"></FilterOption><FilterOption id="7547" count="145" label="Lymphoma - Assessment of Progression Free Survival (PFS)"></FilterOption><FilterOption id="9122" count="142" label="Breast tumor - Assessment of Pharmacokinetic/Pharmacodynamic Parameters"></FilterOption><FilterOption id="8640" count="142" label="Lung tumor - Assessment of Safety and Tolerability - Adverse events as graded by CTCAE/CTC"></FilterOption><FilterOption id="15212" count="142" label="Solid tumor - Assessment of Response Rates (RR) - Assessment of objective response rate (ORR)"></FilterOption><FilterOption id="9218" count="135" label="HIV infection - Assessment of Immune Response"></FilterOption><FilterOption id="7680" count="135" label="Lymphoma - Assessment of adverse events"></FilterOption><FilterOption id="15293" count="134" label="Solid tumor - Assessment of Safety and Tolerability - Assessment of dose limiting toxicity"></FilterOption><FilterOption id="7538" count="133" label="Lymphoma - Assessment of Overall Survival (OS)"></FilterOption><FilterOption id="8721" count="132" label="Breast tumor - Assessment of Response Rates (RR) - Assessment of Complete Response"></FilterOption><FilterOption id="8430" count="132" label="Colorectal tumor - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events"></FilterOption><FilterOption id="9215" count="129" label="HIV infection - Assessment of CD4 Cell Responses - Assessment of CD4 cell count/percentage"></FilterOption><FilterOption id="7569" count="127" label="Lymphoma - Assessment of Response Rates (RR) - Assessment of Overall/Objective Response Rate (ORR)"></FilterOption><FilterOption id="7879" count="126" label="Leukemia - Assessment of Overall Survival (OS)"></FilterOption><FilterOption id="8523" count="124" label="Lung tumor - Assessment of Disease Progression"></FilterOption><FilterOption id="8163" count="122" label="Colorectal tumor - Assessment of Progression Free Survival (PFS)"></FilterOption><FilterOption id="9213" count="122" label="HIV infection - Assessment of Viral Load - Assessment of HIV RNA levels"></FilterOption><FilterOption id="8187" count="121" label="Colorectal tumor - Assessment of Response Rates (RR) - Assessment of Objective/Overall Response Rate (ORR)"></FilterOption><FilterOption id="15207" count="121" label="Solid tumor - Assessment of Progression Free Survival (PFS)"></FilterOption><FilterOption id="8078" count="119" label="Leukemia - Assessment of adverse events"></FilterOption><FilterOption id="8720" count="116" label="Breast tumor - Assessment of Response Rates (RR) - Assessment of Partial Response (PR)"></FilterOption><FilterOption id="8722" count="113" label="Breast tumor - Assessment of Response Rates (RR) - Assessment of Clinical Benefit Rate (CBR)"></FilterOption><FilterOption id="7563" count="107" label="Lymphoma - Assessment of Response Rates (RR) - Assessment of Complete Response"></FilterOption><FilterOption id="7611" count="107" label="Lymphoma - Assessment of Response Rates (RR) - Assessment of tumor response rate (Duration of response)"></FilterOption><FilterOption id="1503" count="107" label="Non-insulin dependent diabetes - Anthropometric Assessments - Assessment of body weight"></FilterOption><FilterOption id="6863" count="105" label="Hepatitis C virus infection - Assessment of Viral Load/Viral Kinetics"></FilterOption><FilterOption id="15285" count="99" label="Solid tumor - Assessment of Safety and Tolerability"></FilterOption><FilterOption id="3736" count="97" label="Hepatitis C virus infection - Assessment of Sustained Virologic Response (SVR)"></FilterOption><FilterOption id="8151" count="95" label="Colorectal tumor - Assessment of Overall Survival (OS)"></FilterOption><FilterOption id="8744" count="94" label="Breast tumor - Assessment of Disease Progression"></FilterOption><FilterOption id="7908" count="94" label="Leukemia - Assessment of Response Rates (RR) - Assessment of Complete Response"></FilterOption><FilterOption id="1624" count="94" label="Non-insulin dependent diabetes - Assessment of Safety and Tolerability"></FilterOption><FilterOption id="1359" count="92" label="Non-insulin dependent diabetes - Assessment of Hemoglobin A1c (HbA1c) Levels - Change in HbA1c"></FilterOption><FilterOption id="26033" count="92" label="Pain - Assessment of adverse events"></FilterOption><FilterOption id="15218" count="91" label="Solid tumor - Assessment of Response Rates (RR) - Assessment of duration of tumor response"></FilterOption><FilterOption id="1626" count="90" label="Non-insulin dependent diabetes - Assessment of Adverse Events"></FilterOption><FilterOption id="8451" count="89" label="Colorectal tumor - Assessment of Pharmacokinetic/Pharmacodynamic Parameters"></FilterOption><FilterOption id="22595" count="89" label="End stage renal disease - Assessment of adverse events"></FilterOption><FilterOption id="9155" count="89" label="Lung tumor - Assessment of Safety and Tolerability - Assessment of dose limiting toxicity"></FilterOption><FilterOption id="1345" count="89" label="Non-insulin dependent diabetes - Glycemic Control Analysis - Assessment of fasting blood glucose"></FilterOption><FilterOption id="10830" count="89" label="Ovary tumor - Assessment of Progression Free Survival (PFS)"></FilterOption><FilterOption id="8077" count="86" label="Leukemia - Assessment of Safety and Tolerability"></FilterOption><FilterOption id="8519" count="86" label="Lung tumor - Assessment of Response Rates (RR) - Assessment of Tumor Growth Control Rate (TGCR)"></FilterOption><FilterOption id="8997" count="85" label="Breast tumor - Assessment of Safety and Tolerability - Assessment of serious adverse events"></FilterOption><FilterOption id="8651" count="85" label="Lung tumor - Assessment of Laboratory/Diagnostic Measures"></FilterOption><FilterOption id="6940" count="85" label="Melanoma - Assessment of Response Rates (RR) - Assessment of overall/objective response rate"></FilterOption><FilterOption id="7045" count="85" label="Prostate tumor - Assessment of Overall Survival (OS)"></FilterOption><FilterOption id="37159" count="84" label="Breast tumor - Assessment of Laboratory/Diagnostic Measures"></FilterOption><FilterOption id="8555" count="84" label="Lung tumor - Assessment of Mortality/Death Rates"></FilterOption><FilterOption id="6924" count="83" label="Melanoma - Assessment of Progression Free Survival (PFS)"></FilterOption><FilterOption id="7190" count="83" label="Prostate tumor - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events"></FilterOption><FilterOption id="3900" count="83" label="Rheumatoid arthritis - DAS-28 (Disease Activity Score) Response"></FilterOption><FilterOption id="2622" count="82" label="Coronary artery disease - Assessment of Mortality/Death Rates - Cardiovascular mortality"></FilterOption><FilterOption id="8508" count="82" label="Lung tumor - Assessment of Overall Response"></FilterOption><FilterOption id="8725" count="81" label="Breast tumor - Assessment of Response Rates (RR) - Assessment of Stable Disease"></FilterOption><FilterOption id="8641" count="81" label="Lung tumor - Assessment of Safety and Tolerability - Assessment of frequency and severity of adverse events"></FilterOption><FilterOption id="7027" count="81" label="Melanoma - Assessment of adverse events"></FilterOption><FilterOption id="7367" count="81" label="Multiple myeloma - Assessment of Response Rates (RR) - Assessment of Overall/Objective Response Rate (ORR)"></FilterOption><FilterOption id="8516" count="80" label="Lung tumor - Assessment of Response Rates (RR) - Assessment of Stable Disease"></FilterOption><FilterOption id="7679" count="80" label="Lymphoma - Assessment of Safety and Tolerability"></FilterOption><FilterOption id="7360" count="80" label="Multiple myeloma - Assessment of Progression Free Survival (PFS)"></FilterOption><FilterOption id="7049" count="79" label="Prostate tumor - Assessment of Progression Free Survival (PFS)"></FilterOption><FilterOption id="6919" count="78" label="Melanoma - Assessment of Overall Survival (OS)"></FilterOption><FilterOption id="9008" count="77" label="Breast tumor - Assessment of Safety and Tolerability - Assessment of dose limiting toxicity"></FilterOption><FilterOption id="8189" count="76" label="Colorectal tumor - Assessment of Response Rates (RR) - Assessment of duration of response"></FilterOption><FilterOption id="7564" count="75" label="Lymphoma - Assessment of Response Rates (RR) - Assessment of Partial Response (PR)"></FilterOption><FilterOption id="10828" count="74" label="Ovary tumor - Assessment of Overall Survival (OS)"></FilterOption><FilterOption id="9242" count="73" label="HIV infection - Assessment of lipid profiles"></FilterOption><FilterOption id="7354" count="73" label="Multiple myeloma - Assessment of Overall Survival (OS)"></FilterOption><FilterOption id="7891" count="70" label="Leukemia - Assessment of Progression Free Survival (PFS)"></FilterOption><FilterOption id="7909" count="70" label="Leukemia - Assessment of Response Rates (RR) - Assessment of Overall/Objective Response Rate (ORR)"></FilterOption><FilterOption id="15286" count="70" label="Solid tumor - Assessment of Safety and Tolerability - Assessment of serious adverse events"></FilterOption><FilterOption id="10545" count="69" label="Renal cell carcinoma - Assessment of Progression Free Survival (PFS)"></FilterOption><FilterOption id="4144" count="69" label="Rheumatoid arthritis - Assessment of adverse events"></FilterOption><FilterOption id="11717" count="68" label="Bladder cancer - Assessment of Overall Survival (OS)"></FilterOption><FilterOption id="15214" count="68" label="Solid tumor - Assessment of Response Rates (RR) - Assessment of Partial Response (PR)"></FilterOption><FilterOption id="26827" count="68" label="Solid tumor - Imaging/Radiological Assessments - Assessment by Response Evaluation Criteria in Solid Tumors (RECIST) Criteria"></FilterOption><FilterOption id="8759" count="67" label="Breast tumor - Patient Reported Outcomes/Quality of Life Assessments"></FilterOption><FilterOption id="9246" count="67" label="HIV infection - Assessment of Safety and Tolerability"></FilterOption><FilterOption id="1358" count="67" label="Non-insulin dependent diabetes - Assessment of Hemoglobin A1c (HbA1c) Levels"></FilterOption><FilterOption id="13352" count="67" label="Pancreas tumor - Assessment of Progression Free Survival (PFS)"></FilterOption><FilterOption id="13357" count="67" label="Pancreas tumor - Assessment of Response Rates (RR) - Assessment of objective response rate (ORR)"></FilterOption><FilterOption id="8754" count="66" label="Breast tumor - Assessment of Mortality/Death Rates"></FilterOption></Filter><Filter label="Trial Drug Phase Highest" name="trialDrugPhaseHighest" total="12"><FilterOption id="L" count="4204" label="Launched"></FilterOption><FilterOption id="C3" count="659" label="Phase 3 Clinical"></FilterOption><FilterOption id="C2" count="558" label="Phase 2 Clinical"></FilterOption><FilterOption id="DX" count="501" label="Discontinued"></FilterOption><FilterOption id="PR" count="119" label="Pre-registration"></FilterOption><FilterOption id="C1" count="111" label="Phase 1 Clinical"></FilterOption><FilterOption id="NDR" count="86" label="No Development Reported"></FilterOption><FilterOption id="R" count="70" label="Registered"></FilterOption><FilterOption id="W" count="44" label="Withdrawn"></FilterOption><FilterOption id="DR" count="35" label="Discovery"></FilterOption><FilterOption id="S" count="9" label="Suspended"></FilterOption><FilterOption id="CU" count="4" label="Clinical"></FilterOption></Filter><Filter label="Trial Company Sponsor" name="trialCompaniesSponsor" total="100"><FilterOption id="23137" count="446" label="Novartis AG"></FilterOption><FilterOption id="19446" count="361" label="Roche Holding AG"></FilterOption><FilterOption id="18767" count="289" label="Pfizer Inc"></FilterOption><FilterOption id="28355" count="243" label="GlaxoSmithKline plc"></FilterOption><FilterOption id="17810" count="196" label="Eli Lilly &amp; Co"></FilterOption><FilterOption id="14190" count="185" label="AstraZeneca plc"></FilterOption><FilterOption id="15065" count="180" label="Bristol-Myers Squibb Co"></FilterOption><FilterOption id="1009547" count="176" label="Sanofi SA"></FilterOption><FilterOption id="26178" count="174" label="F Hoffmann-La Roche AG"></FilterOption><FilterOption id="14455" count="157" label="Bayer AG"></FilterOption><FilterOption id="14881" count="134" label="Boehringer Ingelheim International GmbH"></FilterOption><FilterOption id="1144568" count="132" label="Novartis Pharma Services AG"></FilterOption><FilterOption id="1067538" count="123" label="Janssen Research &amp; Development LLC"></FilterOption><FilterOption id="1039423" count="119" label="Hospital Clinic of Barcelona"></FilterOption><FilterOption id="25599" count="116" label="Novartis Pharma AG"></FilterOption><FilterOption id="1091809" count="106" label="Janssen-Cilag International NV (BE)"></FilterOption><FilterOption id="15331" count="105" label="Celgene Corp"></FilterOption><FilterOption id="14109" count="97" label="Amgen Inc"></FilterOption><FilterOption id="16450" count="93" label="Gilead Sciences Inc"></FilterOption><FilterOption id="1072507" count="92" label="AbbVie Inc"></FilterOption><FilterOption id="30062" count="88" label="AstraZeneca AB"></FilterOption><FilterOption id="1003065" count="82" label="Hospital Vall D'Hebron"></FilterOption><FilterOption id="1121088" count="76" label="Novartis Farmaceutica SA"></FilterOption><FilterOption id="15133" count="71" label="Bristol-Myers Squibb International Corp"></FilterOption><FilterOption id="19453" count="70" label="Genentech Inc"></FilterOption><FilterOption id="29218" count="67" label="AbbVie Deutschland GmbH &amp; Co KG"></FilterOption><FilterOption id="1079783" count="65" label="FUNDACIÓ INSTITUT DE RECERCA DE L'HOSPITAL DE LA SANTA CREU I SANT PAU"></FilterOption><FilterOption id="1003983" count="59" label="Bayer HealthCare AG"></FilterOption><FilterOption id="1038736" count="58" label="PETHEMA Foundation"></FilterOption><FilterOption id="1119200" count="54" label="Sanofi-Aventis Research and Development"></FilterOption><FilterOption id="18614" count="53" label="Novo Nordisk A/S"></FilterOption><FilterOption id="1059823" count="49" label="Merck Sharp &amp; Dohme Corp"></FilterOption><FilterOption id="22546" count="48" label="Boehringer Ingelheim GmbH"></FilterOption><FilterOption id="1068202" count="46" label="Parc de Salut Mar"></FilterOption><FilterOption id="1039086" count="44" label="Germans Trias i Pujol Hospital"></FilterOption><FilterOption id="1110770" count="43" label="Novartis Farma SpA"></FilterOption><FilterOption id="1040940" count="42" label="Hospital Universitari de Bellvitge"></FilterOption><FilterOption id="17839" count="41" label="Eli Lilly SA"></FilterOption><FilterOption id="1005244" count="38" label="Biogen Inc"></FilterOption><FilterOption id="15414" count="38" label="Chugai Pharmaceutical Co Ltd"></FilterOption><FilterOption id="22586" count="36" label="Boehringer Ingelheim Corp"></FilterOption><FilterOption id="23119" count="35" label="European Organisation for Research and Treatment of Cancer (EORTC)"></FilterOption><FilterOption id="1087775" count="35" label="Novartis Oncology"></FilterOption><FilterOption id="13601" count="34" label="Abbott Laboratories"></FilterOption><FilterOption id="1013295" count="34" label="Astellas Pharma Inc"></FilterOption><FilterOption id="1081359" count="34" label="Corporacion Parc Tauli"></FilterOption><FilterOption id="23780" count="33" label="Actelion Ltd"></FilterOption><FilterOption id="1050515" count="33" label="ViiV Healthcare Ltd"></FilterOption><FilterOption id="1145220" count="32" label="GlaxoSmithKline Research &amp; Development Ltd"></FilterOption><FilterOption id="1122528" count="32" label="SCS Boehringer Ingelheim Comm.V"></FilterOption><FilterOption id="1095980" count="31" label="NOVARTIS FARMACEUTICA, S.A. DE C.V."></FilterOption><FilterOption id="24652" count="31" label="Shire plc"></FilterOption><FilterOption id="21991" count="31" label="Takeda Oncology"></FilterOption><FilterOption id="17216" count="30" label="Incyte Corp"></FilterOption><FilterOption id="18008" count="30" label="MedImmune LLC"></FilterOption><FilterOption id="1103352" count="28" label="Boehringer Ingelheim Espana Sa"></FilterOption><FilterOption id="22563" count="28" label="Boehringer Ingelheim Ltd"></FilterOption><FilterOption id="1020322" count="28" label="Daiichi Sankyo Inc"></FilterOption><FilterOption id="19620" count="28" label="Eisai Inc"></FilterOption><FilterOption id="27053" count="28" label="Glaxo Group Research Ltd"></FilterOption><FilterOption id="20452" count="27" label="UCB SA"></FilterOption><FilterOption id="1110884" count="26" label="Biogen Idec Research Ltd"></FilterOption><FilterOption id="15121" count="26" label="Bristol-Myers Squibb Belgium SA"></FilterOption><FilterOption id="17259" count="26" label="Ipsen"></FilterOption><FilterOption id="1003570" count="25" label="Janssen R&amp;D (Ireland)"></FilterOption><FilterOption id="1042061" count="25" label="Spanish Breast Cancer Research Group"></FilterOption><FilterOption id="14913" count="24" label="Eisai Ltd"></FilterOption><FilterOption id="18101" count="24" label="Merck KGaA"></FilterOption><FilterOption id="16299" count="24" label="Sanofi Genzyme"></FilterOption><FilterOption id="20348" count="24" label="Teva Pharmaceutical Industries Ltd"></FilterOption><FilterOption id="22554" count="23" label="Boehringer Ingelheim BV"></FilterOption><FilterOption id="19461" count="22" label="Hoffmann-La Roche Inc"></FilterOption><FilterOption id="22598" count="22" label="Unilfarma Lda"></FilterOption><FilterOption id="28611" count="20" label="Actelion Pharmaceuticals Ltd"></FilterOption><FilterOption id="1037956" count="20" label="Astellas Pharma Global Development Inc"></FilterOption><FilterOption id="27847" count="20" label="Boston Scientific Corp"></FilterOption><FilterOption id="27108" count="20" label="Glaxo SA"></FilterOption><FilterOption id="25902" count="19" label="Array BioPharma Inc"></FilterOption><FilterOption id="22555" count="19" label="Boehringer Ingelheim Ellas AE"></FilterOption><FilterOption id="1035512" count="19" label="EMD Serono Inc"></FilterOption><FilterOption id="1045513" count="19" label="Spanish Lung Cancer Group"></FilterOption><FilterOption id="13979" count="18" label="Alexion Pharmaceuticals Inc"></FilterOption><FilterOption id="17332" count="18" label="Johnson &amp; Johnson"></FilterOption><FilterOption id="1042371" count="18" label="Spanish Oncology Genito-Urinary Group"></FilterOption><FilterOption id="22549" count="17" label="Boehringer Ingelheim Austria GmbH"></FilterOption><FilterOption id="1122527" count="17" label="Boehringer Ingelheim Finland Ky"></FilterOption><FilterOption id="24166" count="17" label="GlaxoSmithKline Biologicals"></FilterOption><FilterOption id="1048099" count="17" label="Queen Mary Hospital"></FilterOption><FilterOption id="14112" count="17" label="Wyeth"></FilterOption><FilterOption id="22545" count="16" label="Boehringer Ingelheim AB"></FilterOption><FilterOption id="22590" count="16" label="Boehringer Ingelheim SA"></FilterOption><FilterOption id="1053612" count="16" label="Fundacion Clinic per a la Recerca Biomédica"></FilterOption><FilterOption id="1084801" count="16" label="Medica Scientia Innovation Research"></FilterOption><FilterOption id="1090120" count="16" label="NOVARTIS (SINGAPORE) PTE LTD"></FilterOption><FilterOption id="19214" count="16" label="Regeneron Pharmaceuticals Inc"></FilterOption><FilterOption id="1143375" count="15" label="AbbVie Pte Ltd"></FilterOption><FilterOption id="22556" count="15" label="Boehringer Ingelheim France SARL"></FilterOption><FilterOption id="1056053" count="15" label="Celgene International Sarl"></FilterOption><FilterOption id="1046616" count="14" label="European Organization for Research and Treatment of Cancer"></FilterOption><FilterOption id="1039087" count="14" label="Fundacio Lluita Contra La Sida"></FilterOption></Filter><Filter label="Trial Recruitment Status" name="trialRecruitmentStatus" total="7"><FilterOption id="4" count="3400" label="Completed"></FilterOption><FilterOption id="2" count="1435" label="Recruiting"></FilterOption><FilterOption id="3" count="965" label="No longer recruiting"></FilterOption><FilterOption id="6" count="628" label="Terminated"></FilterOption><FilterOption id="1" count="93" label="Not yet recruiting"></FilterOption><FilterOption id="5" count="26" label="Suspended"></FilterOption><FilterOption id="12" count="3" label="Status not specified"></FilterOption></Filter><Filter label="Trial Commercially Significant" name="trialIsCommerciallySignificant" total="2"><FilterOption id="YES" count="4253" label="Yes"></FilterOption><FilterOption id="NO" count="2297" label="No"></FilterOption></Filter><Filter label="Trial Indications Pioneer" name="trialIndicationsPioneer" total="100"><FilterOption id="3713" count="137" label="Advanced solid tumor"></FilterOption><FilterOption id="3665" count="107" label="Metastatic non small cell lung cancer"></FilterOption><FilterOption id="3657" count="90" label="Metastatic breast cancer"></FilterOption><FilterOption id="2399" count="77" label="Adenocarcinoma"></FilterOption><FilterOption id="3658" count="69" label="Metastatic colorectal cancer"></FilterOption><FilterOption id="1069" count="66" label="Metastasis"></FilterOption><FilterOption id="307" count="58" label="Squamous cell carcinoma"></FilterOption><FilterOption id="3866" count="46" label="Metastatic ovary cancer"></FilterOption><FilterOption id="3669" count="45" label="Metastatic pancreas cancer"></FilterOption><FilterOption id="3666" count="45" label="Metastatic stomach cancer"></FilterOption><FilterOption id="3673" count="40" label="Metastatic head and neck cancer"></FilterOption><FilterOption id="1771" count="38" label="Transitional cell carcinoma"></FilterOption><FilterOption id="3667" count="35" label="Metastatic esophageal cancer"></FilterOption><FilterOption id="3257" count="34" label="Stage IV melanoma"></FilterOption><FilterOption id="1705" count="31" label="Endometrioid carcinoma"></FilterOption><FilterOption id="3466" count="30" label="Metastatic bladder cancer"></FilterOption><FilterOption id="4250" count="29" label="Metastatic renal cell carcinoma"></FilterOption><FilterOption id="319" count="28" label="Non-Hodgkin lymphoma"></FilterOption><FilterOption id="1767" count="27" label="Hepatocellular carcinoma"></FilterOption><FilterOption id="1262" count="27" label="Non-small-cell lung cancer"></FilterOption><FilterOption id="1745" count="25" label="Follicle center lymphoma"></FilterOption><FilterOption id="3246" count="25" label="Hormone refractory prostate cancer"></FilterOption><FilterOption id="1261" count="25" label="Small-cell lung cancer"></FilterOption><FilterOption id="427" count="25" label="Uterine cervix tumor"></FilterOption><FilterOption id="2454" count="24" label="Glioblastoma"></FilterOption><FilterOption id="49" count="23" label="Breast tumor"></FilterOption><FilterOption id="1828" count="23" label="Multiple myeloma"></FilterOption><FilterOption id="57" count="22" label="Cardiovascular disease"></FilterOption><FilterOption id="1731" count="21" label="Acute myelogenous leukemia"></FilterOption><FilterOption id="1749" count="21" label="Diffuse large B-cell lymphoma"></FilterOption><FilterOption id="3664" count="21" label="Metastatic prostate cancer"></FilterOption><FilterOption id="1765" count="19" label="Cholangiocarcinoma"></FilterOption><FilterOption id="793" count="19" label="Mouth tumor"></FilterOption><FilterOption id="2243" count="18" label="Fallopian tube cancer"></FilterOption><FilterOption id="2380" count="17" label="Bladder cancer"></FilterOption><FilterOption id="989" count="17" label="Colorectal tumor"></FilterOption><FilterOption id="159" count="17" label="HIV-1 infection"></FilterOption><FilterOption id="224" count="17" label="Myocardial infarction"></FilterOption><FilterOption id="3198" count="16" label="Larynx tumor"></FilterOption><FilterOption id="203" count="16" label="Lymphoma"></FilterOption><FilterOption id="799" count="16" label="Ovary tumor"></FilterOption><FilterOption id="3083" count="16" label="Peritoneal tumor"></FilterOption><FilterOption id="794" count="16" label="Pharynx tumor"></FilterOption><FilterOption id="3378" count="16" label="Soft tissue sarcoma"></FilterOption><FilterOption id="725" count="16" label="Solid tumor"></FilterOption><FilterOption id="316" count="15" label="B-cell lymphoma"></FilterOption><FilterOption id="1734" count="15" label="Chronic lymphocytic leukemia"></FilterOption><FilterOption id="837" count="15" label="Non-insulin dependent diabetes"></FilterOption><FilterOption id="1272" count="14" label="Myelodysplastic syndrome"></FilterOption><FilterOption id="291" count="14" label="Rheumatoid arthritis"></FilterOption><FilterOption id="760" count="13" label="Brain tumor"></FilterOption><FilterOption id="3676" count="13" label="Ischemic stroke"></FilterOption><FilterOption id="3467" count="13" label="Metastatic renal cancer"></FilterOption><FilterOption id="3256" count="13" label="Stage III melanoma"></FilterOption><FilterOption id="3678" count="13" label="Urethral cancer"></FilterOption><FilterOption id="14" count="12" label="Alzheimers disease"></FilterOption><FilterOption id="1815" count="11" label="Bacterial pneumonia"></FilterOption><FilterOption id="84" count="11" label="Crohns disease"></FilterOption><FilterOption id="1108" count="11" label="Glioma"></FilterOption><FilterOption id="623" count="11" label="Head and neck tumor"></FilterOption><FilterOption id="161" count="11" label="Hodgkins disease"></FilterOption><FilterOption id="1240" count="11" label="Mesothelioma"></FilterOption><FilterOption id="1128" count="11" label="Neuroendocrine tumor"></FilterOption><FilterOption id="3258" count="10" label="Acute coronary syndrome"></FilterOption><FilterOption id="651" count="10" label="Cancer"></FilterOption><FilterOption id="55" count="10" label="Cardiac failure"></FilterOption><FilterOption id="2054" count="10" label="Hematological neoplasm"></FilterOption><FilterOption id="158" count="10" label="HIV infection"></FilterOption><FilterOption id="1744" count="10" label="Mantle cell lymphoma"></FilterOption><FilterOption id="3668" count="10" label="Metastatic lung cancer"></FilterOption><FilterOption id="213" count="10" label="Multiple sclerosis"></FilterOption><FilterOption id="2726" count="10" label="Neuroblastoma"></FilterOption><FilterOption id="65" count="10" label="Stroke"></FilterOption><FilterOption id="1728" count="9" label="Acute lymphoblastic leukemia"></FilterOption><FilterOption id="759" count="9" label="Central nervous system tumor"></FilterOption><FilterOption id="90" count="9" label="Dementia"></FilterOption><FilterOption id="2975" count="9" label="Ewing sarcoma"></FilterOption><FilterOption id="1080" count="9" label="Female infertility"></FilterOption><FilterOption id="2447" count="9" label="Liposarcoma"></FilterOption><FilterOption id="20" count="9" label="Pain"></FilterOption><FilterOption id="337" count="9" label="Ulcerative colitis"></FilterOption><FilterOption id="3251" count="8" label="End stage renal disease"></FilterOption><FilterOption id="131" count="8" label="Gastrointestinal tumor"></FilterOption><FilterOption id="2446" count="8" label="Leiomyosarcoma"></FilterOption><FilterOption id="1746" count="8" label="Marginal zone B-cell lymphoma"></FilterOption><FilterOption id="3235" count="8" label="Merkel cell carcinoma"></FilterOption><FilterOption id="249" count="8" label="Pancreas tumor"></FilterOption><FilterOption id="3351" count="8" label="Papillary thyroid tumor"></FilterOption><FilterOption id="360" count="8" label="Pneumonia"></FilterOption><FilterOption id="286" count="8" label="Renal disease"></FilterOption><FilterOption id="2448" count="8" label="Rhabdomyosarcoma"></FilterOption><FilterOption id="318" count="8" label="Systemic lupus erythematosus"></FilterOption><FilterOption id="2193" count="7" label="Anal tumor"></FilterOption><FilterOption id="1755" count="7" label="Anaplastic large cell lymphoma"></FilterOption><FilterOption id="1516" count="7" label="Biliary cancer"></FilterOption><FilterOption id="100" count="7" label="Diabetic nephropathy"></FilterOption><FilterOption id="3771" count="7" label="Idiopathic pulmonary fibrosis"></FilterOption><FilterOption id="70" count="7" label="Liver cirrhosis"></FilterOption><FilterOption id="3240" count="7" label="Medullary thyroid cancer"></FilterOption><FilterOption id="1507" count="7" label="Pancreatic ductal adenocarcinoma"></FilterOption></Filter><Filter label="Registry Id" name="trialRegistries" total="32"><FilterOption id="1000" count="6504" label="CT.gov"></FilterOption><FilterOption id="1001" count="4760" label="EudraCT"></FilterOption><FilterOption id="1030" count="1015" label="RSRM CTR"></FilterOption><FilterOption id="1006" count="684" label="JapicCTI"></FilterOption><FilterOption id="1023" count="505" label="UKCRN"></FilterOption><FilterOption id="1019" count="388" label="DRKS"></FilterOption><FilterOption id="1004" count="300" label="WHO ICTRP"></FilterOption><FilterOption id="1012" count="277" label="CTRI"></FilterOption><FilterOption id="1035" count="277" label="Singapore HSA CTR"></FilterOption><FilterOption id="1021" count="214" label="NMRR"></FilterOption><FilterOption id="1033" count="158" label="Mexico CTR"></FilterOption><FilterOption id="1039" count="151" label="CDE"></FilterOption><FilterOption id="1009" count="150" label="HKClinicalTrials.com"></FilterOption><FilterOption id="1038" count="101" label="PHRR"></FilterOption><FilterOption id="1002" count="79" label="ISRCTN"></FilterOption><FilterOption id="1011" count="55" label="ANZCTR"></FilterOption><FilterOption id="1020" count="28" label="ReBec"></FilterOption><FilterOption id="1010" count="16" label="CRiS"></FilterOption><FilterOption id="1003" count="15" label="UMIN"></FilterOption><FilterOption id="1008" count="13" label="Hong Kong CCTCTR"></FilterOption><FilterOption id="1015" count="10" label="NTR"></FilterOption><FilterOption id="1040" count="8" label="REec"></FilterOption><FilterOption id="1018" count="8" label="SLCTR"></FilterOption><FilterOption id="1007" count="2" label="ChiCTR"></FilterOption><FilterOption id="1031" count="2" label="Estonia CTR"></FilterOption><FilterOption id="1014" count="2" label="IRCT"></FilterOption><FilterOption id="1005" count="2" label="JMACCT CTR"></FilterOption><FilterOption id="1016" count="2" label="PACTR"></FilterOption><FilterOption id="1013" count="1" label="RPCEC"></FilterOption><FilterOption id="1026" count="1" label="SANCTR"></FilterOption><FilterOption id="1037" count="1" label="TCTR"></FilterOption><FilterOption id="1024" count="1" label="TzCTR"></FilterOption></Filter><Filter label="Trial Reason for Discontinuation" name="trialReasonForDiscontinuation" total="8"><FilterOption id="1" count="160" label="Lack of Efficacy"></FilterOption><FilterOption id="5" count="129" label="Patient Enrollment Issues"></FilterOption><FilterOption id="2" count="115" label="Not Reported"></FilterOption><FilterOption id="4" count="98" label="Other"></FilterOption><FilterOption id="8" count="79" label="Sponsor/Business Decision"></FilterOption><FilterOption id="7" count="45" label="Safety Issues"></FilterOption><FilterOption id="3" count="35" label="Operational Issues"></FilterOption><FilterOption id="6" count="1" label="Planned, not Initiated"></FilterOption></Filter><Filter label="Active Controls" name="trialActiveControls" total="100"><FilterOption id="3803" count="106" label="paclitaxel"></FilterOption><FilterOption id="44383" count="102" label="carboplatin"></FilterOption><FilterOption id="3199" count="91" label="gemcitabine"></FilterOption><FilterOption id="2953" count="84" label="docetaxel"></FilterOption><FilterOption id="12205" count="49" label="capecitabine"></FilterOption><FilterOption id="6736" count="48" label="rituximab"></FilterOption><FilterOption id="3536" count="47" label="pemetrexed disodium"></FilterOption><FilterOption id="8047" count="38" label="bevacizumab"></FilterOption><FilterOption id="6050" count="37" label="metformin hydrochloride"></FilterOption><FilterOption id="3792" count="34" label="oxaliplatin"></FilterOption><FilterOption id="6386" count="34" label="trastuzumab"></FilterOption><FilterOption id="7310" count="28" label="ritonavir"></FilterOption><FilterOption id="13928" count="27" label="enoxaparin sodium"></FilterOption><FilterOption id="49219" count="26" label="tenofovir disoproxil fumarate + emtricitabine (fixed dose), Gilead Sciences"></FilterOption><FilterOption id="6408" count="26" label="vinorelbine"></FilterOption><FilterOption id="44375" count="24" label="warfarin"></FilterOption><FilterOption id="3072" count="23" label="etoposide phosphate"></FilterOption><FilterOption id="10252" count="23" label="insulin glargine"></FilterOption><FilterOption id="29016" count="21" label="paclitaxel (albumin-bound nanoparticle, intravenous), Celgene"></FilterOption><FilterOption id="14163" count="20" label="adalimumab"></FilterOption><FilterOption id="2871" count="20" label="irinotecan"></FilterOption><FilterOption id="3669" count="20" label="mycophenolate mofetil"></FilterOption><FilterOption id="37370" count="19" label="azacitidine"></FilterOption><FilterOption id="7413" count="19" label="darbepoetin alfa"></FilterOption><FilterOption id="11961" count="19" label="erlotinib"></FilterOption><FilterOption id="4510" count="19" label="tacrolimus"></FilterOption><FilterOption id="15954" count="18" label="bortezomib"></FilterOption><FilterOption id="3313" count="18" label="fulvestrant"></FilterOption><FilterOption id="2784" count="18" label="letrozole"></FilterOption><FilterOption id="2836" count="17" label="clopidogrel"></FilterOption><FilterOption id="70667" count="17" label="pembrolizumab"></FilterOption><FilterOption id="44401" count="17" label="vancomycin"></FilterOption><FilterOption id="15254" count="16" label="atazanavir"></FilterOption><FilterOption id="32981" count="16" label="darunavir"></FilterOption><FilterOption id="8165" count="16" label="tiotropium bromide"></FilterOption><FilterOption id="10388" count="15" label="cetuximab"></FilterOption><FilterOption id="23625" count="15" label="peginterferon alfa-2a"></FilterOption><FilterOption id="4529" count="15" label="temozolomide"></FilterOption><FilterOption id="4577" count="15" label="topotecan"></FilterOption><FilterOption id="47000" count="14" label="bendamustine"></FilterOption><FilterOption id="7934" count="14" label="doxorubicin (liposomal, STEALTH), Alza"></FilterOption><FilterOption id="3353" count="14" label="insulin lispro"></FilterOption><FilterOption id="29831" count="14" label="sorafenib"></FilterOption><FilterOption id="3081" count="13" label="exemestane"></FilterOption><FilterOption id="11460" count="13" label="imatinib"></FilterOption><FilterOption id="48181" count="13" label="lamivudine + abacavir, GlaxoSmithKline"></FilterOption><FilterOption id="14681" count="13" label="lopinavir + ritonavir"></FilterOption><FilterOption id="12973" count="13" label="sunitinib"></FilterOption><FilterOption id="14493" count="13" label="tenofovir disoproxil fumarate"></FilterOption><FilterOption id="3321" count="12" label="anastrozole"></FilterOption><FilterOption id="2807" count="12" label="atorvastatin"></FilterOption><FilterOption id="13340" count="12" label="everolimus"></FilterOption><FilterOption id="10309" count="11" label="abiraterone"></FilterOption><FilterOption id="10172" count="11" label="efavirenz"></FilterOption><FilterOption id="27572" count="11" label="lenalidomide"></FilterOption><FilterOption id="3616" count="11" label="meropenem"></FilterOption><FilterOption id="5369" count="11" label="ribavirin"></FilterOption><FilterOption id="5999" count="10" label="ciclosporin, Novartis"></FilterOption><FilterOption id="4567" count="10" label="etanercept"></FilterOption><FilterOption id="54804" count="10" label="nivolumab"></FilterOption><FilterOption id="13239" count="9" label="decitabine"></FilterOption><FilterOption id="13022" count="9" label="epirubicin"></FilterOption><FilterOption id="6156" count="9" label="fludarabine"></FilterOption><FilterOption id="14336" count="9" label="fluticasone propionate + salmeterol (asthma and COPD), GlaxoSmithKline"></FilterOption><FilterOption id="3474" count="9" label="lamivudine"></FilterOption><FilterOption id="33591" count="9" label="lapatinib"></FilterOption><FilterOption id="22395" count="9" label="ranibizumab"></FilterOption><FilterOption id="28773" count="8" label="eribulin mesylate"></FilterOption><FilterOption id="6140" count="8" label="formoterol"></FilterOption><FilterOption id="8832" count="8" label="glimepiride"></FilterOption><FilterOption id="10411" count="8" label="insulin aspart"></FilterOption><FilterOption id="3360" count="8" label="interferon beta-1a, Biogen"></FilterOption><FilterOption id="11519" count="8" label="mitoxantrone"></FilterOption><FilterOption id="53547" count="7" label="aflibercept (intravitreal, wet AMD, macular edema, diabetic retinopathy), Regeneron/Bayer"></FilterOption><FilterOption id="17518" count="7" label="escitalopram"></FilterOption><FilterOption id="3159" count="7" label="fluticasone propionate"></FilterOption><FilterOption id="36630" count="7" label="ipilimumab"></FilterOption><FilterOption id="5148" count="7" label="liraglutide"></FilterOption><FilterOption id="27696" count="7" label="pomalidomide"></FilterOption><FilterOption id="72699" count="6" label="atezolizumab"></FilterOption><FilterOption id="11141" count="6" label="basiliximab"></FilterOption><FilterOption id="5907" count="6" label="duloxetine"></FilterOption><FilterOption id="53981" count="6" label="enzalutamide"></FilterOption><FilterOption id="11367" count="6" label="ezetimibe"></FilterOption><FilterOption id="11036" count="6" label="linezolid"></FilterOption><FilterOption id="53227" count="6" label="obinutuzumab"></FilterOption><FilterOption id="3738" count="6" label="olanzapine"></FilterOption><FilterOption id="54488" count="6" label="raltegravir"></FilterOption><FilterOption id="15130" count="6" label="vinflunine"></FilterOption><FilterOption id="6242" count="5" label="abacavir"></FilterOption><FilterOption id="7781" count="5" label="aripiprazole"></FilterOption><FilterOption id="44384" count="5" label="ceftriaxone"></FilterOption><FilterOption id="59062" count="5" label="dolutegravir"></FilterOption><FilterOption id="44289" count="5" label="enalapril"></FilterOption><FilterOption id="8710" count="5" label="glatiramer acetate"></FilterOption><FilterOption id="6850" count="5" label="infliximab"></FilterOption><FilterOption id="5267" count="5" label="leuprorelin acetate"></FilterOption><FilterOption id="12978" count="5" label="moxifloxacin"></FilterOption><FilterOption id="13460" count="5" label="oseltamivir"></FilterOption><FilterOption id="43738" count="5" label="pazopanib"></FilterOption></Filter><Filter label="Exclusion Criteria Index" name="trialExclusionCriteriaIndex" total="100"><FilterOption id="5125" count="241" label="Lung tumor - Subjects with Evidence of Metastasis - Subjects with central nervous system metastases"></FilterOption><FilterOption id="6258" count="239" label="Breast tumor - Subjects co-morbid with cardiovascular diseases/disorders"></FilterOption><FilterOption id="5132" count="228" label="Lung tumor - Subjects co-morbid with cardiovascular diseases/disorders"></FilterOption><FilterOption id="10704" count="223" label="Solid tumor - Subjects with Co-morbid Conditions"></FilterOption><FilterOption id="20282" count="219" label="Lung tumor - Subjects co-morbid with inflammatory disorders"></FilterOption><FilterOption id="5193" count="218" label="Lung tumor - Subjects with History of/Active Malignancy/Cancer"></FilterOption><FilterOption id="6247" count="216" label="Breast tumor - Subjects by disease severity - Subjects with Brain/Leptomeningeal metastases"></FilterOption><FilterOption id="6294" count="202" label="Breast tumor - Subjects with History of/Active Malignancy/Cancer"></FilterOption><FilterOption id="6859" count="193" label="HIV infection - Pregnant or Breast Feeding Subjects"></FilterOption><FilterOption id="5365" count="177" label="Lung tumor - Protocol Specified Other Exclusion Criteria - Protocol specified exclusion criteria for females"></FilterOption><FilterOption id="4702" count="174" label="Lymphoma - Subjects with Co-morbid Conditions"></FilterOption><FilterOption id="6272" count="173" label="Breast tumor - Subjects co-morbid with inflammatory disorders"></FilterOption><FilterOption id="6393" count="172" label="Breast tumor - Subjects with History of/Scheduled to Receive Therapy"></FilterOption><FilterOption id="6554" count="171" label="Leukemia - Subjects with Co-morbid Conditions"></FilterOption><FilterOption id="5270" count="169" label="Lung tumor - Subjects with History of/Scheduled to Receive Therapy - Subjects with history of/scheduled for chemotherapy"></FilterOption><FilterOption id="6328" count="168" label="Breast tumor - Subjects with History of/Scheduled for Anti-neoplastic Therapy"></FilterOption><FilterOption id="5345" count="166" label="Lung tumor - Subjects with History of/Scheduled to Receive Therapy - Subjects with history of/scheduled to receive an investigational drug"></FilterOption><FilterOption id="5291" count="159" label="Lung tumor - Subjects with History of/Scheduled for Other Treatments"></FilterOption><FilterOption id="10761" count="157" label="Solid tumor - Subjects with Evidence of Metastasis - Subjects with brain/CNS metastasis"></FilterOption><FilterOption id="5282" count="153" label="Lung tumor - Subjects with History of/Scheduled to Receive Therapy - Subjects with history of/scheduled for radiation therapy"></FilterOption><FilterOption id="6377" count="152" label="Breast tumor - Subjects with history of/planned radiotherapy"></FilterOption><FilterOption id="6331" count="146" label="Breast tumor - Subjects with History of/Scheduled to Receive Therapy - Subjects with history of/scheduled for chemotherapy"></FilterOption><FilterOption id="5139" count="141" label="Lung tumor - Subjects co-morbid with Respiratory Diseases/Disorders - Subjects co-morbid with pulmonary diseases/disorders"></FilterOption><FilterOption id="6252" count="136" label="Breast tumor - Subjects with Co-morbid Conditions"></FilterOption><FilterOption id="6845" count="136" label="HIV infection - Subjects with Co-morbid Conditions - Subjects co-morbid with hepatobiliary diseases/disorders"></FilterOption><FilterOption id="5149" count="119" label="Lung tumor - Subjects co-morbid with gastrointestinal diseases/disorders"></FilterOption><FilterOption id="20281" count="119" label="Lung tumor - Subjects with Co-morbid Conditions"></FilterOption><FilterOption id="6756" count="118" label="Lung tumor - Subjects with History of/Scheduled for Other Cancer Therapies"></FilterOption><FilterOption id="5269" count="118" label="Lung tumor - Subjects with History of/Scheduled to Receive Therapy"></FilterOption><FilterOption id="6253" count="117" label="Breast tumor - Subjects with Co-morbid Conditions - Subjects with central nervous system diseases"></FilterOption><FilterOption id="5349" count="117" label="Lung tumor - Subjects with Protocol Specified Compliance Status - Subjects unable/unwilling to comply with protocol requirements"></FilterOption><FilterOption id="4692" count="116" label="Lymphoma - Subjects with History of/Active Malignancy/Cancer"></FilterOption><FilterOption id="6260" count="115" label="Breast tumor - Subjects co-morbid with gastrointestinal diseases/disorders"></FilterOption><FilterOption id="6820" count="115" label="HIV infection - Subjects with Opportunistic/Other Infections"></FilterOption><FilterOption id="5128" count="115" label="Lung tumor - Subjects with Co-morbid Conditions - Subjects with central nervous system diseases/disorders"></FilterOption><FilterOption id="5163" count="114" label="Lung tumor - Subjects with Co-morbid Conditions - Subjects co-morbid with hepatobiliary diseases/disorders"></FilterOption><FilterOption id="20290" count="111" label="Breast tumor - Subjects with History of/Scheduled for Intervention/Surgery - Subjects with history of/scheduled for surgery"></FilterOption><FilterOption id="5826" count="108" label="Colorectal tumor - Subjects with Metastatic Colorectal Cancer - Subjects with brain metastases or leptomeningeal carcinomatosis"></FilterOption><FilterOption id="6302" count="107" label="Breast tumor - Subjects with Hypersensitivity/Contraindications to Drugs/Excipients - Subjects with hypersensitivity/contraindication to any investigational agents"></FilterOption><FilterOption id="6892" count="105" label="HIV infection - Subjects with history of/scheduled to receive therapy for other indication"></FilterOption><FilterOption id="20112" count="105" label="Pain - Subjects with Co-morbid Conditions"></FilterOption><FilterOption id="5285" count="104" label="Lung tumor - Subjects with History of/Scheduled for Intervention/Surgery - Subjects with history of/scheduled for surgery"></FilterOption><FilterOption id="5277" count="103" label="Lung tumor - Subjects with History of/Scheduled to Receive Therapy - Subjects with history of/scheduled for biological therapy"></FilterOption><FilterOption id="5864" count="102" label="Colorectal tumor - Subjects co-morbid with cardiovascular diseases/disorders"></FilterOption><FilterOption id="12316" count="102" label="Solid tumor - Subjects with History of/Active Malignancy/Cancer"></FilterOption><FilterOption id="10739" count="101" label="Solid tumor - Subjects with History of Other Non Anti-cancer Drugs/Agents"></FilterOption><FilterOption id="5841" count="100" label="Colorectal tumor - Subjects with History of/Active Malignancy/Cancer"></FilterOption><FilterOption id="6941" count="100" label="HIV infection - Subjects with Hypersensitivity/Contraindications to Drugs/Excipients - Hypersensitivity/Contraindications to study medications or its excipients"></FilterOption><FilterOption id="6534" count="99" label="Leukemia - Subjects with History of/Active Malignancy/Cancer"></FilterOption><FilterOption id="20114" count="99" label="Pain - Subjects with Co-morbid Conditions - Subjects co-morbid with CNS disorders/diseases"></FilterOption><FilterOption id="20289" count="98" label="Breast tumor - Subjects with History of/Scheduled for Disease Specific Pharmacological Therapy - Subjects with history of biologic therapy"></FilterOption><FilterOption id="17519" count="98" label="End stage renal disease - Subjects co-morbid with cardiovascular diseases/disorders"></FilterOption><FilterOption id="4769" count="97" label="Lymphoma - Subjects with History of/Scheduled to Receive Therapy - Subjects with history of/scheduled for chemotherapy"></FilterOption><FilterOption id="6783" count="96" label="Lung tumor - Subjects with History of/Scheduled to Receive Therapy - Subjects with history of/scheduled for immunotherapy"></FilterOption><FilterOption id="6065" count="94" label="Multiple myeloma - Subjects with Co-morbid Conditions"></FilterOption><FilterOption id="9810" count="94" label="Ovary tumor - Subjects with Co-morbid Conditions"></FilterOption><FilterOption id="4909" count="94" label="Prostate tumor - Subjects with History of/Active Malignancy/Cancer"></FilterOption><FilterOption id="6259" count="93" label="Breast tumor - Subjects co-morbid with Respiratory Diseases/Disorders - Subjects co-morbid with pulmonary diseases/disorders"></FilterOption><FilterOption id="4847" count="93" label="Prostate tumor - Subjects with Advanced/Metastatic Prostate Cancer - Subjects with brain metastasis"></FilterOption><FilterOption id="5347" count="91" label="Lung tumor - Protocol Specified Other Exclusion Criteria - Subjects with abnormal laboratory values"></FilterOption><FilterOption id="6261" count="88" label="Breast tumor - Subjects with Co-morbid Conditions - Subjects co-morbid with hepatobiliary diseases/disorders"></FilterOption><FilterOption id="5962" count="88" label="Colorectal tumor - Subjects with history of/scheduled to receive therapy for other indication"></FilterOption><FilterOption id="4967" count="88" label="Prostate tumor - Subjects with History of/Scheduled to Receive Therapy - Subjects with history of/scheduled for chemotherapy"></FilterOption><FilterOption id="10717" count="87" label="Solid tumor - Subjects with Abnormal Organ Function - Subjects with abnormal/unacceptable cardiac function"></FilterOption><FilterOption id="10736" count="87" label="Solid tumor - Subjects with History of/Scheduled to Receive Therapy - Subjects with history of radiotherapy"></FilterOption><FilterOption id="3058" count="85" label="Chronic obstructive pulmonary disease - Subjects co-morbid with Respiratory Diseases/Disorders"></FilterOption><FilterOption id="6660" count="84" label="Leukemia - Subjects with History of Treatment with Non-chemotherapeutic Drugs"></FilterOption><FilterOption id="5344" count="84" label="Lung tumor - Protocol Specified Other Exclusion Criteria"></FilterOption><FilterOption id="5856" count="82" label="Colorectal tumor - Subjects co-morbid with inflammatory disorders"></FilterOption><FilterOption id="6767" count="82" label="Lymphoma - Lymphoma Subjects with Advanced Disease - Subjects with central nervous system involvement of lymphoma"></FilterOption><FilterOption id="4810" count="82" label="Lymphoma - Subjects with History of Treatment with Non-chemotherapeutic Drugs"></FilterOption><FilterOption id="5879" count="81" label="Colorectal tumor - Subjects with Co-morbid Conditions"></FilterOption><FilterOption id="5744" count="80" label="Head and neck tumor - Subjects with Co-morbid Conditions"></FilterOption><FilterOption id="10738" count="80" label="Solid tumor - Subjects with History of/Scheduled to Receive Therapy - Subjects with history of/scheduled to receive an investigational drug"></FilterOption><FilterOption id="17531" count="79" label="End stage renal disease - Subjects co-morbid with infections"></FilterOption><FilterOption id="9003" count="78" label="Bladder cancer - Subjects with Co-morbid Conditions"></FilterOption><FilterOption id="4864" count="78" label="Prostate tumor - Subjects co-morbid with cardiovascular diseases/disorders"></FilterOption><FilterOption id="6474" count="77" label="Breast tumor - Protocol Specified Other Exclusion Criteria - Protocol specified exclusion criteria for females"></FilterOption><FilterOption id="17557" count="77" label="Breast tumor - Subjects with Abnormal Laboratory Findings"></FilterOption><FilterOption id="837" count="77" label="Non-insulin dependent diabetes - Subjects co-morbid with renal disease/disorder"></FilterOption><FilterOption id="10378" count="77" label="Pancreas tumor - Subjects with Co-morbid Conditions"></FilterOption><FilterOption id="6257" count="76" label="Breast tumor - Subjects co-morbid with endocrine/metabolic diseases/disorders"></FilterOption><FilterOption id="6951" count="76" label="HIV infection - Subjects with AIDS/AIDS Defining Events"></FilterOption><FilterOption id="6361" count="75" label="Breast tumor - Subjects with History of/Scheduled for Anti-neoplastic Therapy - Subjects with history of/scheduled for targeted therapy"></FilterOption><FilterOption id="5848" count="75" label="Colorectal tumor - Subjects co-morbid with gastrointestinal diseases/disorders"></FilterOption><FilterOption id="6757" count="75" label="Lung tumor - Subjects with Protocol Specified Participation Status - Subjects with history of/current participation in other clinical trials"></FilterOption><FilterOption id="4764" count="75" label="Lymphoma - Subjects with History of/Scheduled to Receive Therapy - Subjects with history of stem cell therapy"></FilterOption><FilterOption id="4783" count="75" label="Lymphoma - Subjects with History of/Scheduled to Receive Therapy - Subjects with history of/scheduled to receive an investigational drug"></FilterOption><FilterOption id="9484" count="75" label="Stomach tumor - Subjects with Co-morbid Conditions"></FilterOption><FilterOption id="925" count="74" label="Non-insulin dependent diabetes - Subjects with History of/Active Malignancy/Cancer"></FilterOption><FilterOption id="10732" count="74" label="Solid tumor - Subjects with History of/Scheduled to Receive Therapy - Subjects with history of/scheduled for chemotherapy"></FilterOption><FilterOption id="6843" count="73" label="HIV infection - Subjects with Co-morbid Conditions"></FilterOption><FilterOption id="5949" count="72" label="Colorectal tumor - Subjects with history of/scheduled to receive radiation therapy"></FilterOption><FilterOption id="20115" count="72" label="Pain - Subjects co-morbid with cardiovascular diseases/disorders"></FilterOption><FilterOption id="4918" count="72" label="Prostate tumor - Subjects with Co-morbid Conditions"></FilterOption><FilterOption id="4968" count="72" label="Prostate tumor - Subjects with History of/Scheduled to Receive Therapy - Subjects on prior/concurrent radiotherapy"></FilterOption><FilterOption id="17541" count="71" label="End stage renal disease - Subjects with History of/Scheduled for Disease Specific Pharmacological Therapy"></FilterOption><FilterOption id="6850" count="71" label="HIV infection - Subjects with History of/Active Malignancy/Cancer"></FilterOption><FilterOption id="911" count="71" label="Non-insulin dependent diabetes - Subjects co-morbid with hepatobiliary disorders/diseases"></FilterOption><FilterOption id="20174" count="71" label="Pain - Subjects with History/ Scheduled to Undergo Other Therapy/Procedures - Subjects with history/scheduled to receive other drug therapies"></FilterOption></Filter><Filter label="Trial Date Enrollment End By Month" name="trialDateEnrollmentEndByMonth" total="100"><FilterOption count="48" label="201607"></FilterOption><FilterOption count="46" label="201905"></FilterOption><FilterOption count="42" label="201802"></FilterOption><FilterOption count="40" label="201506"></FilterOption><FilterOption count="40" label="201510"></FilterOption><FilterOption count="40" label="201705"></FilterOption><FilterOption count="39" label="201906"></FilterOption><FilterOption count="38" label="201708"></FilterOption><FilterOption count="37" label="201509"></FilterOption><FilterOption count="37" label="201812"></FilterOption><FilterOption count="37" label="201901"></FilterOption><FilterOption count="37" label="201904"></FilterOption><FilterOption count="36" label="201512"></FilterOption><FilterOption count="36" label="201803"></FilterOption><FilterOption count="35" label="201603"></FilterOption><FilterOption count="35" label="201608"></FilterOption><FilterOption count="35" label="201806"></FilterOption><FilterOption count="34" label="201210"></FilterOption><FilterOption count="34" label="201601"></FilterOption><FilterOption count="34" label="201807"></FilterOption><FilterOption count="34" label="201809"></FilterOption><FilterOption count="33" label="201504"></FilterOption><FilterOption count="33" label="201604"></FilterOption><FilterOption count="33" label="201709"></FilterOption><FilterOption count="33" label="201710"></FilterOption><FilterOption count="33" label="201801"></FilterOption><FilterOption count="32" label="201503"></FilterOption><FilterOption count="32" label="201612"></FilterOption><FilterOption count="32" label="201706"></FilterOption><FilterOption count="32" label="201810"></FilterOption><FilterOption count="32" label="201903"></FilterOption><FilterOption count="31" label="201902"></FilterOption><FilterOption count="30" label="201402"></FilterOption><FilterOption count="30" label="201701"></FilterOption><FilterOption count="29" label="201711"></FilterOption><FilterOption count="28" label="201301"></FilterOption><FilterOption count="28" label="201302"></FilterOption><FilterOption count="28" label="201507"></FilterOption><FilterOption count="28" label="201712"></FilterOption><FilterOption count="28" label="201811"></FilterOption><FilterOption count="27" label="201305"></FilterOption><FilterOption count="27" label="201311"></FilterOption><FilterOption count="27" label="201406"></FilterOption><FilterOption count="27" label="201410"></FilterOption><FilterOption count="27" label="201609"></FilterOption><FilterOption count="27" label="201707"></FilterOption><FilterOption count="27" label="201805"></FilterOption><FilterOption count="26" label="201110"></FilterOption><FilterOption count="26" label="201401"></FilterOption><FilterOption count="26" label="201605"></FilterOption><FilterOption count="26" label="201606"></FilterOption><FilterOption count="26" label="201808"></FilterOption><FilterOption count="25" label="201109"></FilterOption><FilterOption count="25" label="201207"></FilterOption><FilterOption count="25" label="201310"></FilterOption><FilterOption count="25" label="201502"></FilterOption><FilterOption count="25" label="201703"></FilterOption><FilterOption count="24" label="201112"></FilterOption><FilterOption count="24" label="201306"></FilterOption><FilterOption count="24" label="201308"></FilterOption><FilterOption count="24" label="201309"></FilterOption><FilterOption count="24" label="201404"></FilterOption><FilterOption count="24" label="201408"></FilterOption><FilterOption count="24" label="201409"></FilterOption><FilterOption count="24" label="201501"></FilterOption><FilterOption count="23" label="201107"></FilterOption><FilterOption count="22" label="200909"></FilterOption><FilterOption count="22" label="201002"></FilterOption><FilterOption count="22" label="201103"></FilterOption><FilterOption count="22" label="201209"></FilterOption><FilterOption count="22" label="201405"></FilterOption><FilterOption count="22" label="201411"></FilterOption><FilterOption count="22" label="201505"></FilterOption><FilterOption count="22" label="201511"></FilterOption><FilterOption count="22" label="201602"></FilterOption><FilterOption count="22" label="201610"></FilterOption><FilterOption count="22" label="201611"></FilterOption><FilterOption count="21" label="201001"></FilterOption><FilterOption count="21" label="201102"></FilterOption><FilterOption count="21" label="201105"></FilterOption><FilterOption count="21" label="201203"></FilterOption><FilterOption count="21" label="201312"></FilterOption><FilterOption count="21" label="201704"></FilterOption><FilterOption count="20" label="200810"></FilterOption><FilterOption count="20" label="200905"></FilterOption><FilterOption count="20" label="200906"></FilterOption><FilterOption count="20" label="200911"></FilterOption><FilterOption count="20" label="201003"></FilterOption><FilterOption count="20" label="201201"></FilterOption><FilterOption count="20" label="201307"></FilterOption><FilterOption count="20" label="201804"></FilterOption><FilterOption count="19" label="200910"></FilterOption><FilterOption count="19" label="200912"></FilterOption><FilterOption count="19" label="201202"></FilterOption><FilterOption count="19" label="201508"></FilterOption><FilterOption count="19" label="201702"></FilterOption><FilterOption count="18" label="201106"></FilterOption><FilterOption count="18" label="201206"></FilterOption><FilterOption count="18" label="201407"></FilterOption><FilterOption count="18" label="201412"></FilterOption></Filter><Filter label="Funder Type" name="trialFunderType" total="5"><FilterOption id="CMP" count="5540" label="Company"></FilterOption><FilterOption id="ACA" count="1460" label="Academic"></FilterOption><FilterOption id="GOV" count="55" label="Government"></FilterOption><FilterOption id="OTH" count="40" label="Others"></FilterOption><FilterOption id="NGO" count="15" label="Non-Government"></FilterOption></Filter><Filter label="Trial Region" name="trialRegions" total="11"><FilterOption id="NSWE" count="6550" label="Northern, Southern &amp; Western Europe"></FilterOption><FilterOption id="USCA" count="3989" label="US &amp; Canada"></FilterOption><FilterOption id="EEUR" count="3475" label="Eastern Europe"></FilterOption><FilterOption id="EAPO" count="2189" label="East Asia &amp; Pacific Ocean"></FilterOption><FilterOption id="AUNZ" count="2186" label="Australia &amp; New Zealand"></FilterOption><FilterOption id="MENA" count="1924" label="Middle East &amp; North Africa"></FilterOption><FilterOption id="SOAM" count="1804" label="South America"></FilterOption><FilterOption id="CAAC" count="1378" label="Central America &amp; Caribbean"></FilterOption><FilterOption id="CSAF" count="878" label="Central &amp; Southern Africa"></FilterOption><FilterOption id="SOCA" count="581" label="Southern &amp; Central Asia"></FilterOption><FilterOption id="INDO" count="4" label="Indian Ocean"></FilterOption></Filter><Filter label="Patient Segment Index" name="trialPatientSegmentIndex" total="100"><FilterOption id="3634" count="307" label="Lung tumor - Subjects with Advanced Stage Lung Cancer - Subjects with metastatic/stage IV lung cancer"></FilterOption><FilterOption id="3954" count="295" label="Breast tumor - Subjects with Advanced/Metastatic Breast Cancer/Stage IV Breast Cancer"></FilterOption><FilterOption id="3617" count="279" label="Lung tumor - Subjects with Non Small Cell Lung Cancer (NSCLC)"></FilterOption><FilterOption id="7126" count="237" label="HIV infection - Subjects with HIV Infection - Subjects with HIV-1 Infection"></FilterOption><FilterOption id="10295" count="220" label="Lung tumor - Subjects with Advanced Stage Lung Cancer - Subjects with locally advanced/stage III lung cancer"></FilterOption><FilterOption id="7961" count="210" label="Solid tumor - Subjects with Advanced/Metastatic Solid Tumors"></FilterOption><FilterOption id="3623" count="162" label="Lung tumor - Subjects with Advanced Stage Lung Cancer"></FilterOption><FilterOption id="3824" count="160" label="Colorectal tumor - Subjects with TNM stage IV/Metastatic/Advanced Colorectal Cancer"></FilterOption><FilterOption id="7967" count="157" label="Solid tumor - Subjects with Treatment Resistant Disease"></FilterOption><FilterOption id="3952" count="150" label="Breast tumor - Subjects with Locally Advanced Breast Cancer"></FilterOption><FilterOption id="3965" count="148" label="Breast tumor - Subjects with Treatment Resistant Disease"></FilterOption><FilterOption id="3937" count="147" label="Breast tumor - Subjects with HER-2 Negative Breast Cancer"></FilterOption><FilterOption id="3530" count="124" label="Lymphoma - Subjects with Treatment Resistant Disease"></FilterOption><FilterOption id="3647" count="120" label="Lung tumor - Subjects with Treatment Resistant Disease"></FilterOption><FilterOption id="3936" count="119" label="Breast tumor - Subjects with HER-2 Positive Breast Cancer"></FilterOption><FilterOption id="3564" count="117" label="Prostate tumor - Subjects with Advanced/Metastatic Prostate Cancer"></FilterOption><FilterOption id="461" count="114" label="Hepatitis C virus infection - Subjects with Chronic Hepatitis C Infection"></FilterOption><FilterOption id="3525" count="113" label="Lymphoma - Subjects with Relapse/Recurrent Lymphoma"></FilterOption><FilterOption id="145" count="111" label="Non-insulin dependent diabetes - Subjects with Moderate Glycemic Control"></FilterOption><FilterOption id="103" count="108" label="Non-insulin dependent diabetes - Subjects with Poor/Inadequate Glycemic Control"></FilterOption><FilterOption id="12053" count="100" label="Lung tumor - Treatment Naive Subjects"></FilterOption><FilterOption id="3966" count="98" label="Breast tumor - Subjects with Relapsed/Recurrent Breast cancer"></FilterOption><FilterOption id="3931" count="97" label="Breast tumor - Subjects with Hormone Receptor Positive Breast Cancer - Estrogen receptor positive (ER+) breast cancer"></FilterOption><FilterOption id="3667" count="89" label="Melanoma - Subjects with Advanced/Metastatic Cancer"></FilterOption><FilterOption id="3938" count="88" label="Breast tumor - Subjects with Triple Negative Breast Cancer"></FilterOption><FilterOption id="7877" count="85" label="Lung tumor - Subjects with Non Small Cell Lung Cancer (NSCLC) - Subjects with non-squamous cell lung cancer"></FilterOption><FilterOption id="3565" count="83" label="Prostate tumor - Subjects with Stage IV Prostate Cancer"></FilterOption><FilterOption id="3650" count="82" label="Lung tumor - Subjects with Recurrent/Relapsed Lung Cancer"></FilterOption><FilterOption id="3814" count="81" label="Colorectal tumor - Subjects with Colon Cancer"></FilterOption><FilterOption id="502" count="81" label="Rheumatoid arthritis - Active Rheumatoid Arthritis"></FilterOption><FilterOption id="3977" count="79" label="Leukemia - Subjects with Acute Myeloid Leukemia (AML)"></FilterOption><FilterOption id="128" count="78" label="Multiple sclerosis - Subjects with Relapsing Remitting Multiple Sclerosis (RRMS)"></FilterOption><FilterOption id="3813" count="77" label="Colorectal tumor - Subjects with Rectal Cancer"></FilterOption><FilterOption id="8073" count="77" label="Pancreas tumor - Subjects with Advanced/Metastatic Pancreatic Cancer"></FilterOption><FilterOption id="3926" count="76" label="Multiple myeloma - Subjects with Relapsed/Recurrent Multiple Myeloma"></FilterOption><FilterOption id="3583" count="75" label="Prostate tumor - Subjects with Castrate Resistant Prostate Cancer"></FilterOption><FilterOption id="3586" count="75" label="Prostate tumor - Subjects with Treatment Resistant Disease"></FilterOption><FilterOption id="7487" count="74" label="Hepatitis C virus infection - Subjects Infected with HCV Genotype 1"></FilterOption><FilterOption id="3472" count="73" label="Lymphoma - Subjects with B Cell Non Hodgkin's Lymphoma - Subjects with diffuse large B cell lymphoma"></FilterOption><FilterOption id="3680" count="73" label="Melanoma - Subjects with Stage IV Melanoma"></FilterOption><FilterOption id="3945" count="72" label="Breast tumor - Subjects with Stage III Breast Cancer"></FilterOption><FilterOption id="7108" count="72" label="HIV infection - Subjects on Prior/Concurrent Antiretroviral Therapy"></FilterOption><FilterOption id="3923" count="72" label="Multiple myeloma - Subjects with Treatment Resistant Disease"></FilterOption><FilterOption id="8010" count="72" label="Stomach tumor - Subjects with Advanced/Metastatic Gastric Cancer"></FilterOption><FilterOption id="3956" count="71" label="Breast tumor - Subjects with Un-resectable/Non-operable Breast Cancer"></FilterOption><FilterOption id="3473" count="71" label="Lymphoma - Subjects with B Cell Non Hodgkin's Lymphoma - Subjects with follicular lymphoma"></FilterOption><FilterOption id="562" count="69" label="Chronic obstructive pulmonary disease - Subjects with GOLD Stage 3/Severe COPD"></FilterOption><FilterOption id="3502" count="69" label="Lymphoma - Subjects with Specific Grade of Lymphoma - Subjects with Aggressive (high grade) Lymphoma"></FilterOption><FilterOption id="3860" count="68" label="Colorectal tumor - Subjects with Treatment Resistant Disease"></FilterOption><FilterOption id="3778" count="68" label="Head and neck tumor - Subjects with Specific Histological Sub-type of HNC - Subjects with squamous cell carcinoma"></FilterOption><FilterOption id="102" count="68" label="Non-insulin dependent diabetes - Subjects with Good Glycemic Control"></FilterOption><FilterOption id="561" count="67" label="Chronic obstructive pulmonary disease - Subjects with GOLD Stage 2/Moderate COPD"></FilterOption><FilterOption id="7810" count="66" label="Bladder cancer - Subjects with Metastatic Bladder Cancer"></FilterOption><FilterOption id="7415" count="66" label="Renal cell carcinoma - Subjects with Metastatic Renal Cell Carcinoma"></FilterOption><FilterOption id="3774" count="65" label="Head and neck tumor - Subjects with Advanced/Metastatic Head and Neck Cancer"></FilterOption><FilterOption id="7107" count="65" label="HIV infection - Treatment Naive Subjects"></FilterOption><FilterOption id="3489" count="65" label="Lymphoma - Subjects with B Cell Non Hodgkin's Lymphoma"></FilterOption><FilterOption id="12018" count="65" label="Prostate tumor - Subjects with adenocarcinoma of prostate"></FilterOption><FilterOption id="7960" count="65" label="Solid tumor - Subjects with Locally Advanced Solid Tumors"></FilterOption><FilterOption id="3500" count="64" label="Lymphoma - Subjects with Specific Grade of Lymphoma - Subjects with Indolent (slow-growing, low grade) Lymphoma"></FilterOption><FilterOption id="100" count="64" label="Non-insulin dependent diabetes - Subjects on Treatment/Requiring &gt;1 Antidiabetic Agent"></FilterOption><FilterOption id="12845" count="62" label="Breast tumor - Subjects with gene variants - ERBB2_HUMAN_Amplification"></FilterOption><FilterOption id="3736" count="62" label="Chronic obstructive pulmonary disease - Subjects at risk of developing disease - Smokers"></FilterOption><FilterOption id="513" count="62" label="Rheumatoid arthritis - Subjects with Treatment Resistant Disease"></FilterOption><FilterOption id="161" count="60" label="Alzheimers disease - Subjects with Mild Alzheimer's Disease"></FilterOption><FilterOption id="108" count="60" label="Non-insulin dependent diabetes - Subjects with comorbid conditions - Subjects with obesity"></FilterOption><FilterOption id="7486" count="59" label="Lung tumor - Subjects with Non Small Cell Lung Cancer (NSCLC) - Subjects with squamous cell lung cancer"></FilterOption><FilterOption id="7879" count="59" label="Ovary tumor - Subjects with Ovarian Epithelial Tumor"></FilterOption><FilterOption id="3950" count="58" label="Breast tumor - Subjects with Early Stage Breast Cancer"></FilterOption><FilterOption id="4003" count="58" label="Leukemia - Subjects with Relapsed/Recurrent Leukemia"></FilterOption><FilterOption id="10129" count="56" label="Lung tumor - Subjects with EGFR Positive Lung Cancer"></FilterOption><FilterOption id="11954" count="55" label="Bladder cancer - Subjects with Urothelial cell/Transitional Cell Bladder Cancer"></FilterOption><FilterOption id="3980" count="55" label="Leukemia - Subjects with Chronic Lymphocytic Leukemia (CLL)"></FilterOption><FilterOption id="3999" count="55" label="Leukemia - Subjects with Treatment Resistant Disease"></FilterOption><FilterOption id="11631" count="55" label="Stroke - Subjects with Ischemic Stroke"></FilterOption><FilterOption id="3637" count="53" label="Lung tumor - Subjects with Unresectable/In-operable Lung Cancer"></FilterOption><FilterOption id="3932" count="52" label="Breast tumor - Subjects with Hormone Receptor Positive Breast Cancer - Progesterone receptor positive (PR+) breast cancer"></FilterOption><FilterOption id="7700" count="52" label="End stage renal disease - Subjects with Non-Dialysis Dependant Chronic Kidney Disease(NDD-CKD) - Subjects with stage 3 chronic kidney disease"></FilterOption><FilterOption id="3681" count="52" label="Melanoma - Subjects with Evidence of Metastasis"></FilterOption><FilterOption id="3944" count="51" label="Breast tumor - Subjects with Stage II Breast Cancer"></FilterOption><FilterOption id="3698" count="51" label="Melanoma - Subjects with Surgically Non-resectable Melanoma"></FilterOption><FilterOption id="7414" count="51" label="Renal cell carcinoma - Advanced Stage Renal Cell Carcinoma"></FilterOption><FilterOption id="3434" count="50" label="Psoriasis - Subjects with Plaque Psoriasis/Psoriasis Vulgaris"></FilterOption><FilterOption id="7895" count="49" label="Ovary tumor - Platinum-Resistant/Refractory Ovarian Cancer Subjects"></FilterOption><FilterOption id="489" count="48" label="Hepatitis C virus infection - Treatment Naive Subjects"></FilterOption><FilterOption id="3975" count="48" label="Leukemia - Subjects with Acute Leukemia Unspecified Type"></FilterOption><FilterOption id="8387" count="48" label="Pain - Subjects with Chronic Pain"></FilterOption><FilterOption id="8414" count="48" label="Pain - Subjects with Somatic Pain - Subjects with arthritic pain"></FilterOption><FilterOption id="7402" count="48" label="Renal cell carcinoma - Subjects with Clear Cell Renal Cell Carcinoma"></FilterOption><FilterOption id="7111" count="47" label="HIV infection - Subjects on Prior/Concurrent Antiretroviral Therapy - Subjects on prior/concurrent protease inhibitors"></FilterOption><FilterOption id="499" count="47" label="Rheumatoid arthritis - Moderate Rheumatoid Arthritis"></FilterOption><FilterOption id="3501" count="46" label="Lymphoma - Subjects with Specific Grade of Lymphoma - Subjects with Moderately Aggressive (intermediate grade) Lymphoma"></FilterOption><FilterOption id="7918" count="46" label="Ovary tumor - Advanced Ovarian Cancer Subjects - Stage IV or metastatic ovarian cancer subjects"></FilterOption><FilterOption id="7966" count="46" label="Solid tumor - Subjects with Relapsed/Recurrent Solid Tumors"></FilterOption><FilterOption id="7411" count="45" label="Renal cell carcinoma - Subjects with TNM Stage IV Renal Cell Carcinoma"></FilterOption><FilterOption id="500" count="45" label="Rheumatoid arthritis - Severe Rheumatoid Arthritis"></FilterOption><FilterOption id="8953" count="45" label="Soft tissue sarcoma - Subjects with Advanced/Metastatic Soft Tissue Sarcoma"></FilterOption><FilterOption id="8025" count="45" label="Stomach tumor - Subjects with adenocarcinoma of the gastroesophageal junction"></FilterOption><FilterOption id="162" count="44" label="Alzheimers disease - Subjects with Moderate Alzheimer's Disease"></FilterOption><FilterOption id="3452" count="44" label="Psoriasis - Subjects with Severe Psoriasis"></FilterOption></Filter><Filter label="Primary Completion Filter by Month" name="trialPrimaryCompletionDateByMonth" total="100"><FilterOption count="121" label="201912"></FilterOption><FilterOption count="81" label="201906"></FilterOption><FilterOption count="73" label="202012"></FilterOption><FilterOption count="68" label="202003"></FilterOption><FilterOption count="67" label="202006"></FilterOption><FilterOption count="66" label="201909"></FilterOption><FilterOption count="62" label="201812"></FilterOption><FilterOption count="59" label="201907"></FilterOption><FilterOption count="57" label="201707"></FilterOption><FilterOption count="57" label="201905"></FilterOption><FilterOption count="57" label="201910"></FilterOption><FilterOption count="54" label="201712"></FilterOption><FilterOption count="53" label="201803"></FilterOption><FilterOption count="52" label="201512"></FilterOption><FilterOption count="50" label="201911"></FilterOption><FilterOption count="49" label="201612"></FilterOption><FilterOption count="49" label="201810"></FilterOption><FilterOption count="48" label="201809"></FilterOption><FilterOption count="48" label="202011"></FilterOption><FilterOption count="46" label="201606"></FilterOption><FilterOption count="46" label="201705"></FilterOption><FilterOption count="46" label="201706"></FilterOption><FilterOption count="45" label="201901"></FilterOption><FilterOption count="44" label="201507"></FilterOption><FilterOption count="44" label="201808"></FilterOption><FilterOption count="43" label="201806"></FilterOption><FilterOption count="43" label="201908"></FilterOption><FilterOption count="42" label="201404"></FilterOption><FilterOption count="42" label="201609"></FilterOption><FilterOption count="42" label="201701"></FilterOption><FilterOption count="42" label="201805"></FilterOption><FilterOption count="42" label="202001"></FilterOption><FilterOption count="41" label="201407"></FilterOption><FilterOption count="41" label="201511"></FilterOption><FilterOption count="41" label="201605"></FilterOption><FilterOption count="41" label="201607"></FilterOption><FilterOption count="41" label="201704"></FilterOption><FilterOption count="41" label="201801"></FilterOption><FilterOption count="41" label="201807"></FilterOption><FilterOption count="41" label="202005"></FilterOption><FilterOption count="41" label="202007"></FilterOption><FilterOption count="41" label="202009"></FilterOption><FilterOption count="40" label="201604"></FilterOption><FilterOption count="40" label="201710"></FilterOption><FilterOption count="40" label="201904"></FilterOption><FilterOption count="40" label="202112"></FilterOption><FilterOption count="39" label="201310"></FilterOption><FilterOption count="39" label="201503"></FilterOption><FilterOption count="39" label="201602"></FilterOption><FilterOption count="39" label="201811"></FilterOption><FilterOption count="39" label="201903"></FilterOption><FilterOption count="39" label="202106"></FilterOption><FilterOption count="38" label="201505"></FilterOption><FilterOption count="38" label="201603"></FilterOption><FilterOption count="38" label="201611"></FilterOption><FilterOption count="38" label="201703"></FilterOption><FilterOption count="38" label="202002"></FilterOption><FilterOption count="38" label="202004"></FilterOption><FilterOption count="37" label="202010"></FilterOption><FilterOption count="37" label="202104"></FilterOption><FilterOption count="36" label="201402"></FilterOption><FilterOption count="36" label="201410"></FilterOption><FilterOption count="36" label="201709"></FilterOption><FilterOption count="36" label="202103"></FilterOption><FilterOption count="35" label="201406"></FilterOption><FilterOption count="35" label="201506"></FilterOption><FilterOption count="35" label="201804"></FilterOption><FilterOption count="34" label="201206"></FilterOption><FilterOption count="34" label="202109"></FilterOption><FilterOption count="33" label="201409"></FilterOption><FilterOption count="33" label="201502"></FilterOption><FilterOption count="33" label="201510"></FilterOption><FilterOption count="32" label="201112"></FilterOption><FilterOption count="32" label="201305"></FilterOption><FilterOption count="32" label="201312"></FilterOption><FilterOption count="32" label="201403"></FilterOption><FilterOption count="32" label="201504"></FilterOption><FilterOption count="32" label="201708"></FilterOption><FilterOption count="31" label="200912"></FilterOption><FilterOption count="31" label="201304"></FilterOption><FilterOption count="31" label="201702"></FilterOption><FilterOption count="30" label="201303"></FilterOption><FilterOption count="30" label="201711"></FilterOption><FilterOption count="30" label="202101"></FilterOption><FilterOption count="29" label="201301"></FilterOption><FilterOption count="29" label="201411"></FilterOption><FilterOption count="29" label="201610"></FilterOption><FilterOption count="29" label="201802"></FilterOption><FilterOption count="29" label="202008"></FilterOption><FilterOption count="28" label="201309"></FilterOption><FilterOption count="28" label="201501"></FilterOption><FilterOption count="28" label="201601"></FilterOption><FilterOption count="27" label="201006"></FilterOption><FilterOption count="27" label="201106"></FilterOption><FilterOption count="27" label="201204"></FilterOption><FilterOption count="27" label="201205"></FilterOption><FilterOption count="27" label="201311"></FilterOption><FilterOption count="27" label="201902"></FilterOption><FilterOption count="26" label="200810"></FilterOption><FilterOption count="26" label="200906"></FilterOption></Filter><Filter label="Trial Country" name="trialCountries" total="100"><FilterOption id="ES" count="6550" label="Spain"></FilterOption><FilterOption id="DE" count="3783" label="Germany"></FilterOption><FilterOption id="US" count="3708" label="US"></FilterOption><FilterOption id="FR" count="3586" label="France"></FilterOption><FilterOption id="IT" count="3465" label="Italy"></FilterOption><FilterOption id="GB" count="3324" label="UK"></FilterOption><FilterOption id="CA" count="2739" label="Canada"></FilterOption><FilterOption id="BE" count="2677" label="Belgium"></FilterOption><FilterOption id="PL" count="2414" label="Poland"></FilterOption><FilterOption id="AU" count="2144" label="Australia"></FilterOption><FilterOption id="NL" count="2140" label="Netherlands"></FilterOption><FilterOption id="RU" count="1770" label="Russian Federation"></FilterOption><FilterOption id="HU" count="1757" label="Hungary"></FilterOption><FilterOption id="CZ" count="1710" label="Czech Republic"></FilterOption><FilterOption id="AT" count="1613" label="Austria"></FilterOption><FilterOption id="SE" count="1483" label="Sweden"></FilterOption><FilterOption id="KR" count="1448" label="South Korea"></FilterOption><FilterOption id="IL" count="1424" label="Israel"></FilterOption><FilterOption id="DK" count="1297" label="Denmark"></FilterOption><FilterOption id="BR" count="1259" label="Brazil"></FilterOption><FilterOption id="AR" count="1185" label="Argentina"></FilterOption><FilterOption id="CH" count="1185" label="Switzerland"></FilterOption><FilterOption id="MX" count="1126" label="Mexico"></FilterOption><FilterOption id="TW" count="1088" label="Taiwan"></FilterOption><FilterOption id="GR" count="1051" label="Greece"></FilterOption><FilterOption id="PT" count="1030" label="Portugal"></FilterOption><FilterOption id="RO" count="996" label="Romania"></FilterOption><FilterOption id="JP" count="956" label="Japan"></FilterOption><FilterOption id="TR" count="920" label="Turkey"></FilterOption><FilterOption id="ZA" count="873" label="South Africa"></FilterOption><FilterOption id="FI" count="843" label="Finland"></FilterOption><FilterOption id="BG" count="821" label="Bulgaria"></FilterOption><FilterOption id="SK" count="765" label="Slovakia"></FilterOption><FilterOption id="UA" count="735" label="Ukraine"></FilterOption><FilterOption id="NO" count="700" label="Norway"></FilterOption><FilterOption id="IE" count="654" label="Ireland"></FilterOption><FilterOption id="CL" count="582" label="Chile"></FilterOption><FilterOption id="NZ" count="582" label="New Zealand"></FilterOption><FilterOption id="SG" count="562" label="Singapore"></FilterOption><FilterOption id="IN" count="560" label="India"></FilterOption><FilterOption id="CN" count="557" label="China"></FilterOption><FilterOption id="HK" count="539" label="Hong Kong"></FilterOption><FilterOption id="CO" count="450" label="Colombia"></FilterOption><FilterOption id="TH" count="450" label="Thailand"></FilterOption><FilterOption id="RS" count="441" label="Serbia"></FilterOption><FilterOption id="PR" count="429" label="Puerto Rico"></FilterOption><FilterOption id="LT" count="411" label="Lithuania"></FilterOption><FilterOption id="HR" count="386" label="Croatia"></FilterOption><FilterOption id="EE" count="384" label="Estonia"></FilterOption><FilterOption id="PE" count="382" label="Peru"></FilterOption><FilterOption id="LV" count="368" label="Latvia"></FilterOption><FilterOption id="MY" count="346" label="Malaysia"></FilterOption><FilterOption id="PH" count="279" label="Philippines"></FilterOption><FilterOption id="X5" count="243" label="Europe"></FilterOption><FilterOption id="SI" count="205" label="Slovenia"></FilterOption><FilterOption id="EG" count="128" label="Egypt"></FilterOption><FilterOption id="BY" count="108" label="Belarus"></FilterOption><FilterOption id="GE" count="107" label="Georgia"></FilterOption><FilterOption id="GT" count="104" label="Guatemala"></FilterOption><FilterOption id="LB" count="102" label="Lebanon"></FilterOption><FilterOption id="SA" count="96" label="Saudi Arabia"></FilterOption><FilterOption id="BA" count="95" label="Bosnia and Herzegovina"></FilterOption><FilterOption id="XD" count="90" label="North America"></FilterOption><FilterOption id="VN" count="83" label="Vietnam"></FilterOption><FilterOption id="PA" count="82" label="Panama"></FilterOption><FilterOption id="X2" count="76" label="Asia"></FilterOption><FilterOption id="CR" count="54" label="Costa Rica"></FilterOption><FilterOption id="KP" count="54" label="North Korea"></FilterOption><FilterOption id="IS" count="53" label="Iceland"></FilterOption><FilterOption id="LU" count="48" label="Luxembourg"></FilterOption><FilterOption id="TN" count="48" label="Tunisia"></FilterOption><FilterOption id="EU" count="45" label="EU"></FilterOption><FilterOption id="VE" count="43" label="Venezuela"></FilterOption><FilterOption id="MK" count="42" label="Macedonia, The Former Yugoslav Republic of"></FilterOption><FilterOption id="XE" count="39" label="South America"></FilterOption><FilterOption id="MD" count="35" label="Moldova, Republic of"></FilterOption><FilterOption id="ID" count="34" label="Indonesia"></FilterOption><FilterOption id="EC" count="33" label="Ecuador"></FilterOption><FilterOption id="AE" count="33" label="United Arab Emirates"></FilterOption><FilterOption id="JO" count="31" label="Jordan"></FilterOption><FilterOption id="PK" count="31" label="Pakistan"></FilterOption><FilterOption id="DO" count="29" label="Dominican Republic"></FilterOption><FilterOption id="MA" count="29" label="Morocco"></FilterOption><FilterOption id="DZ" count="22" label="Algeria"></FilterOption><FilterOption id="CY" count="19" label="Cyprus"></FilterOption><FilterOption id="UY" count="17" label="Uruguay"></FilterOption><FilterOption id="KW" count="16" label="Kuwait"></FilterOption><FilterOption id="SV" count="15" label="El Salvador"></FilterOption><FilterOption id="ME" count="13" label="Montenegro"></FilterOption><FilterOption id="XW" count="13" label="Western Europe"></FilterOption><FilterOption id="KZ" count="11" label="Kazakhstan"></FilterOption><FilterOption id="MT" count="11" label="Malta"></FilterOption><FilterOption id="LK" count="11" label="Sri Lanka"></FilterOption><FilterOption id="AL" count="9" label="Albania"></FilterOption><FilterOption id="AS" count="9" label="American Samoa"></FilterOption><FilterOption id="X0" count="8" label="Africa"></FilterOption><FilterOption id="BS" count="8" label="Bahamas"></FilterOption><FilterOption id="MC" count="8" label="Monaco"></FilterOption><FilterOption id="BD" count="7" label="Bangladesh"></FilterOption><FilterOption id="QA" count="7" label="Qatar"></FilterOption></Filter><Filter label="Trial Patient Selection" name="trialTermsPatientSelection" total="18"><FilterOption id="EAMAA" count="5934" label="Middle-aged Adults (45-64 yrs)"></FilterOption><FilterOption id="EAYAD" count="5835" label="Young Adults (18-44 yrs)"></FilterOption><FilterOption id="EAAAD" count="5692" label="Aged Adults (65-79 yrs)"></FilterOption><FilterOption id="EAELD" count="4890" label="Elderly Adults (80 and over)"></FilterOption><FilterOption id="EAADL" count="618" label="Adolescents (13-17 yrs)"></FilterOption><FilterOption id="EACHI" count="562" label="Children (6-12 yrs)"></FilterOption><FilterOption id="EGFEM" count="507" label="Female"></FilterOption><FilterOption id="EAPRE" count="326" label="Preschool Children (2-5 yrs)"></FilterOption><FilterOption id="EGMAL" count="238" label="Male"></FilterOption><FilterOption id="EVHVA" count="222" label="Healthy volunteers accepted"></FilterOption><FilterOption id="EAINF" count="207" label="Infants (6-23 months)"></FilterOption><FilterOption id="EANEW" count="145" label="Newborn Infants (up to 5 months)"></FilterOption><FilterOption id="ECASI" count="60" label="Asian Ancestry"></FilterOption><FilterOption id="ECJAP" count="58" label="Japanese Ancestry"></FilterOption><FilterOption id="ECEUR" count="40" label="European Ancestry"></FilterOption><FilterOption id="EVHVO" count="18" label="Healthy volunteers only"></FilterOption><FilterOption id="ECAFR" count="11" label="African Ancestry"></FilterOption><FilterOption id="ECOCE" count="1" label="Oceanic Ancestry"></FilterOption></Filter><Filter label="Trial Terms Design" name="trialTermsDesign" total="27"><FilterOption id="SSTINV" count="6053" label="Interventional"></FilterOption><FilterOption id="SIPTRE" count="5654" label="Treatment"></FilterOption><FilterOption id="SISPRL" count="4429" label="Parallel Assignment"></FilterOption><FilterOption id="SIARND" count="4404" label="Randomized"></FilterOption><FilterOption id="SIMOPN" count="3149" label="Open Label"></FilterOption><FilterOption id="SIMMBD" count="2669" label="Multiple Blind"></FilterOption><FilterOption id="SICPLC" count="2342" label="Placebo Control"></FilterOption><FilterOption id="SICACT" count="1487" label="Active Control"></FilterOption><FilterOption id="SISSNG" count="1309" label="Single Group Assignment"></FilterOption><FilterOption id="SIANON" count="1247" label="Non-Randomized"></FilterOption><FilterOption id="SICNOC" count="902" label="No Control"></FilterOption><FilterOption id="SSTOBS" count="493" label="Observational"></FilterOption><FilterOption id="SOTPRO" count="383" label="Prospective"></FilterOption><FilterOption id="SIPPRE" count="351" label="Prevention"></FilterOption><FilterOption id="SOSCOH" count="312" label="Cohort"></FilterOption><FilterOption id="SIMSBD" count="194" label="Single Blind"></FilterOption><FilterOption id="SISXOV" count="132" label="Crossover Assignment"></FilterOption><FilterOption id="SOTRET" count="83" label="Retrospective"></FilterOption><FilterOption id="SOSCSC" count="43" label="Case Control"></FilterOption><FilterOption id="SODXSC" count="41" label="Cross-sectional"></FilterOption><FilterOption id="SIPDIA" count="39" label="Diagnosis"></FilterOption><FilterOption id="SICDSC" count="27" label="Dose Comparison"></FilterOption><FilterOption id="SODLNG" count="21" label="Longitudinal"></FilterOption><FilterOption id="SICHST" count="17" label="Historical Control"></FilterOption><FilterOption id="SISFCT" count="12" label="Factorial Assignment"></FilterOption><FilterOption id="SISEAA" count="5" label="Expanded Access Assignment"></FilterOption><FilterOption id="SOSDEF" count="1" label="Defined Population"></FilterOption></Filter><Filter label="Trial Source" name="trialSources" total="3"><FilterOption id="CTGOVOTHERS" count="4095" label="ClinicalTrials.gov and others"></FilterOption><FilterOption id="CTGOV" count="2371" label="ClinicalTrials.gov only"></FilterOption><FilterOption id="OTHERS" count="54" label="Others only"></FilterOption></Filter><Filter label="Trial Actions Secondary Interventions Primary" name="trialActionsSecondaryInterventionsPrimary" total="100"><FilterOption id="1545" count="2288" label="Anticancer"></FilterOption><FilterOption id="2953" count="1487" label="Anti-inflammatory"></FilterOption><FilterOption id="55685" count="1135" label="Anticancer monoclonal antibody"></FilterOption><FilterOption id="62255" count="1124" label="Anticancer protein kinase inhibitor"></FilterOption><FilterOption id="991" count="812" label="Antiviral"></FilterOption><FilterOption id="1589" count="704" label="Apoptosis stimulator"></FilterOption><FilterOption id="767" count="637" label="Cell cycle inhibitor"></FilterOption><FilterOption id="61" count="600" label="Angiogenesis inhibitor"></FilterOption><FilterOption id="7293" count="539" label="Synergist"></FilterOption><FilterOption id="393" count="496" label="Immunostimulant"></FilterOption><FilterOption id="7761" count="467" label="T-lymphocyte stimulator"></FilterOption><FilterOption id="140" count="348" label="DNA synthesis inhibitor"></FilterOption><FilterOption id="50" count="323" label="Anticancer alkylating agent"></FilterOption><FilterOption id="1596" count="294" label="Immunomodulator"></FilterOption><FilterOption id="1569" count="293" label="Anticancer antimetabolite"></FilterOption><FilterOption id="399" count="276" label="Hypoglycemic agent"></FilterOption><FilterOption id="2946" count="260" label="Analgesic"></FilterOption><FilterOption id="396" count="245" label="Immunosuppressant"></FilterOption><FilterOption id="15184" count="236" label="Systemic antipsoriatic product"></FilterOption><FilterOption id="1615" count="233" label="Neuroprotectant"></FilterOption><FilterOption id="2657" count="225" label="Antihypertensive"></FilterOption><FilterOption id="2575" count="223" label="Microtubule inhibitor"></FilterOption><FilterOption id="2576" count="211" label="Microtubule stabilizer"></FilterOption><FilterOption id="2660" count="191" label="Vasoprotectant"></FilterOption><FilterOption id="70" count="163" label="Anticonvulsant agent"></FilterOption><FilterOption id="1594" count="149" label="Antibacterial"></FilterOption><FilterOption id="2947" count="125" label="Antiparkinsonian"></FilterOption><FilterOption id="646" count="120" label="Bronchodilator"></FilterOption><FilterOption id="2941" count="112" label="Antidepressant"></FilterOption><FilterOption id="284" count="111" label="Nootropic agent"></FilterOption><FilterOption id="2943" count="107" label="Antipsychotic"></FilterOption><FilterOption id="2659" count="104" label="Cardioprotectant"></FilterOption><FilterOption id="695" count="101" label="Metastasis inhibitor"></FilterOption><FilterOption id="2667" count="99" label="Antiarteriosclerotic"></FilterOption><FilterOption id="659" count="98" label="Coagulation inhibitor"></FilterOption><FilterOption id="449" count="94" label="Antiarrhythmic agent"></FilterOption><FilterOption id="610" count="86" label="Hematopoietic stimulator"></FilterOption><FilterOption id="747" count="86" label="HIV replication inhibitor"></FilterOption><FilterOption id="382" count="81" label="TNF alpha synthesis inhibitor"></FilterOption><FilterOption id="71" count="80" label="Antihypercholesterolemic agent"></FilterOption><FilterOption id="12378" count="79" label="Prophylactic vaccine"></FilterOption><FilterOption id="59620" count="75" label="Unspecified drug target"></FilterOption><FilterOption id="664" count="74" label="Fibrosuppressant"></FilterOption><FilterOption id="439" count="72" label="RNA synthesis inhibitor"></FilterOption><FilterOption id="388" count="72" label="Vasodilator"></FilterOption><FilterOption id="2942" count="71" label="Anxiolytic"></FilterOption><FilterOption id="12379" count="71" label="Therapeutic vaccine"></FilterOption><FilterOption id="62254" count="70" label="Anticancer hormone antagonist"></FilterOption><FilterOption id="750" count="69" label="DNA intercalator"></FilterOption><FilterOption id="1470" count="67" label="Respiratory system agent"></FilterOption><FilterOption id="805" count="65" label="Folate modulator"></FilterOption><FilterOption id="539" count="65" label="Immunotoxin"></FilterOption><FilterOption id="38206" count="63" label="Biguanide antidiabetic product"></FilterOption><FilterOption id="55684" count="60" label="Anticancer antibody"></FilterOption><FilterOption id="1332" count="60" label="Gastrointestinal system agent"></FilterOption><FilterOption id="72" count="58" label="Antihyperlipidemic agent"></FilterOption><FilterOption id="15128" count="56" label="Ophthalmological agent"></FilterOption><FilterOption id="312" count="56" label="Platelet aggregation inhibitor"></FilterOption><FilterOption id="15187" count="54" label="Systemic dermatological antibacterial product"></FilterOption><FilterOption id="7760" count="54" label="T-lymphocyte inhibitor"></FilterOption><FilterOption id="3189" count="51" label="Corticosteroid agonist"></FilterOption><FilterOption id="285" count="50" label="Norepinephrine uptake inhibitor"></FilterOption><FilterOption id="2954" count="48" label="Steroidal anti-inflammatory"></FilterOption><FilterOption id="15319" count="47" label="Hepatitis C virus replication inhibitor"></FilterOption><FilterOption id="12372" count="45" label="Protein subunit vaccine"></FilterOption><FilterOption id="89" count="44" label="Bone resorption inhibitor"></FilterOption><FilterOption id="3" count="42" label="5-HT uptake inhibitor"></FilterOption><FilterOption id="15148" count="40" label="Ocular antineovascularisation agent"></FilterOption><FilterOption id="7292" count="38" label="Vulnerary agent"></FilterOption><FilterOption id="104" count="35" label="Bacterial cell wall synthesis inhibitor"></FilterOption><FilterOption id="1538" count="35" label="Bacterial protein synthesis inhibitor"></FilterOption><FilterOption id="463" count="35" label="Ribosome binding agent"></FilterOption><FilterOption id="1748" count="34" label="Fungicide"></FilterOption><FilterOption id="2970" count="33" label="Anti-emetic"></FilterOption><FilterOption id="968" count="33" label="Coagulation stimulator"></FilterOption><FilterOption id="38439" count="33" label="DPP IV inhibitor antidiabetic product"></FilterOption><FilterOption id="3272" count="33" label="Growth hormone release inhibitor"></FilterOption><FilterOption id="1532" count="33" label="Viral replication inhibitor"></FilterOption><FilterOption id="5580" count="32" label="Chemotaxis inhibitor"></FilterOption><FilterOption id="12371" count="32" label="Subunit vaccine"></FilterOption><FilterOption id="5704" count="30" label="B-lymphocyte adhesion inhibitor"></FilterOption><FilterOption id="5710" count="30" label="B-lymphocyte migration inhibitor"></FilterOption><FilterOption id="937" count="29" label="Androgen synthesis inhibitor"></FilterOption><FilterOption id="2939" count="29" label="CNS modulator"></FilterOption><FilterOption id="7294" count="28" label="Antisense oligonucleotide inhibitor"></FilterOption><FilterOption id="3984" count="27" label="Bacterial nucleic acid synthesis inhibitor"></FilterOption><FilterOption id="1537" count="27" label="Cephalosporin"></FilterOption><FilterOption id="32411" count="26" label="Hepatitis B virus replication inhibitor"></FilterOption><FilterOption id="38212" count="26" label="Human insulin intermediate acting product"></FilterOption><FilterOption id="38215" count="26" label="Human insulin long acting product"></FilterOption><FilterOption id="3980" count="25" label="HIV fusion inhibitor"></FilterOption><FilterOption id="2955" count="25" label="Non-steroidal anti-inflammatory"></FilterOption><FilterOption id="2658" count="24" label="Hypertensive"></FilterOption><FilterOption id="7018" count="23" label="Antihypertriglyceridemic agent"></FilterOption><FilterOption id="38211" count="23" label="Human insulin fast acting product"></FilterOption><FilterOption id="12364" count="23" label="Live attenuated viral vaccine"></FilterOption><FilterOption id="7220" count="23" label="Neoplasm diagnostic agent"></FilterOption><FilterOption id="12596" count="23" label="Osteoclast inhibitor"></FilterOption><FilterOption id="74" count="22" label="Antioxidant agent"></FilterOption><FilterOption id="1590" count="22" label="Apoptosis inhibitor"></FilterOption></Filter><Filter label="Trial Endpoint Achieved" name="trialEndpointsAchieved" total="3"><FilterOption id="UNSPECIFIED" count="1702" label="Unspecified"></FilterOption><FilterOption id="YES" count="1211" label="Yes"></FilterOption><FilterOption id="NO" count="475" label="No"></FilterOption></Filter><Filter label="Endpoint Index Secondary" name="trialEndpointIndexSecondary" total="100"><FilterOption id="8489" count="211" label="Lung tumor - Assessment of Progression Free Survival (PFS)"></FilterOption><FilterOption id="8712" count="207" label="Breast tumor - Assessment of Overall Survival (OS)"></FilterOption><FilterOption id="8719" count="193" label="Breast tumor - Assessment of Response Rates (RR) - Assessment of Overall/Objective Response Rate (ORR)"></FilterOption><FilterOption id="8481" count="188" label="Lung tumor - Assessment of Overall Survival (OS)"></FilterOption><FilterOption id="8663" count="188" label="Lung tumor - Assessment of Pharmacokinetic/Pharmacodynamic Parameters"></FilterOption><FilterOption id="15312" count="172" label="Solid tumor - Assessment of Pharmacokinetic/Pharmacodynamic Parameters"></FilterOption><FilterOption id="8998" count="170" label="Breast tumor - Assessment of adverse events"></FilterOption><FilterOption id="8522" count="160" label="Lung tumor - Assessment of Response Rates (RR) - Assessment of duration of response"></FilterOption><FilterOption id="8738" count="157" label="Breast tumor - Assessment of Response Rates (RR) - Assessment of duration of tumor response"></FilterOption><FilterOption id="8713" count="149" label="Breast tumor - Assessment of Progression Free Survival (PFS)"></FilterOption><FilterOption id="8505" count="140" label="Lung tumor - Assessment of Objective Response - Assessment of objective response rate(ORR)"></FilterOption><FilterOption id="8639" count="125" label="Lung tumor - Assessment of Safety and Tolerability"></FilterOption><FilterOption id="7538" count="121" label="Lymphoma - Assessment of Overall Survival (OS)"></FilterOption><FilterOption id="9153" count="120" label="Lung tumor - Imaging/Radiological Assessments - Assessment by Response Evaluation Criteria in Solid Tumors (RECIST) Criteria"></FilterOption><FilterOption id="8514" count="117" label="Lung tumor - Assessment of Response Rates (RR) - Assessment of Complete Response"></FilterOption><FilterOption id="9122" count="114" label="Breast tumor - Assessment of Pharmacokinetic/Pharmacodynamic Parameters"></FilterOption><FilterOption id="9215" count="113" label="HIV infection - Assessment of CD4 Cell Responses - Assessment of CD4 cell count/percentage"></FilterOption><FilterOption id="9218" count="113" label="HIV infection - Assessment of Immune Response"></FilterOption><FilterOption id="15207" count="111" label="Solid tumor - Assessment of Progression Free Survival (PFS)"></FilterOption><FilterOption id="9247" count="108" label="HIV infection - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events"></FilterOption><FilterOption id="8513" count="106" label="Lung tumor - Assessment of Response Rates (RR) - Assessment of Partial Response (PR)"></FilterOption><FilterOption id="15212" count="106" label="Solid tumor - Assessment of Response Rates (RR) - Assessment of objective response rate (ORR)"></FilterOption><FilterOption id="7547" count="102" label="Lymphoma - Assessment of Progression Free Survival (PFS)"></FilterOption><FilterOption id="1503" count="98" label="Non-insulin dependent diabetes - Anthropometric Assessments - Assessment of body weight"></FilterOption><FilterOption id="8721" count="97" label="Breast tumor - Assessment of Response Rates (RR) - Assessment of Complete Response"></FilterOption><FilterOption id="7611" count="97" label="Lymphoma - Assessment of Response Rates (RR) - Assessment of tumor response rate (Duration of response)"></FilterOption><FilterOption id="8187" count="94" label="Colorectal tumor - Assessment of Response Rates (RR) - Assessment of Objective/Overall Response Rate (ORR)"></FilterOption><FilterOption id="7879" count="94" label="Leukemia - Assessment of Overall Survival (OS)"></FilterOption><FilterOption id="7680" count="91" label="Lymphoma - Assessment of adverse events"></FilterOption><FilterOption id="8640" count="90" label="Lung tumor - Assessment of Safety and Tolerability - Adverse events as graded by CTCAE/CTC"></FilterOption><FilterOption id="8722" count="87" label="Breast tumor - Assessment of Response Rates (RR) - Assessment of Clinical Benefit Rate (CBR)"></FilterOption><FilterOption id="8996" count="87" label="Breast tumor - Assessment of Safety and Tolerability"></FilterOption><FilterOption id="15218" count="87" label="Solid tumor - Assessment of Response Rates (RR) - Assessment of duration of tumor response"></FilterOption><FilterOption id="8720" count="86" label="Breast tumor - Assessment of Response Rates (RR) - Assessment of Partial Response (PR)"></FilterOption><FilterOption id="8430" count="85" label="Colorectal tumor - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events"></FilterOption><FilterOption id="9213" count="84" label="HIV infection - Assessment of Viral Load - Assessment of HIV RNA levels"></FilterOption><FilterOption id="1345" count="84" label="Non-insulin dependent diabetes - Glycemic Control Analysis - Assessment of fasting blood glucose"></FilterOption><FilterOption id="8523" count="82" label="Lung tumor - Assessment of Disease Progression"></FilterOption><FilterOption id="8451" count="81" label="Colorectal tumor - Assessment of Pharmacokinetic/Pharmacodynamic Parameters"></FilterOption><FilterOption id="8163" count="80" label="Colorectal tumor - Assessment of Progression Free Survival (PFS)"></FilterOption><FilterOption id="8078" count="80" label="Leukemia - Assessment of adverse events"></FilterOption><FilterOption id="15287" count="80" label="Solid tumor - Assessment of adverse events"></FilterOption><FilterOption id="8151" count="79" label="Colorectal tumor - Assessment of Overall Survival (OS)"></FilterOption><FilterOption id="7563" count="79" label="Lymphoma - Assessment of Response Rates (RR) - Assessment of Complete Response"></FilterOption><FilterOption id="8519" count="74" label="Lung tumor - Assessment of Response Rates (RR) - Assessment of Tumor Growth Control Rate (TGCR)"></FilterOption><FilterOption id="8189" count="73" label="Colorectal tumor - Assessment of Response Rates (RR) - Assessment of duration of response"></FilterOption><FilterOption id="22595" count="73" label="End stage renal disease - Assessment of adverse events"></FilterOption><FilterOption id="6863" count="72" label="Hepatitis C virus infection - Assessment of Viral Load/Viral Kinetics"></FilterOption><FilterOption id="7569" count="71" label="Lymphoma - Assessment of Response Rates (RR) - Assessment of Overall/Objective Response Rate (ORR)"></FilterOption><FilterOption id="6940" count="71" label="Melanoma - Assessment of Response Rates (RR) - Assessment of overall/objective response rate"></FilterOption><FilterOption id="6924" count="67" label="Melanoma - Assessment of Progression Free Survival (PFS)"></FilterOption><FilterOption id="7354" count="67" label="Multiple myeloma - Assessment of Overall Survival (OS)"></FilterOption><FilterOption id="26033" count="67" label="Pain - Assessment of adverse events"></FilterOption><FilterOption id="7908" count="66" label="Leukemia - Assessment of Response Rates (RR) - Assessment of Complete Response"></FilterOption><FilterOption id="10828" count="66" label="Ovary tumor - Assessment of Overall Survival (OS)"></FilterOption><FilterOption id="3900" count="66" label="Rheumatoid arthritis - DAS-28 (Disease Activity Score) Response"></FilterOption><FilterOption id="8516" count="65" label="Lung tumor - Assessment of Response Rates (RR) - Assessment of Stable Disease"></FilterOption><FilterOption id="8651" count="63" label="Lung tumor - Assessment of Laboratory/Diagnostic Measures"></FilterOption><FilterOption id="37159" count="61" label="Breast tumor - Assessment of Laboratory/Diagnostic Measures"></FilterOption><FilterOption id="2622" count="61" label="Coronary artery disease - Assessment of Mortality/Death Rates - Cardiovascular mortality"></FilterOption><FilterOption id="9242" count="61" label="HIV infection - Assessment of lipid profiles"></FilterOption><FilterOption id="8555" count="61" label="Lung tumor - Assessment of Mortality/Death Rates"></FilterOption><FilterOption id="6919" count="61" label="Melanoma - Assessment of Overall Survival (OS)"></FilterOption><FilterOption id="7393" count="60" label="Multiple myeloma - Assessment of Response Rates (RR) - Assessment of tumor response rate (Duration of response)"></FilterOption><FilterOption id="7190" count="60" label="Prostate tumor - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events"></FilterOption><FilterOption id="10830" count="59" label="Ovary tumor - Assessment of Progression Free Survival (PFS)"></FilterOption><FilterOption id="10939" count="57" label="Ovary tumor - Assessment of Pharmacokinetic/Pharmacodynamic Parameters"></FilterOption><FilterOption id="8508" count="56" label="Lung tumor - Assessment of Overall Response"></FilterOption><FilterOption id="7564" count="56" label="Lymphoma - Assessment of Response Rates (RR) - Assessment of Partial Response (PR)"></FilterOption><FilterOption id="7045" count="56" label="Prostate tumor - Assessment of Overall Survival (OS)"></FilterOption><FilterOption id="1626" count="55" label="Non-insulin dependent diabetes - Assessment of Adverse Events"></FilterOption><FilterOption id="26827" count="55" label="Solid tumor - Imaging/Radiological Assessments - Assessment by Response Evaluation Criteria in Solid Tumors (RECIST) Criteria"></FilterOption><FilterOption id="11717" count="54" label="Bladder cancer - Assessment of Overall Survival (OS)"></FilterOption><FilterOption id="8744" count="54" label="Breast tumor - Assessment of Disease Progression"></FilterOption><FilterOption id="8563" count="54" label="Lung tumor - Patient Reported Outcomes/Quality of Life Assessments"></FilterOption><FilterOption id="13357" count="54" label="Pancreas tumor - Assessment of Response Rates (RR) - Assessment of objective response rate (ORR)"></FilterOption><FilterOption id="8725" count="53" label="Breast tumor - Assessment of Response Rates (RR) - Assessment of Stable Disease"></FilterOption><FilterOption id="8999" count="53" label="Breast tumor - Assessment of Safety and Tolerability - Assessment of safety as measured by NCI CTCAE/NCI-CTC criteria"></FilterOption><FilterOption id="7027" count="53" label="Melanoma - Assessment of adverse events"></FilterOption><FilterOption id="7367" count="53" label="Multiple myeloma - Assessment of Response Rates (RR) - Assessment of Overall/Objective Response Rate (ORR)"></FilterOption><FilterOption id="1624" count="53" label="Non-insulin dependent diabetes - Assessment of Safety and Tolerability"></FilterOption><FilterOption id="8759" count="52" label="Breast tumor - Patient Reported Outcomes/Quality of Life Assessments"></FilterOption><FilterOption id="7679" count="52" label="Lymphoma - Assessment of Safety and Tolerability"></FilterOption><FilterOption id="7049" count="52" label="Prostate tumor - Assessment of Progression Free Survival (PFS)"></FilterOption><FilterOption id="8997" count="51" label="Breast tumor - Assessment of Safety and Tolerability - Assessment of serious adverse events"></FilterOption><FilterOption id="8641" count="51" label="Lung tumor - Assessment of Safety and Tolerability - Assessment of frequency and severity of adverse events"></FilterOption><FilterOption id="7360" count="51" label="Multiple myeloma - Assessment of Progression Free Survival (PFS)"></FilterOption><FilterOption id="3736" count="50" label="Hepatitis C virus infection - Assessment of Sustained Virologic Response (SVR)"></FilterOption><FilterOption id="13352" count="50" label="Pancreas tumor - Assessment of Progression Free Survival (PFS)"></FilterOption><FilterOption id="15215" count="50" label="Solid tumor - Assessment of Response Rates (RR) - Assessment of Complete Response"></FilterOption><FilterOption id="12156" count="49" label="Stomach tumor - Assessment of Response Rates (RR) - Assessment of objective/overall response rate (ORR)"></FilterOption><FilterOption id="10540" count="48" label="Renal cell carcinoma - Assessment of Overall Survival (OS)"></FilterOption><FilterOption id="11728" count="47" label="Bladder cancer - Assessment of Response Rates (RR) - Assessment of objective/overall response rate (ORR)"></FilterOption><FilterOption id="8754" count="47" label="Breast tumor - Assessment of Mortality/Death Rates"></FilterOption><FilterOption id="7891" count="47" label="Leukemia - Assessment of Progression Free Survival (PFS)"></FilterOption><FilterOption id="8509" count="47" label="Lung tumor - Assessment of Overall Response - Assessment of best overall response"></FilterOption><FilterOption id="28074" count="47" label="Lung tumor - Patient Reported Outcomes/Quality of Life Assessments - Assessment by EORTC QLQ-C30"></FilterOption><FilterOption id="10839" count="47" label="Ovary tumor - Assessment of Response Rates (RR) - Assessment of overall/objective response rate(ORR)"></FilterOption><FilterOption id="15214" count="47" label="Solid tumor - Assessment of Response Rates (RR) - Assessment of Partial Response (PR)"></FilterOption><FilterOption id="9238" count="46" label="HIV infection - Assessment of Laboratory/Diagnostic Measures"></FilterOption></Filter><Filter label="Biomarker" name="trialBiomarkerNames" total="100"><FilterOption id="1211" count="643" label="Alanine transaminase"></FilterOption><FilterOption id="12058" count="555" label="Total body mass"></FilterOption><FilterOption id="2527" count="546" label="Aspartate aminotransferase"></FilterOption><FilterOption id="213" count="482" label="Creatinine"></FilterOption><FilterOption id="1236" count="458" label="Hemoglobin"></FilterOption><FilterOption id="2054" count="417" label="Blood platelets"></FilterOption><FilterOption id="1904" count="407" label="Heart rate"></FilterOption><FilterOption id="1735" count="395" label="Glucose"></FilterOption><FilterOption id="2586" count="351" label="Blood pressure"></FilterOption><FilterOption id="2387" count="345" label="Bilirubin"></FilterOption><FilterOption id="46" count="345" label="C-reactive protein"></FilterOption><FilterOption id="1925" count="345" label="Neutrophils"></FilterOption><FilterOption id="3" count="336" label="HER2"></FilterOption><FilterOption id="330" count="303" label="Systolic blood pressure"></FilterOption><FilterOption id="125" count="290" label="Leukocyte count"></FilterOption><FilterOption id="28899" count="268" label="Alkaline phosphatase"></FilterOption><FilterOption id="332" count="267" label="Diastolic blood pressure"></FilterOption><FilterOption id="133" count="260" label="Total cholesterol"></FilterOption><FilterOption id="289" count="256" label="Hemoglobin A, glycosylated"></FilterOption><FilterOption id="217" count="248" label="Triglycerides"></FilterOption><FilterOption id="152" count="244" label="Low-density lipoprotein cholesterol"></FilterOption><FilterOption id="4806" count="239" label="Lymphocytes"></FilterOption><FilterOption id="118" count="232" label="Albumin"></FilterOption><FilterOption id="1857" count="224" label="T-cell surface glycoprotein CD4"></FilterOption><FilterOption id="153" count="220" label="High-density lipoprotein cholesterol"></FilterOption><FilterOption id="7895" count="219" label="Estimated glomerular filtration rate"></FilterOption><FilterOption id="8" count="202" label="Epidermal growth factor receptor"></FilterOption><FilterOption id="113" count="191" label="Body Mass Index"></FilterOption><FilterOption id="2713" count="191" label="Forced expiratory volume"></FilterOption><FilterOption id="824" count="191" label="Programmed cell death 1 ligand 1"></FilterOption><FilterOption id="5" count="181" label="Estrogen receptor"></FilterOption><FilterOption id="1880" count="168" label="T-Helper Lymphocytes"></FilterOption><FilterOption id="44216" count="165" label="Body temperature"></FilterOption><FilterOption id="8458" count="163" label="gamma-Glutamyltransferase"></FilterOption><FilterOption id="2098" count="161" label="Potassium"></FilterOption><FilterOption id="3447" count="158" label="T-cell surface glycoprotein CD8 alpha chain"></FilterOption><FilterOption id="2417" count="155" label="Calcium"></FilterOption><FilterOption id="148" count="153" label="QT interval"></FilterOption><FilterOption id="2662" count="146" label="Sodium"></FilterOption><FilterOption id="176" count="145" label="Interleukin-6"></FilterOption><FilterOption id="8024" count="142" label="Creatine kinase"></FilterOption><FilterOption id="14767" count="141" label="Lipids"></FilterOption><FilterOption id="1289" count="135" label="Tumor mass"></FilterOption><FilterOption id="46506" count="134" label="T-Lymphocytes"></FilterOption><FilterOption id="46505" count="133" label="Cytotoxic T-Lymphocytes"></FilterOption><FilterOption id="147" count="132" label="Six-minute walk distance"></FilterOption><FilterOption id="6" count="131" label="Progesterone receptor"></FilterOption><FilterOption id="4522" count="126" label="Erythrocytes"></FilterOption><FilterOption id="248" count="125" label="Eosinophils"></FilterOption><FilterOption id="1912" count="120" label="Forced Vital Capacity"></FilterOption><FilterOption id="1945" count="118" label="Left ventricular ejection fraction"></FilterOption><FilterOption id="6663" count="115" label="B-lymphocytes"></FilterOption><FilterOption id="36136" count="115" label="Cytokines"></FilterOption><FilterOption id="82" count="112" label="B-Raf proto-oncogene serine/threonine-protein kinase"></FilterOption><FilterOption id="7033" count="112" label="Lipase"></FilterOption><FilterOption id="1221" count="111" label="Hematocrit"></FilterOption><FilterOption id="52" count="109" label="GTPase KRas"></FilterOption><FilterOption id="44218" count="108" label="Human immunodeficiency virus RNA"></FilterOption><FilterOption id="38" count="108" label="Prostate-specific antigen"></FilterOption><FilterOption id="2358" count="105" label="Urea nitrogen"></FilterOption><FilterOption id="154" count="100" label="Lactate dehydrogenase"></FilterOption><FilterOption id="18315" count="95" label="Visual acuity"></FilterOption><FilterOption id="17697" count="93" label="Body height"></FilterOption><FilterOption id="106" count="92" label="N-terminal Pro Brain Natriuretic Peptide"></FilterOption><FilterOption id="44186" count="91" label="Hepatitis C virus RNA"></FilterOption><FilterOption id="808" count="89" label="Insulin"></FilterOption><FilterOption id="30214" count="87" label="Joint swelling"></FilterOption><FilterOption id="8097" count="86" label="Monocytes"></FilterOption><FilterOption id="10260" count="86" label="Respiratory frequency"></FilterOption><FilterOption id="274" count="85" label="Tumor necrosis factor"></FilterOption><FilterOption id="30217" count="80" label="Joint tenderness"></FilterOption><FilterOption id="5700" count="79" label="ALK receptor"></FilterOption><FilterOption id="252" count="78" label="Interferon gamma"></FilterOption><FilterOption id="288" count="78" label="Uric acid"></FilterOption><FilterOption id="11114" count="77" label="Brain"></FilterOption><FilterOption id="22" count="77" label="Breast cancer type 1 susceptibility protein"></FilterOption><FilterOption id="1183" count="77" label="Urinary albumin to creatinine ratio"></FilterOption><FilterOption id="7" count="76" label="Antigen KI-67"></FilterOption><FilterOption id="3374" count="76" label="Bone mineral density"></FilterOption><FilterOption id="6993" count="74" label="Alpha-amylase 1"></FilterOption><FilterOption id="9807" count="74" label="Basophils"></FilterOption><FilterOption id="92" count="74" label="Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha isoform"></FilterOption><FilterOption id="1731" count="73" label="B-lymphocyte antigen CD20"></FilterOption><FilterOption id="41" count="73" label="Breast cancer type 2 susceptibility protein"></FilterOption><FilterOption id="12516" count="73" label="Urinary protein"></FilterOption><FilterOption id="11857" count="72" label="Transaminases"></FilterOption><FilterOption id="3247" count="70" label="Chlorides"></FilterOption><FilterOption id="19714" count="69" label="Muscle strength"></FilterOption><FilterOption id="3083" count="69" label="Phosphate"></FilterOption><FilterOption id="2382" count="67" label="Phosphorus"></FilterOption><FilterOption id="2626" count="67" label="Total protein"></FilterOption><FilterOption id="418" count="67" label="Waist circumference"></FilterOption><FilterOption id="3451" count="66" label="Immunoglobulin G"></FilterOption><FilterOption id="10684" count="65" label="Blood cells"></FilterOption><FilterOption id="781" count="65" label="Erythrocyte sedimentation rate"></FilterOption><FilterOption id="2515" count="63" label="Magnesium"></FilterOption><FilterOption id="215" count="60" label="Apolipoprotein B-100"></FilterOption><FilterOption id="9" count="59" label="Cellular tumor antigen p53"></FilterOption><FilterOption id="71" count="58" label="CA-125 antigen"></FilterOption><FilterOption id="10" count="58" label="Phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN"></FilterOption></Filter><Filter label="Trial Terms Endpoint" name="trialTermsEndpoint" total="6"><FilterOption id="SIEEFC" count="5934" label="Efficacy"></FilterOption><FilterOption id="SIESFT" count="5765" label="Safety"></FilterOption><FilterOption id="SIEPCK" count="2815" label="Pharmacokinetics"></FilterOption><FilterOption id="SIEPCD" count="1629" label="Pharmacodynamics"></FilterOption><FilterOption id="SIEBAV" count="23" label="Bioavailability"></FilterOption><FilterOption id="SIEBEQ" count="17" label="Bioequivalence"></FilterOption></Filter><Filter label="Trial Interventions Primary In Regimen Name Display" name="trialInterventionsPrimaryInRegimenNameDisplay" total="100"><FilterOption id="3803" count="163" label="paclitaxel"></FilterOption><FilterOption id="44383" count="146" label="carboplatin"></FilterOption><FilterOption id="3199" count="115" label="gemcitabine"></FilterOption><FilterOption id="2953" count="102" label="docetaxel"></FilterOption><FilterOption id="8047" count="95" label="bevacizumab"></FilterOption><FilterOption id="6736" count="79" label="rituximab"></FilterOption><FilterOption id="54804" count="75" label="nivolumab"></FilterOption><FilterOption id="72699" count="73" label="atezolizumab"></FilterOption><FilterOption id="3792" count="72" label="oxaliplatin"></FilterOption><FilterOption id="12205" count="70" label="capecitabine"></FilterOption><FilterOption id="6386" count="67" label="trastuzumab"></FilterOption><FilterOption id="7310" count="65" label="ritonavir"></FilterOption><FilterOption id="70667" count="64" label="pembrolizumab"></FilterOption><FilterOption id="5369" count="63" label="ribavirin"></FilterOption><FilterOption id="3536" count="58" label="pemetrexed disodium"></FilterOption><FilterOption id="23625" count="55" label="peginterferon alfa-2a"></FilterOption><FilterOption id="6050" count="53" label="metformin hydrochloride"></FilterOption><FilterOption id="36630" count="50" label="ipilimumab"></FilterOption><FilterOption id="3072" count="45" label="etoposide phosphate"></FilterOption><FilterOption id="15954" count="44" label="bortezomib"></FilterOption><FilterOption id="2871" count="41" label="irinotecan"></FilterOption><FilterOption id="13340" count="39" label="everolimus"></FilterOption><FilterOption id="29016" count="38" label="paclitaxel (albumin-bound nanoparticle, intravenous), Celgene"></FilterOption><FilterOption id="81193" count="35" label="durvalumab"></FilterOption><FilterOption id="27572" count="34" label="lenalidomide"></FilterOption><FilterOption id="2784" count="34" label="letrozole"></FilterOption><FilterOption id="10388" count="33" label="cetuximab"></FilterOption><FilterOption id="3313" count="32" label="fulvestrant"></FilterOption><FilterOption id="11961" count="31" label="erlotinib"></FilterOption><FilterOption id="28532" count="30" label="pertuzumab"></FilterOption><FilterOption id="47000" count="29" label="bendamustine"></FilterOption><FilterOption id="32981" count="28" label="darunavir"></FilterOption><FilterOption id="4510" count="28" label="tacrolimus"></FilterOption><FilterOption id="53227" count="26" label="obinutuzumab"></FilterOption><FilterOption id="10309" count="25" label="abiraterone"></FilterOption><FilterOption id="6156" count="25" label="fludarabine"></FilterOption><FilterOption id="3669" count="25" label="mycophenolate mofetil"></FilterOption><FilterOption id="53200" count="24" label="daratumumab"></FilterOption><FilterOption id="55237" count="22" label="ibrutinib"></FilterOption><FilterOption id="14681" count="22" label="lopinavir + ritonavir"></FilterOption><FilterOption id="3081" count="21" label="exemestane"></FilterOption><FilterOption id="96193" count="21" label="spartalizumab"></FilterOption><FilterOption id="56544" count="20" label="cobimetinib"></FilterOption><FilterOption id="13022" count="20" label="epirubicin"></FilterOption><FilterOption id="3474" count="20" label="lamivudine"></FilterOption><FilterOption id="33591" count="20" label="lapatinib"></FilterOption><FilterOption id="6408" count="20" label="vinorelbine"></FilterOption><FilterOption id="61901" count="19" label="buparlisib"></FilterOption><FilterOption id="7934" count="19" label="doxorubicin (liposomal, STEALTH), Alza"></FilterOption><FilterOption id="71886" count="19" label="ribavirin (oral tablet, HCV), Roche"></FilterOption><FilterOption id="4529" count="19" label="temozolomide"></FilterOption><FilterOption id="55288" count="19" label="trametinib"></FilterOption><FilterOption id="16063" count="18" label="olaparib"></FilterOption><FilterOption id="12646" count="18" label="panitumumab"></FilterOption><FilterOption id="54488" count="18" label="raltegravir"></FilterOption><FilterOption id="14493" count="18" label="tenofovir disoproxil fumarate"></FilterOption><FilterOption id="15254" count="17" label="atazanavir"></FilterOption><FilterOption id="37370" count="17" label="azacitidine"></FilterOption><FilterOption id="58741" count="17" label="daclatasvir"></FilterOption><FilterOption id="27696" count="17" label="pomalidomide"></FilterOption><FilterOption id="65360" count="17" label="ribociclib"></FilterOption><FilterOption id="2807" count="16" label="atorvastatin"></FilterOption><FilterOption id="2836" count="16" label="clopidogrel"></FilterOption><FilterOption id="12973" count="16" label="sunitinib"></FilterOption><FilterOption id="49219" count="16" label="tenofovir disoproxil fumarate + emtricitabine (fixed dose), Gilead Sciences"></FilterOption><FilterOption id="55305" count="15" label="binimetinib"></FilterOption><FilterOption id="10271" count="15" label="palbociclib"></FilterOption><FilterOption id="45562" count="15" label="tremelimumab"></FilterOption><FilterOption id="53133" count="14" label="dabrafenib"></FilterOption><FilterOption id="10172" count="14" label="efavirenz"></FilterOption><FilterOption id="48181" count="14" label="lamivudine + abacavir, GlaxoSmithKline"></FilterOption><FilterOption id="45902" count="14" label="ramucirumab"></FilterOption><FilterOption id="65353" count="13" label="alpelisib"></FilterOption><FilterOption id="11141" count="13" label="basiliximab"></FilterOption><FilterOption id="54601" count="13" label="carfilzomib"></FilterOption><FilterOption id="59062" count="13" label="dolutegravir"></FilterOption><FilterOption id="10252" count="13" label="insulin glargine"></FilterOption><FilterOption id="45841" count="13" label="lenvatinib mesylate"></FilterOption><FilterOption id="70895" count="13" label="venetoclax"></FilterOption><FilterOption id="59953" count="12" label="capmatinib"></FilterOption><FilterOption id="5999" count="12" label="ciclosporin, Novartis"></FilterOption><FilterOption id="3130" count="12" label="filgrastim"></FilterOption><FilterOption id="54915" count="12" label="ganitumab"></FilterOption><FilterOption id="66051" count="12" label="ipatasertib dihydrochloride"></FilterOption><FilterOption id="39069" count="12" label="simeprevir"></FilterOption><FilterOption id="29831" count="12" label="sorafenib"></FilterOption><FilterOption id="12731" count="12" label="tipranavir"></FilterOption><FilterOption id="83065" count="11" label="avelumab"></FilterOption><FilterOption id="4728" count="11" label="emtricitabine"></FilterOption><FilterOption id="73843" count="11" label="encorafenib"></FilterOption><FilterOption id="53981" count="11" label="enzalutamide"></FilterOption><FilterOption id="4200" count="11" label="sirolimus"></FilterOption><FilterOption id="6242" count="10" label="abacavir"></FilterOption><FilterOption id="14163" count="10" label="adalimumab"></FilterOption><FilterOption id="3321" count="10" label="anastrozole"></FilterOption><FilterOption id="39209" count="10" label="axitinib"></FilterOption><FilterOption id="17518" count="10" label="escitalopram"></FilterOption><FilterOption id="61668" count="10" label="faldaprevir"></FilterOption><FilterOption id="44314" count="10" label="tamoxifen"></FilterOption><FilterOption id="54469" count="10" label="vemurafenib"></FilterOption></Filter><Filter label="Trial Document Source" name="trialDocumentSource" total="5"><FilterOption id="OTHER" count="2534" label="Other Publications"></FilterOption><FilterOption id="PR" count="2453" label="Press Releases"></FilterOption><FilterOption id="SERIAL" count="2269" label="Serial Publications"></FilterOption><FilterOption id="CORPORATE" count="622" label="Corporate Publications"></FilterOption><FilterOption id="CONFERENCE" count="497" label="Conference Reports"></FilterOption></Filter><Filter label="Trial Interventions Primary Alone Name Display" name="trialInterventionsPrimaryAloneNameDisplay" total="100"><FilterOption id="54804" count="44" label="nivolumab"></FilterOption><FilterOption id="55275" count="31" label="secukinumab"></FilterOption><FilterOption id="14163" count="30" label="adalimumab"></FilterOption><FilterOption id="72699" count="26" label="atezolizumab"></FilterOption><FilterOption id="32677" count="26" label="rivaroxaban"></FilterOption><FilterOption id="81193" count="25" label="durvalumab"></FilterOption><FilterOption id="16063" count="25" label="olaparib"></FilterOption><FilterOption id="13340" count="23" label="everolimus"></FilterOption><FilterOption id="12973" count="21" label="sunitinib"></FilterOption><FilterOption id="27572" count="20" label="lenalidomide"></FilterOption><FilterOption id="45499" count="20" label="tofacitinib citrate (oral, inflammation), Pfizer"></FilterOption><FilterOption id="6259" count="19" label="tocilizumab (intravenous), Roche/Chugai"></FilterOption><FilterOption id="74726" count="19" label="upadacitinib"></FilterOption><FilterOption id="53981" count="18" label="enzalutamide"></FilterOption><FilterOption id="52967" count="17" label="apixaban"></FilterOption><FilterOption id="24343" count="17" label="dabigatran etexilate"></FilterOption><FilterOption id="35644" count="17" label="methoxy polyethylene glycol-epoetin beta"></FilterOption><FilterOption id="8047" count="16" label="bevacizumab"></FilterOption><FilterOption id="11961" count="16" label="erlotinib"></FilterOption><FilterOption id="43738" count="16" label="pazopanib"></FilterOption><FilterOption id="70667" count="16" label="pembrolizumab"></FilterOption><FilterOption id="14681" count="15" label="lopinavir + ritonavir"></FilterOption><FilterOption id="17814" count="15" label="pregabalin"></FilterOption><FilterOption id="4567" count="14" label="etanercept"></FilterOption><FilterOption id="10154" count="14" label="fingolimod"></FilterOption><FilterOption id="55237" count="14" label="ibrutinib"></FilterOption><FilterOption id="6736" count="14" label="rituximab"></FilterOption><FilterOption id="58782" count="14" label="sacubitril + valsartan trisodium hemipentahydrate"></FilterOption><FilterOption id="42858" count="14" label="ustekinumab"></FilterOption><FilterOption id="59098" count="13" label="baricitinib"></FilterOption><FilterOption id="2953" count="13" label="docetaxel"></FilterOption><FilterOption id="65240" count="13" label="evolocumab"></FilterOption><FilterOption id="36630" count="13" label="ipilimumab"></FilterOption><FilterOption id="6050" count="13" label="metformin hydrochloride"></FilterOption><FilterOption id="51160" count="13" label="nintedanib"></FilterOption><FilterOption id="83873" count="13" label="osimertinib"></FilterOption><FilterOption id="22395" count="13" label="ranibizumab"></FilterOption><FilterOption id="29831" count="13" label="sorafenib"></FilterOption><FilterOption id="36669" count="13" label="trastuzumab emtansine"></FilterOption><FilterOption id="54449" count="12" label="afatinib"></FilterOption><FilterOption id="52854" count="12" label="macitentan"></FilterOption><FilterOption id="37613" count="12" label="maraviroc"></FilterOption><FilterOption id="6692" count="12" label="natalizumab"></FilterOption><FilterOption id="51388" count="12" label="nilotinib"></FilterOption><FilterOption id="54488" count="12" label="raltegravir"></FilterOption><FilterOption id="8165" count="12" label="tiotropium bromide"></FilterOption><FilterOption id="58762" count="11" label="empagliflozin"></FilterOption><FilterOption id="77337" count="11" label="risankizumab"></FilterOption><FilterOption id="21994" count="11" label="vardenafil hydrochloride"></FilterOption><FilterOption id="32355" count="10" label="indacaterol"></FilterOption><FilterOption id="62451" count="10" label="ixekizumab"></FilterOption><FilterOption id="53172" count="10" label="mavoglurant"></FilterOption><FilterOption id="12037" count="10" label="mepolizumab"></FilterOption><FilterOption id="3700" count="10" label="nevirapine"></FilterOption><FilterOption id="3803" count="10" label="paclitaxel"></FilterOption><FilterOption id="8713" count="10" label="sildenafil citrate"></FilterOption><FilterOption id="2765" count="10" label="zoledronic acid"></FilterOption><FilterOption id="72538" count="9" label="abemaciclib"></FilterOption><FilterOption id="53547" count="9" label="aflibercept (intravitreal, wet AMD, macular edema, diabetic retinopathy), Regeneron/Bayer"></FilterOption><FilterOption id="12205" count="9" label="capecitabine"></FilterOption><FilterOption id="49721" count="9" label="denosumab"></FilterOption><FilterOption id="10606" count="9" label="eltrombopag"></FilterOption><FilterOption id="67629" count="9" label="filgotinib"></FilterOption><FilterOption id="47941" count="9" label="GSK-1437173A"></FilterOption><FilterOption id="6386" count="9" label="trastuzumab"></FilterOption><FilterOption id="47205" count="8" label="ataluren"></FilterOption><FilterOption id="69858" count="8" label="ceritinib"></FilterOption><FilterOption id="55798" count="8" label="crizotinib"></FilterOption><FilterOption id="48946" count="8" label="dasatinib"></FilterOption><FilterOption id="51255" count="8" label="edoxaban"></FilterOption><FilterOption id="57369" count="8" label="etrolizumab"></FilterOption><FilterOption id="25049" count="8" label="laquinimod"></FilterOption><FilterOption id="55852" count="8" label="linagliptin"></FilterOption><FilterOption id="4151" count="8" label="pramipexole"></FilterOption><FilterOption id="4529" count="8" label="temozolomide"></FilterOption><FilterOption id="2716" count="7" label="alemtuzumab"></FilterOption><FilterOption id="44897" count="7" label="apremilast"></FilterOption><FilterOption id="2807" count="7" label="atorvastatin"></FilterOption><FilterOption id="5871" count="7" label="bosentan"></FilterOption><FilterOption id="37592" count="7" label="brivaracetam"></FilterOption><FilterOption id="52192" count="7" label="dapagliflozin propanediol"></FilterOption><FilterOption id="61317" count="7" label="daprodustat (oral, anemia), GlaxoSmithKline"></FilterOption><FilterOption id="47019" count="7" label="dimethyl fumarate"></FilterOption><FilterOption id="64060" count="7" label="guselkumab"></FilterOption><FilterOption id="9313" count="7" label="lanreotide"></FilterOption><FilterOption id="64962" count="7" label="ozanimod"></FilterOption><FilterOption id="54662" count="7" label="ruxolitinib (oral, myeloproliferative disorders), Incyte/Novartis"></FilterOption><FilterOption id="56776" count="7" label="SHP-647"></FilterOption><FilterOption id="69066" count="6" label="alectinib"></FilterOption><FilterOption id="16905" count="6" label="atomoxetine"></FilterOption><FilterOption id="31831" count="6" label="belimumab"></FilterOption><FilterOption id="46721" count="6" label="benralizumab"></FilterOption><FilterOption id="28035" count="6" label="cabazitaxel"></FilterOption><FilterOption id="47733" count="6" label="canakinumab"></FilterOption><FilterOption id="16242" count="6" label="cinacalcet"></FilterOption><FilterOption id="59062" count="6" label="dolutegravir"></FilterOption><FilterOption id="40735" count="6" label="dovitinib"></FilterOption><FilterOption id="14336" count="6" label="fluticasone propionate + salmeterol (asthma and COPD), GlaxoSmithKline"></FilterOption><FilterOption id="33591" count="6" label="lapatinib"></FilterOption><FilterOption id="48638" count="6" label="ocrelizumab"></FilterOption></Filter><Filter label="Trial Interventions Control In Regimen Name Display" name="trialInterventionsControlInRegimenNameDisplay" total="100"><FilterOption id="44383" count="100" label="carboplatin"></FilterOption><FilterOption id="3803" count="73" label="paclitaxel"></FilterOption><FilterOption id="3199" count="66" label="gemcitabine"></FilterOption><FilterOption id="2953" count="41" label="docetaxel"></FilterOption><FilterOption id="3536" count="39" label="pemetrexed disodium"></FilterOption><FilterOption id="6736" count="37" label="rituximab"></FilterOption><FilterOption id="8047" count="35" label="bevacizumab"></FilterOption><FilterOption id="3792" count="34" label="oxaliplatin"></FilterOption><FilterOption id="6386" count="32" label="trastuzumab"></FilterOption><FilterOption id="12205" count="30" label="capecitabine"></FilterOption><FilterOption id="6050" count="28" label="metformin hydrochloride"></FilterOption><FilterOption id="7310" count="27" label="ritonavir"></FilterOption><FilterOption id="3072" count="23" label="etoposide phosphate"></FilterOption><FilterOption id="49219" count="22" label="tenofovir disoproxil fumarate + emtricitabine (fixed dose), Gilead Sciences"></FilterOption><FilterOption id="29016" count="18" label="paclitaxel (albumin-bound nanoparticle, intravenous), Celgene"></FilterOption><FilterOption id="15954" count="16" label="bortezomib"></FilterOption><FilterOption id="32981" count="16" label="darunavir"></FilterOption><FilterOption id="3669" count="16" label="mycophenolate mofetil"></FilterOption><FilterOption id="15254" count="15" label="atazanavir"></FilterOption><FilterOption id="10252" count="15" label="insulin glargine"></FilterOption><FilterOption id="6408" count="15" label="vinorelbine"></FilterOption><FilterOption id="47000" count="14" label="bendamustine"></FilterOption><FilterOption id="2836" count="14" label="clopidogrel"></FilterOption><FilterOption id="2871" count="14" label="irinotecan"></FilterOption><FilterOption id="23625" count="12" label="peginterferon alfa-2a"></FilterOption><FilterOption id="10309" count="11" label="abiraterone"></FilterOption><FilterOption id="48181" count="11" label="lamivudine + abacavir, GlaxoSmithKline"></FilterOption><FilterOption id="4510" count="11" label="tacrolimus"></FilterOption><FilterOption id="10388" count="10" label="cetuximab"></FilterOption><FilterOption id="3353" count="10" label="insulin lispro"></FilterOption><FilterOption id="27572" count="10" label="lenalidomide"></FilterOption><FilterOption id="14681" count="10" label="lopinavir + ritonavir"></FilterOption><FilterOption id="44375" count="10" label="warfarin"></FilterOption><FilterOption id="10172" count="9" label="efavirenz"></FilterOption><FilterOption id="13022" count="9" label="epirubicin"></FilterOption><FilterOption id="5369" count="9" label="ribavirin"></FilterOption><FilterOption id="6156" count="8" label="fludarabine"></FilterOption><FilterOption id="11519" count="8" label="mitoxantrone"></FilterOption><FilterOption id="14163" count="7" label="adalimumab"></FilterOption><FilterOption id="37370" count="6" label="azacitidine"></FilterOption><FilterOption id="44384" count="6" label="ceftriaxone"></FilterOption><FilterOption id="59062" count="6" label="dolutegravir"></FilterOption><FilterOption id="13928" count="6" label="enoxaparin sodium"></FilterOption><FilterOption id="13340" count="6" label="everolimus"></FilterOption><FilterOption id="3081" count="6" label="exemestane"></FilterOption><FilterOption id="8832" count="6" label="glimepiride"></FilterOption><FilterOption id="3474" count="6" label="lamivudine"></FilterOption><FilterOption id="33591" count="6" label="lapatinib"></FilterOption><FilterOption id="2784" count="6" label="letrozole"></FilterOption><FilterOption id="27696" count="6" label="pomalidomide"></FilterOption><FilterOption id="14493" count="6" label="tenofovir disoproxil fumarate"></FilterOption><FilterOption id="44401" count="6" label="vancomycin"></FilterOption><FilterOption id="3321" count="5" label="anastrozole"></FilterOption><FilterOption id="2807" count="5" label="atorvastatin"></FilterOption><FilterOption id="11141" count="5" label="basiliximab"></FilterOption><FilterOption id="5999" count="5" label="ciclosporin, Novartis"></FilterOption><FilterOption id="7934" count="5" label="doxorubicin (liposomal, STEALTH), Alza"></FilterOption><FilterOption id="5907" count="5" label="duloxetine"></FilterOption><FilterOption id="17518" count="5" label="escitalopram"></FilterOption><FilterOption id="53227" count="5" label="obinutuzumab"></FilterOption><FilterOption id="28532" count="5" label="pertuzumab"></FilterOption><FilterOption id="12150" count="5" label="vincristine sulfate (liposomal injection), Spectrum Pharmaceuticals"></FilterOption><FilterOption id="54601" count="4" label="carfilzomib"></FilterOption><FilterOption id="62275" count="4" label="cobicistat"></FilterOption><FilterOption id="13239" count="4" label="decitabine"></FilterOption><FilterOption id="11367" count="4" label="ezetimibe"></FilterOption><FilterOption id="24471" count="4" label="fosamprenavir"></FilterOption><FilterOption id="10411" count="4" label="insulin aspart"></FilterOption><FilterOption id="3488" count="4" label="leflunomide"></FilterOption><FilterOption id="54804" count="4" label="nivolumab"></FilterOption><FilterOption id="21374" count="4" label="pegfilgrastim"></FilterOption><FilterOption id="70667" count="4" label="pembrolizumab"></FilterOption><FilterOption id="52857" count="4" label="rilpivirine hydrochloride"></FilterOption><FilterOption id="4259" count="4" label="saquinavir"></FilterOption><FilterOption id="36332" count="4" label="ticagrelor"></FilterOption><FilterOption id="8165" count="4" label="tiotropium bromide"></FilterOption><FilterOption id="6242" count="3" label="abacavir"></FilterOption><FilterOption id="72699" count="3" label="atezolizumab"></FilterOption><FilterOption id="16915" count="3" label="calcium levofolinate"></FilterOption><FilterOption id="72148" count="3" label="darunavir + cobicistat (fixed dose, HIV infection), Janssen R&amp;D/ Gilead"></FilterOption><FilterOption id="4728" count="3" label="emtricitabine"></FilterOption><FilterOption id="25880" count="3" label="enteric-coated mycophenolate sodium, Novartis"></FilterOption><FilterOption id="11961" count="3" label="erlotinib"></FilterOption><FilterOption id="30682" count="3" label="etravirine"></FilterOption><FilterOption id="3130" count="3" label="filgrastim"></FilterOption><FilterOption id="7286" count="3" label="goserelin acetate"></FilterOption><FilterOption id="59269" count="3" label="insulin degludec"></FilterOption><FilterOption id="17426" count="3" label="insulin detemir"></FilterOption><FilterOption id="36630" count="3" label="ipilimumab"></FilterOption><FilterOption id="5148" count="3" label="liraglutide"></FilterOption><FilterOption id="3616" count="3" label="meropenem"></FilterOption><FilterOption id="3700" count="3" label="nevirapine"></FilterOption><FilterOption id="54488" count="3" label="raltegravir"></FilterOption><FilterOption id="71886" count="3" label="ribavirin (oral tablet, HCV), Roche"></FilterOption><FilterOption id="15183" count="3" label="sertraline"></FilterOption><FilterOption id="44314" count="3" label="tamoxifen"></FilterOption><FilterOption id="2500" count="2" label="amlodipine"></FilterOption><FilterOption id="7867" count="2" label="amprenavir"></FilterOption><FilterOption id="7781" count="2" label="aripiprazole"></FilterOption><FilterOption id="5957" count="2" label="budesonide (inhaled formulations), AstraZeneca"></FilterOption></Filter><Filter label="Trial Category" name="trialCategory" total="17"><FilterOption id="4" count="4417" label="Small molecule"></FilterOption><FilterOption id="3" count="2357" label="Biological"></FilterOption><FilterOption id="8" count="385" label="Medical device"></FilterOption><FilterOption id="9" count="271" label="Medical procedure"></FilterOption><FilterOption id="16" count="171" label="Behavioral intervention"></FilterOption><FilterOption id="5" count="158" label="Vaccine"></FilterOption><FilterOption id="15" count="126" label="Radiation therapy"></FilterOption><FilterOption id="11" count="104" label="Dietary supplement"></FilterOption><FilterOption id="7" count="91" label="Gene therapy"></FilterOption><FilterOption id="6" count="79" label="Cell therapy"></FilterOption><FilterOption id="18" count="58" label="Pathophysiology"></FilterOption><FilterOption id="14" count="44" label="Diagnostic"></FilterOption><FilterOption id="17" count="40" label="Biomarker identification"></FilterOption><FilterOption id="10" count="8" label="Borderline product"></FilterOption><FilterOption id="19" count="7" label="Surgical procedure"></FilterOption><FilterOption id="12" count="4" label="Herbal preparation"></FilterOption><FilterOption id="13" count="2" label="Hospital solutions"></FilterOption></Filter><Filter label="Trial Outcome Available" name="trialOutcomesAvailable" total="2"><FilterOption id="YES" count="3408" label="Yes"></FilterOption><FilterOption id="NO" count="3142" label="No"></FilterOption></Filter><Filter label="Trial Actions Primary Interventions Primary" name="trialActionsPrimaryInterventionsPrimary" total="100"><FilterOption id="67136" count="230" label="Programmed cell death protein 1 inhibitor"></FilterOption><FilterOption id="740" count="224" label="Epidermal growth factor receptor antagonist"></FilterOption><FilterOption id="3848" count="219" label="VEGF-2 receptor antagonist"></FilterOption><FilterOption id="3808" count="193" label="Kit tyrosine kinase inhibitor"></FilterOption><FilterOption id="3846" count="192" label="VEGF-1 receptor antagonist"></FilterOption><FilterOption id="3850" count="176" label="VEGF-3 receptor antagonist"></FilterOption><FilterOption id="14007" count="168" label="Programmed cell death ligand 1 inhibitor"></FilterOption><FilterOption id="3756" count="151" label="Erbb2 tyrosine kinase receptor inhibitor"></FilterOption><FilterOption id="372" count="146" label="Thymidylate synthase inhibitor"></FilterOption><FilterOption id="5085" count="139" label="B-lymphocyte antigen CD20 inhibitor"></FilterOption><FilterOption id="3806" count="131" label="Flt3 tyrosine kinase inhibitor"></FilterOption><FilterOption id="48492" count="128" label="PDGF receptor beta antagonist"></FilterOption><FilterOption id="1722" count="111" label="VEGF receptor antagonist"></FilterOption><FilterOption id="10240" count="109" label="mTOR inhibitor"></FilterOption><FilterOption id="948" count="109" label="PDGF receptor antagonist"></FilterOption><FilterOption id="48489" count="107" label="PDGF receptor alpha antagonist"></FilterOption><FilterOption id="12521" count="105" label="VEGF ligand inhibitor"></FilterOption><FilterOption id="1016" count="102" label="HIV-1 reverse transcriptase inhibitor"></FilterOption><FilterOption id="1832" count="102" label="Nucleoside reverse transcriptase inhibitor"></FilterOption><FilterOption id="3816" count="102" label="RET tyrosine kinase receptor family inhibitor"></FilterOption><FilterOption id="142" count="101" label="Topoisomerase II inhibitor"></FilterOption><FilterOption id="138" count="99" label="DNA polymerase inhibitor"></FilterOption><FilterOption id="3688" count="96" label="FGF3 receptor antagonist"></FilterOption><FilterOption id="204" count="95" label="HIV protease inhibitor"></FilterOption><FilterOption id="3754" count="94" label="EGFR family tyrosine kinase receptor inhibitor"></FilterOption><FilterOption id="3682" count="94" label="FGF1 receptor antagonist"></FilterOption><FilterOption id="3562" count="93" label="Jak1 tyrosine kinase inhibitor"></FilterOption><FilterOption id="3154" count="90" label="CSF-1 antagonist"></FilterOption><FilterOption id="5482" count="88" label="Cytotoxic T-lymphocyte protein-4 inhibitor"></FilterOption><FilterOption id="768" count="86" label="HIV-1 protease inhibitor"></FilterOption><FilterOption id="4548" count="85" label="Raf B protein kinase inhibitor"></FilterOption><FilterOption id="76090" count="82" label="mTOR complex 1 inhibitor"></FilterOption><FilterOption id="120" count="81" label="Factor Xa antagonist"></FilterOption><FilterOption id="38283" count="80" label="Poly ADP ribose polymerase 1 inhibitor"></FilterOption><FilterOption id="38286" count="76" label="Poly ADP ribose polymerase 2 inhibitor"></FilterOption><FilterOption id="7424" count="73" label="Cytochrome P450 3A4 inhibitor"></FilterOption><FilterOption id="3685" count="73" label="FGF2 receptor antagonist"></FilterOption><FilterOption id="385" count="72" label="Protein tyrosine kinase inhibitor"></FilterOption><FilterOption id="214" count="69" label="Interferon alpha 2 ligand"></FilterOption><FilterOption id="4762" count="69" label="MEK-1 protein kinase inhibitor"></FilterOption><FilterOption id="4764" count="68" label="MEK-2 protein kinase inhibitor"></FilterOption><FilterOption id="8805" count="67" label="AMP activated protein kinase stimulator"></FilterOption><FilterOption id="135" count="67" label="DHFR inhibitor"></FilterOption><FilterOption id="7588" count="67" label="HIV-1 integrase inhibitor"></FilterOption><FilterOption id="721" count="66" label="TNF binding agent"></FilterOption><FilterOption id="40" count="65" label="Beta 2 adrenoceptor agonist"></FilterOption><FilterOption id="4917" count="65" label="Proteasome inhibitor"></FilterOption><FilterOption id="141" count="65" label="Topoisomerase I inhibitor"></FilterOption><FilterOption id="374" count="64" label="Transferase inhibitor"></FilterOption><FilterOption id="181" count="63" label="GAR transformylase inhibitor"></FilterOption><FilterOption id="675" count="63" label="Hepatocyte growth factor receptor antagonist"></FilterOption><FilterOption id="1575" count="63" label="Phosphoinositide 3-kinase inhibitor"></FilterOption><FilterOption id="4010" count="62" label="Calcineurin inhibitor"></FilterOption><FilterOption id="76" count="60" label="Aromatase inhibitor"></FilterOption><FilterOption id="2585" count="60" label="Glucagon-like peptide 1 receptor agonist"></FilterOption><FilterOption id="2507" count="60" label="PARP inhibitor"></FilterOption><FilterOption id="12349" count="59" label="Hepatitis C virus NS3 protease inhibitor"></FilterOption><FilterOption id="1833" count="59" label="Non-nucleoside reverse transcriptase inhibitor"></FilterOption><FilterOption id="471" count="57" label="IL-6 receptor antagonist"></FilterOption><FilterOption id="3576" count="56" label="Src tyrosine kinase inhibitor"></FilterOption><FilterOption id="381" count="56" label="TNF alpha ligand inhibitor"></FilterOption><FilterOption id="629" count="55" label="Inosine monophosphate dehydrogenase inhibitor"></FilterOption><FilterOption id="3584" count="55" label="Lck tyrosine kinase inhibitor"></FilterOption><FilterOption id="4314" count="54" label="Cyclin-dependent kinase-4 inhibitor"></FilterOption><FilterOption id="4318" count="54" label="Cyclin-dependent kinase-6 inhibitor"></FilterOption><FilterOption id="13571" count="53" label="Bcr protein inhibitor"></FilterOption><FilterOption id="23014" count="53" label="Insulin ligand"></FilterOption><FilterOption id="400" count="53" label="Insulin receptor agonist"></FilterOption><FilterOption id="38289" count="52" label="Poly ADP ribose polymerase 3 inhibitor"></FilterOption><FilterOption id="168" count="51" label="FGF receptor antagonist"></FilterOption><FilterOption id="286" count="50" label="Estrogen receptor antagonist"></FilterOption><FilterOption id="76469" count="47" label="26S proteasome complex inhibitor"></FilterOption><FilterOption id="3592" count="47" label="Btk tyrosine kinase inhibitor"></FilterOption><FilterOption id="3252" count="47" label="Insulin-like growth factor 1 receptor antagonist"></FilterOption><FilterOption id="60" count="46" label="Androgen receptor antagonist"></FilterOption><FilterOption id="205" count="46" label="HMG CoA reductase inhibitor"></FilterOption><FilterOption id="4550" count="45" label="Raf 1 protein kinase inhibitor"></FilterOption><FilterOption id="1689" count="45" label="VEGF-A ligand inhibitor"></FilterOption><FilterOption id="3834" count="43" label="Tek tyrosine kinase receptor inhibitor"></FilterOption><FilterOption id="3524" count="42" label="Abl tyrosine kinase inhibitor"></FilterOption><FilterOption id="4802" count="42" label="IL-17 antagonist"></FilterOption><FilterOption id="541" count="41" label="Tubulin receptor antagonist"></FilterOption><FilterOption id="3564" count="40" label="Jak2 tyrosine kinase inhibitor"></FilterOption><FilterOption id="3796" count="40" label="MET tyrosine kinase receptor family inhibitor"></FilterOption><FilterOption id="4020" count="40" label="Sodium glucose transporter-2 inhibitor"></FilterOption><FilterOption id="770" count="39" label="Endothelin ET-A receptor antagonist"></FilterOption><FilterOption id="3758" count="39" label="Erbb3 tyrosine kinase receptor inhibitor"></FilterOption><FilterOption id="4760" count="39" label="MEK protein kinase inhibitor"></FilterOption><FilterOption id="259" count="39" label="Muscarinic receptor antagonist"></FilterOption><FilterOption id="585" count="37" label="5-HT 2a receptor antagonist"></FilterOption><FilterOption id="5136" count="37" label="ADP ribosyl cyclase-1 inhibitor"></FilterOption><FilterOption id="778" count="37" label="PDE 5 inhibitor"></FilterOption><FilterOption id="3760" count="36" label="Erbb4 tyrosine kinase receptor inhibitor"></FilterOption><FilterOption id="43842" count="36" label="Hepatitis C virus protein NS5A inhibitor"></FilterOption><FilterOption id="262" count="36" label="Muscarinic M3 receptor antagonist"></FilterOption><FilterOption id="3818" count="36" label="Ret tyrosine kinase receptor inhibitor"></FilterOption><FilterOption id="498" count="36" label="Sodium channel inhibitor"></FilterOption><FilterOption id="150" count="35" label="Dopamine D2 receptor antagonist"></FilterOption><FilterOption id="9748" count="35" label="IL-23 antagonist"></FilterOption><FilterOption id="347" count="35" label="RNA polymerase inhibitor"></FilterOption></Filter><Filter label="Trial Company Collaborator" name="trialCompaniesCollaborator" total="100"><FilterOption id="18767" count="58" label="Pfizer Inc"></FilterOption><FilterOption id="1013295" count="54" label="Astellas Pharma Inc"></FilterOption><FilterOption id="28355" count="54" label="GlaxoSmithKline plc"></FilterOption><FilterOption id="1059823" count="47" label="Merck Sharp &amp; Dohme Corp"></FilterOption><FilterOption id="15065" count="46" label="Bristol-Myers Squibb Co"></FilterOption><FilterOption id="1017818" count="46" label="Instituto de Salud Carlos III"></FilterOption><FilterOption id="19446" count="44" label="Roche Holding AG"></FilterOption><FilterOption id="20300" count="44" label="Takeda Pharmaceutical Co Ltd"></FilterOption><FilterOption id="14190" count="42" label="AstraZeneca plc"></FilterOption><FilterOption id="1009547" count="42" label="Sanofi SA"></FilterOption><FilterOption id="19214" count="39" label="Regeneron Pharmaceuticals Inc"></FilterOption><FilterOption id="17810" count="34" label="Eli Lilly &amp; Co"></FilterOption><FilterOption id="23137" count="32" label="Novartis AG"></FilterOption><FilterOption id="18681" count="30" label="Ono Pharmaceutical Co Ltd"></FilterOption><FilterOption id="19453" count="29" label="Genentech Inc"></FilterOption><FilterOption id="14455" count="27" label="Bayer AG"></FilterOption><FilterOption id="1067538" count="27" label="Janssen Research &amp; Development LLC"></FilterOption><FilterOption id="15331" count="25" label="Celgene Corp"></FilterOption><FilterOption id="1039423" count="25" label="Hospital Clinic of Barcelona"></FilterOption><FilterOption id="1003065" count="25" label="Hospital Vall D'Hebron"></FilterOption><FilterOption id="20519" count="23" label="National Cancer Institute"></FilterOption><FilterOption id="14109" count="20" label="Amgen Inc"></FilterOption><FilterOption id="1101929" count="20" label="IQVIA Holdings Inc"></FilterOption><FilterOption id="1039086" count="19" label="Germans Trias i Pujol Hospital"></FilterOption><FilterOption id="20452" count="18" label="UCB SA"></FilterOption><FilterOption id="1072507" count="17" label="AbbVie Inc"></FilterOption><FilterOption id="1059977" count="17" label="European Commission"></FilterOption><FilterOption id="1039087" count="17" label="Fundacio Lluita Contra La Sida"></FilterOption><FilterOption id="18101" count="17" label="Merck KGaA"></FilterOption><FilterOption id="1065900" count="16" label="Apices Soluciones, S.L."></FilterOption><FilterOption id="1040940" count="16" label="Hospital Universitari de Bellvitge"></FilterOption><FilterOption id="1033116" count="16" label="PAREXEL International"></FilterOption><FilterOption id="26178" count="15" label="F Hoffmann-La Roche AG"></FilterOption><FilterOption id="1055006" count="15" label="Ministry of Health, Spain"></FilterOption><FilterOption id="18440" count="15" label="Myriad Genetics Inc"></FilterOption><FilterOption id="1068433" count="15" label="Spanish Clinical Research Network"></FilterOption><FilterOption id="1079783" count="14" label="FUNDACIÓ INSTITUT DE RECERCA DE L'HOSPITAL DE LA SANTA CREU I SANT PAU"></FilterOption><FilterOption id="1116693" count="14" label="Productos Roche, S.A. de C.V."></FilterOption><FilterOption id="1042255" count="13" label="Breast International Group"></FilterOption><FilterOption id="19620" count="13" label="Eisai Inc"></FilterOption><FilterOption id="18077" count="13" label="Merck &amp; Co Inc"></FilterOption><FilterOption id="25554" count="13" label="Seattle Genetics Inc"></FilterOption><FilterOption id="1056444" count="12" label="Foundation Medicine Inc"></FilterOption><FilterOption id="1067340" count="12" label="Pivotal SL"></FilterOption><FilterOption id="13601" count="11" label="Abbott Laboratories"></FilterOption><FilterOption id="14881" count="10" label="Boehringer Ingelheim International GmbH"></FilterOption><FilterOption id="1084506" count="10" label="European Network of Gynaecological Oncological Trial Groups"></FilterOption><FilterOption id="23119" count="10" label="European Organisation for Research and Treatment of Cancer (EORTC)"></FilterOption><FilterOption id="27741" count="10" label="Galapagos NV"></FilterOption><FilterOption id="1041702" count="10" label="Gynecologic Oncology Group"></FilterOption><FilterOption id="17216" count="10" label="Incyte Corp"></FilterOption><FilterOption id="1017771" count="10" label="Institut d'Investigacions Biomediques August Pi I Sunyer"></FilterOption><FilterOption id="17332" count="10" label="Johnson &amp; Johnson"></FilterOption><FilterOption id="29481" count="10" label="Johnson &amp; Johnson Pharmaceutical Research &amp; Development LLC"></FilterOption><FilterOption id="1144568" count="10" label="Novartis Pharma Services AG"></FilterOption><FilterOption id="1033989" count="10" label="Pharmaceutical Product Development LLC"></FilterOption><FilterOption id="19063" count="10" label="Pharmacyclics Inc"></FilterOption><FilterOption id="1100315" count="10" label="PRA Health Sciences"></FilterOption><FilterOption id="1063946" count="10" label="Syneos Health Inc"></FilterOption><FilterOption id="19864" count="9" label="Adir &amp; Co"></FilterOption><FilterOption id="1005244" count="9" label="Biogen Inc"></FilterOption><FilterOption id="22676" count="9" label="Exelixis Inc"></FilterOption><FilterOption id="1073758" count="9" label="Fondo de Investigacion Sanitaria"></FilterOption><FilterOption id="20518" count="9" label="National Institutes of Health"></FilterOption><FilterOption id="24652" count="9" label="Shire plc"></FilterOption><FilterOption id="1061163" count="8" label="Abbott Vascular"></FilterOption><FilterOption id="25902" count="8" label="Array BioPharma Inc"></FilterOption><FilterOption id="29469" count="8" label="Cancer Research UK"></FilterOption><FilterOption id="15414" count="8" label="Chugai Pharmaceutical Co Ltd"></FilterOption><FilterOption id="1104124" count="8" label="GlaxoSmithKline LLC"></FilterOption><FilterOption id="1036091" count="8" label="National Institute of Neurological Disorders and Stroke"></FilterOption><FilterOption id="19863" count="8" label="Servier"></FilterOption><FilterOption id="20348" count="8" label="Teva Pharmaceutical Industries Ltd"></FilterOption><FilterOption id="21082" count="8" label="Walter and Eliza Hall Institute of Medical Research"></FilterOption><FilterOption id="1097931" count="7" label="Andalusian Initiative for Advanced Therapies"></FilterOption><FilterOption id="1018807" count="7" label="Covance Inc"></FilterOption><FilterOption id="1017506" count="7" label="Daiichi Sankyo Co Ltd"></FilterOption><FilterOption id="16450" count="7" label="Gilead Sciences Inc"></FilterOption><FilterOption id="1079458" count="7" label="Hospital de Sant Pau"></FilterOption><FilterOption id="17416" count="7" label="Janssen LP"></FilterOption><FilterOption id="1014884" count="7" label="Medivation Inc"></FilterOption><FilterOption id="1077534" count="7" label="Sociedad Española de Neumología y Cirugía Torácica"></FilterOption><FilterOption id="1125317" count="6" label="ADIR Association"></FilterOption><FilterOption id="1053612" count="6" label="Fundacion Clinic per a la Recerca Biomédica"></FilterOption><FilterOption id="17900" count="6" label="H Lundbeck A/S"></FilterOption><FilterOption id="1056709" count="6" label="ICON Clinical Research"></FilterOption><FilterOption id="1068275" count="6" label="Innovative Medicines Initiative"></FilterOption><FilterOption id="21404" count="6" label="MorphoSys AG"></FilterOption><FilterOption id="20520" count="6" label="National Institute of Allergy and Infectious Diseases"></FilterOption><FilterOption id="1053488" count="6" label="NCIC Clinical Trials Group"></FilterOption><FilterOption id="26414" count="5" label="Elan Pharmaceuticals Inc"></FilterOption><FilterOption id="16198" count="5" label="Forest Laboratories Inc"></FilterOption><FilterOption id="1006639" count="5" label="Hospital Universitario Ramon y Cajal"></FilterOption><FilterOption id="1072647" count="5" label="Institut de Recherches Internationales Servier (France)"></FilterOption><FilterOption id="1056690" count="5" label="Institut Investigació Biomèdica Bellvitge"></FilterOption><FilterOption id="1097361" count="5" label="Medtronic plc"></FilterOption><FilterOption id="1074428" count="5" label="Ministerio de Economia y Competitividad"></FilterOption><FilterOption id="1117605" count="4" label="Adknoma Health Research"></FilterOption><FilterOption id="22586" count="4" label="Boehringer Ingelheim Corp"></FilterOption><FilterOption id="1045739" count="4" label="Chiltern International Inc."></FilterOption></Filter><Filter label="Trial Actions Secondary Interventions Control" name="trialActionsSecondaryInterventionsControl" total="100"><FilterOption id="1545" count="754" label="Anticancer"></FilterOption><FilterOption id="2953" count="281" label="Anti-inflammatory"></FilterOption><FilterOption id="767" count="270" label="Cell cycle inhibitor"></FilterOption><FilterOption id="991" count="220" label="Antiviral"></FilterOption><FilterOption id="55685" count="208" label="Anticancer monoclonal antibody"></FilterOption><FilterOption id="140" count="206" label="DNA synthesis inhibitor"></FilterOption><FilterOption id="1569" count="193" label="Anticancer antimetabolite"></FilterOption><FilterOption id="50" count="172" label="Anticancer alkylating agent"></FilterOption><FilterOption id="62255" count="170" label="Anticancer protein kinase inhibitor"></FilterOption><FilterOption id="61" count="125" label="Angiogenesis inhibitor"></FilterOption><FilterOption id="1589" count="124" label="Apoptosis stimulator"></FilterOption><FilterOption id="2576" count="124" label="Microtubule stabilizer"></FilterOption><FilterOption id="2575" count="112" label="Microtubule inhibitor"></FilterOption><FilterOption id="2660" count="110" label="Vasoprotectant"></FilterOption><FilterOption id="399" count="88" label="Hypoglycemic agent"></FilterOption><FilterOption id="7293" count="79" label="Synergist"></FilterOption><FilterOption id="396" count="70" label="Immunosuppressant"></FilterOption><FilterOption id="2946" count="65" label="Analgesic"></FilterOption><FilterOption id="1594" count="59" label="Antibacterial"></FilterOption><FilterOption id="1596" count="55" label="Immunomodulator"></FilterOption><FilterOption id="15184" count="52" label="Systemic antipsoriatic product"></FilterOption><FilterOption id="646" count="48" label="Bronchodilator"></FilterOption><FilterOption id="2657" count="47" label="Antihypertensive"></FilterOption><FilterOption id="805" count="47" label="Folate modulator"></FilterOption><FilterOption id="659" count="45" label="Coagulation inhibitor"></FilterOption><FilterOption id="747" count="42" label="HIV replication inhibitor"></FilterOption><FilterOption id="104" count="40" label="Bacterial cell wall synthesis inhibitor"></FilterOption><FilterOption id="393" count="38" label="Immunostimulant"></FilterOption><FilterOption id="15187" count="38" label="Systemic dermatological antibacterial product"></FilterOption><FilterOption id="7761" count="38" label="T-lymphocyte stimulator"></FilterOption><FilterOption id="38206" count="37" label="Biguanide antidiabetic product"></FilterOption><FilterOption id="750" count="32" label="DNA intercalator"></FilterOption><FilterOption id="2659" count="29" label="Cardioprotectant"></FilterOption><FilterOption id="610" count="27" label="Hematopoietic stimulator"></FilterOption><FilterOption id="38215" count="25" label="Human insulin long acting product"></FilterOption><FilterOption id="1615" count="25" label="Neuroprotectant"></FilterOption><FilterOption id="62254" count="24" label="Anticancer hormone antagonist"></FilterOption><FilterOption id="2941" count="24" label="Antidepressant"></FilterOption><FilterOption id="312" count="24" label="Platelet aggregation inhibitor"></FilterOption><FilterOption id="2954" count="24" label="Steroidal anti-inflammatory"></FilterOption><FilterOption id="7760" count="24" label="T-lymphocyte inhibitor"></FilterOption><FilterOption id="70" count="23" label="Anticonvulsant agent"></FilterOption><FilterOption id="3189" count="22" label="Corticosteroid agonist"></FilterOption><FilterOption id="38211" count="22" label="Human insulin fast acting product"></FilterOption><FilterOption id="382" count="21" label="TNF alpha synthesis inhibitor"></FilterOption><FilterOption id="2667" count="20" label="Antiarteriosclerotic"></FilterOption><FilterOption id="12378" count="19" label="Prophylactic vaccine"></FilterOption><FilterOption id="71" count="18" label="Antihypercholesterolemic agent"></FilterOption><FilterOption id="15148" count="18" label="Ocular antineovascularisation agent"></FilterOption><FilterOption id="3" count="17" label="5-HT uptake inhibitor"></FilterOption><FilterOption id="1479" count="17" label="RNA synthesis modulator"></FilterOption><FilterOption id="664" count="16" label="Fibrosuppressant"></FilterOption><FilterOption id="285" count="16" label="Norepinephrine uptake inhibitor"></FilterOption><FilterOption id="2943" count="15" label="Antipsychotic"></FilterOption><FilterOption id="2942" count="15" label="Anxiolytic"></FilterOption><FilterOption id="1535" count="15" label="Beta lactam antibiotic"></FilterOption><FilterOption id="73547" count="15" label="Carbapenem"></FilterOption><FilterOption id="388" count="15" label="Vasodilator"></FilterOption><FilterOption id="72" count="14" label="Antihyperlipidemic agent"></FilterOption><FilterOption id="2947" count="14" label="Antiparkinsonian"></FilterOption><FilterOption id="1538" count="14" label="Bacterial protein synthesis inhibitor"></FilterOption><FilterOption id="89" count="14" label="Bone resorption inhibitor"></FilterOption><FilterOption id="1532" count="14" label="Viral replication inhibitor"></FilterOption><FilterOption id="2970" count="13" label="Anti-emetic"></FilterOption><FilterOption id="32411" count="13" label="Hepatitis B virus replication inhibitor"></FilterOption><FilterOption id="439" count="13" label="RNA synthesis inhibitor"></FilterOption><FilterOption id="3984" count="12" label="Bacterial nucleic acid synthesis inhibitor"></FilterOption><FilterOption id="1129" count="12" label="Non-steroid hormone receptor antagonist"></FilterOption><FilterOption id="463" count="12" label="Ribosome binding agent"></FilterOption><FilterOption id="38205" count="12" label="Sulphonylurea antidiabetic product"></FilterOption><FilterOption id="937" count="11" label="Androgen synthesis inhibitor"></FilterOption><FilterOption id="3246" count="11" label="Insulin release stimulator"></FilterOption><FilterOption id="284" count="11" label="Nootropic agent"></FilterOption><FilterOption id="12596" count="11" label="Osteoclast inhibitor"></FilterOption><FilterOption id="1748" count="10" label="Fungicide"></FilterOption><FilterOption id="62253" count="9" label="Anticancer hormone"></FilterOption><FilterOption id="15128" count="9" label="Ophthalmological agent"></FilterOption><FilterOption id="1537" count="7" label="Cephalosporin"></FilterOption><FilterOption id="968" count="7" label="Coagulation stimulator"></FilterOption><FilterOption id="38439" count="7" label="DPP IV inhibitor antidiabetic product"></FilterOption><FilterOption id="3272" count="7" label="Growth hormone release inhibitor"></FilterOption><FilterOption id="12367" count="7" label="Inactivated viral vaccine"></FilterOption><FilterOption id="614" count="7" label="Lipid uptake inhibitor"></FilterOption><FilterOption id="12371" count="7" label="Subunit vaccine"></FilterOption><FilterOption id="59620" count="7" label="Unspecified drug target"></FilterOption><FilterOption id="449" count="6" label="Antiarrhythmic agent"></FilterOption><FilterOption id="695" count="6" label="Metastasis inhibitor"></FilterOption><FilterOption id="563" count="6" label="Microtubule modulator"></FilterOption><FilterOption id="2955" count="6" label="Non-steroidal anti-inflammatory"></FilterOption><FilterOption id="882" count="5" label="5-HETE modulator"></FilterOption><FilterOption id="4007" count="5" label="Antidiarrhoeal"></FilterOption><FilterOption id="7018" count="5" label="Antihypertriglyceridemic agent"></FilterOption><FilterOption id="5704" count="5" label="B-lymphocyte adhesion inhibitor"></FilterOption><FilterOption id="5710" count="5" label="B-lymphocyte migration inhibitor"></FilterOption><FilterOption id="5580" count="5" label="Chemotaxis inhibitor"></FilterOption><FilterOption id="871" count="5" label="GABA modulator"></FilterOption><FilterOption id="3313" count="5" label="Glucagon-like peptide 1 metabolism modulator"></FilterOption><FilterOption id="38212" count="5" label="Human insulin intermediate acting product"></FilterOption><FilterOption id="12364" count="5" label="Live attenuated viral vaccine"></FilterOption><FilterOption id="1470" count="5" label="Respiratory system agent"></FilterOption></Filter><Filter label="Biomarker Type" name="trialBiomarkerTypes" total="7"><FilterOption id="37" count="3292" label="Proteomic"></FilterOption><FilterOption id="38" count="3206" label="Genomic"></FilterOption><FilterOption id="31" count="1801" label="Physiological"></FilterOption><FilterOption id="32" count="1555" label="Biochemical"></FilterOption><FilterOption id="75" count="1157" label="Cellular"></FilterOption><FilterOption id="39" count="712" label="Anthropomorphic"></FilterOption><FilterOption id="40" count="678" label="Structural (imaging)"></FilterOption></Filter><Filter label="Biomarker Role" name="trialBiomarkerRoles" total="4"><FilterOption id="695863716" count="3561" label="Therapeutic effect marker"></FilterOption><FilterOption id="1571666123" count="1592" label="Disease marker"></FilterOption><FilterOption id="730490367" count="1243" label="Toxic effect marker"></FilterOption><FilterOption id="3242045531" count="25" label="Not determined"></FilterOption></Filter><Filter label="Interventions" name="trialInterventions" total="100"><FilterOption id="3803" count="168" label="paclitaxel"></FilterOption><FilterOption id="44383" count="149" label="carboplatin"></FilterOption><FilterOption id="3199" count="115" label="gemcitabine"></FilterOption><FilterOption id="2953" count="109" label="docetaxel"></FilterOption><FilterOption id="8047" count="104" label="bevacizumab"></FilterOption><FilterOption id="54804" count="100" label="nivolumab"></FilterOption><FilterOption id="72699" count="93" label="atezolizumab"></FilterOption><FilterOption id="6736" count="86" label="rituximab"></FilterOption><FilterOption id="12205" count="78" label="capecitabine"></FilterOption><FilterOption id="70667" count="77" label="pembrolizumab"></FilterOption><FilterOption id="3792" count="73" label="oxaliplatin"></FilterOption><FilterOption id="6386" count="73" label="trastuzumab"></FilterOption><FilterOption id="7310" count="67" label="ritonavir"></FilterOption><FilterOption id="5369" count="65" label="ribavirin"></FilterOption><FilterOption id="3536" count="63" label="pemetrexed disodium"></FilterOption><FilterOption id="36630" count="62" label="ipilimumab"></FilterOption><FilterOption id="6050" count="62" label="metformin hydrochloride"></FilterOption><FilterOption id="13340" count="58" label="everolimus"></FilterOption><FilterOption id="23625" count="57" label="peginterferon alfa-2a"></FilterOption><FilterOption id="27572" count="52" label="lenalidomide"></FilterOption><FilterOption id="81193" count="48" label="durvalumab"></FilterOption><FilterOption id="15954" count="47" label="bortezomib"></FilterOption><FilterOption id="3072" count="46" label="etoposide phosphate"></FilterOption><FilterOption id="11961" count="45" label="erlotinib"></FilterOption><FilterOption id="29016" count="45" label="paclitaxel (albumin-bound nanoparticle, intravenous), Celgene"></FilterOption><FilterOption id="2871" count="42" label="irinotecan"></FilterOption><FilterOption id="16063" count="42" label="olaparib"></FilterOption><FilterOption id="2784" count="38" label="letrozole"></FilterOption><FilterOption id="12973" count="37" label="sunitinib"></FilterOption><FilterOption id="10388" count="36" label="cetuximab"></FilterOption><FilterOption id="3313" count="36" label="fulvestrant"></FilterOption><FilterOption id="14163" count="35" label="adalimumab"></FilterOption><FilterOption id="14681" count="35" label="lopinavir + ritonavir"></FilterOption><FilterOption id="28532" count="33" label="pertuzumab"></FilterOption><FilterOption id="4510" count="33" label="tacrolimus"></FilterOption><FilterOption id="54488" count="32" label="raltegravir"></FilterOption><FilterOption id="55275" count="31" label="secukinumab"></FilterOption><FilterOption id="32981" count="30" label="darunavir"></FilterOption><FilterOption id="55237" count="30" label="ibrutinib"></FilterOption><FilterOption id="3669" count="30" label="mycophenolate mofetil"></FilterOption><FilterOption id="32677" count="30" label="rivaroxaban"></FilterOption><FilterOption id="47000" count="29" label="bendamustine"></FilterOption><FilterOption id="53227" count="28" label="obinutuzumab"></FilterOption><FilterOption id="10309" count="27" label="abiraterone"></FilterOption><FilterOption id="4529" count="27" label="temozolomide"></FilterOption><FilterOption id="6259" count="27" label="tocilizumab (intravenous), Roche/Chugai"></FilterOption><FilterOption id="53200" count="26" label="daratumumab"></FilterOption><FilterOption id="53981" count="26" label="enzalutamide"></FilterOption><FilterOption id="6156" count="25" label="fludarabine"></FilterOption><FilterOption id="61901" count="24" label="buparlisib"></FilterOption><FilterOption id="3081" count="24" label="exemestane"></FilterOption><FilterOption id="14493" count="24" label="tenofovir disoproxil fumarate"></FilterOption><FilterOption id="33591" count="23" label="lapatinib"></FilterOption><FilterOption id="51160" count="23" label="nintedanib"></FilterOption><FilterOption id="96193" count="23" label="spartalizumab"></FilterOption><FilterOption id="74726" count="23" label="upadacitinib"></FilterOption><FilterOption id="2807" count="22" label="atorvastatin"></FilterOption><FilterOption id="3474" count="22" label="lamivudine"></FilterOption><FilterOption id="15254" count="21" label="atazanavir"></FilterOption><FilterOption id="56544" count="21" label="cobimetinib"></FilterOption><FilterOption id="43738" count="21" label="pazopanib"></FilterOption><FilterOption id="49219" count="21" label="tenofovir disoproxil fumarate + emtricitabine (fixed dose), Gilead Sciences"></FilterOption><FilterOption id="45499" count="21" label="tofacitinib citrate (oral, inflammation), Pfizer"></FilterOption><FilterOption id="37370" count="20" label="azacitidine"></FilterOption><FilterOption id="2836" count="20" label="clopidogrel"></FilterOption><FilterOption id="24343" count="20" label="dabigatran etexilate"></FilterOption><FilterOption id="59062" count="20" label="dolutegravir"></FilterOption><FilterOption id="7934" count="20" label="doxorubicin (liposomal, STEALTH), Alza"></FilterOption><FilterOption id="13022" count="20" label="epirubicin"></FilterOption><FilterOption id="37613" count="20" label="maraviroc"></FilterOption><FilterOption id="12646" count="20" label="panitumumab"></FilterOption><FilterOption id="27696" count="20" label="pomalidomide"></FilterOption><FilterOption id="71886" count="20" label="ribavirin (oral tablet, HCV), Roche"></FilterOption><FilterOption id="29831" count="20" label="sorafenib"></FilterOption><FilterOption id="55288" count="20" label="trametinib"></FilterOption><FilterOption id="6408" count="20" label="vinorelbine"></FilterOption><FilterOption id="52967" count="19" label="apixaban"></FilterOption><FilterOption id="10271" count="19" label="palbociclib"></FilterOption><FilterOption id="36669" count="19" label="trastuzumab emtansine"></FilterOption><FilterOption id="45562" count="19" label="tremelimumab"></FilterOption><FilterOption id="10172" count="18" label="efavirenz"></FilterOption><FilterOption id="65360" count="18" label="ribociclib"></FilterOption><FilterOption id="54449" count="17" label="afatinib"></FilterOption><FilterOption id="83065" count="17" label="avelumab"></FilterOption><FilterOption id="55305" count="17" label="binimetinib"></FilterOption><FilterOption id="58741" count="17" label="daclatasvir"></FilterOption><FilterOption id="4567" count="17" label="etanercept"></FilterOption><FilterOption id="45841" count="17" label="lenvatinib mesylate"></FilterOption><FilterOption id="35644" count="17" label="methoxy polyethylene glycol-epoetin beta"></FilterOption><FilterOption id="83873" count="17" label="osimertinib"></FilterOption><FilterOption id="4200" count="17" label="sirolimus"></FilterOption><FilterOption id="11141" count="16" label="basiliximab"></FilterOption><FilterOption id="53133" count="16" label="dabrafenib"></FilterOption><FilterOption id="65240" count="16" label="evolocumab"></FilterOption><FilterOption id="17814" count="16" label="pregabalin"></FilterOption><FilterOption id="22395" count="16" label="ranibizumab"></FilterOption><FilterOption id="6242" count="15" label="abacavir"></FilterOption><FilterOption id="5907" count="15" label="duloxetine"></FilterOption><FilterOption id="28773" count="15" label="eribulin mesylate"></FilterOption><FilterOption id="48181" count="15" label="lamivudine + abacavir, GlaxoSmithKline"></FilterOption></Filter><Filter label="Endpoint Index Primary" name="trialEndpointIndexPrimary" total="100"><FilterOption id="15293" count="123" label="Solid tumor - Assessment of Safety and Tolerability - Assessment of dose limiting toxicity"></FilterOption><FilterOption id="8489" count="116" label="Lung tumor - Assessment of Progression Free Survival (PFS)"></FilterOption><FilterOption id="15287" count="112" label="Solid tumor - Assessment of adverse events"></FilterOption><FilterOption id="9153" count="109" label="Lung tumor - Imaging/Radiological Assessments - Assessment by Response Evaluation Criteria in Solid Tumors (RECIST) Criteria"></FilterOption><FilterOption id="8713" count="104" label="Breast tumor - Assessment of Progression Free Survival (PFS)"></FilterOption><FilterOption id="3736" count="88" label="Hepatitis C virus infection - Assessment of Sustained Virologic Response (SVR)"></FilterOption><FilterOption id="1359" count="84" label="Non-insulin dependent diabetes - Assessment of Hemoglobin A1c (HbA1c) Levels - Change in HbA1c"></FilterOption><FilterOption id="9213" count="83" label="HIV infection - Assessment of Viral Load - Assessment of HIV RNA levels"></FilterOption><FilterOption id="6863" count="81" label="Hepatitis C virus infection - Assessment of Viral Load/Viral Kinetics"></FilterOption><FilterOption id="9155" count="79" label="Lung tumor - Assessment of Safety and Tolerability - Assessment of dose limiting toxicity"></FilterOption><FilterOption id="8481" count="77" label="Lung tumor - Assessment of Overall Survival (OS)"></FilterOption><FilterOption id="8505" count="70" label="Lung tumor - Assessment of Objective Response - Assessment of objective response rate(ORR)"></FilterOption><FilterOption id="15285" count="70" label="Solid tumor - Assessment of Safety and Tolerability"></FilterOption><FilterOption id="9008" count="67" label="Breast tumor - Assessment of Safety and Tolerability - Assessment of dose limiting toxicity"></FilterOption><FilterOption id="8719" count="66" label="Breast tumor - Assessment of Response Rates (RR) - Assessment of Overall/Objective Response Rate (ORR)"></FilterOption><FilterOption id="8998" count="64" label="Breast tumor - Assessment of adverse events"></FilterOption><FilterOption id="8523" count="57" label="Lung tumor - Assessment of Disease Progression"></FilterOption><FilterOption id="2622" count="56" label="Coronary artery disease - Assessment of Mortality/Death Rates - Cardiovascular mortality"></FilterOption><FilterOption id="8513" count="56" label="Lung tumor - Assessment of Response Rates (RR) - Assessment of Partial Response (PR)"></FilterOption><FilterOption id="15212" count="56" label="Solid tumor - Assessment of Response Rates (RR) - Assessment of objective response rate (ORR)"></FilterOption><FilterOption id="8514" count="55" label="Lung tumor - Assessment of Response Rates (RR) - Assessment of Complete Response"></FilterOption><FilterOption id="7547" count="55" label="Lymphoma - Assessment of Progression Free Survival (PFS)"></FilterOption><FilterOption id="15312" count="55" label="Solid tumor - Assessment of Pharmacokinetic/Pharmacodynamic Parameters"></FilterOption><FilterOption id="8436" count="53" label="Colorectal tumor - Assessment of Safety and Tolerability - Assessment of dose limiting toxicity"></FilterOption><FilterOption id="7569" count="53" label="Lymphoma - Assessment of Response Rates (RR) - Assessment of Overall/Objective Response Rate (ORR)"></FilterOption><FilterOption id="10830" count="53" label="Ovary tumor - Assessment of Progression Free Survival (PFS)"></FilterOption><FilterOption id="8721" count="52" label="Breast tumor - Assessment of Response Rates (RR) - Assessment of Complete Response"></FilterOption><FilterOption id="9247" count="50" label="HIV infection - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events"></FilterOption><FilterOption id="8163" count="45" label="Colorectal tumor - Assessment of Progression Free Survival (PFS)"></FilterOption><FilterOption id="7563" count="44" label="Lymphoma - Assessment of Response Rates (RR) - Assessment of Complete Response"></FilterOption><FilterOption id="7704" count="43" label="Lymphoma - Assessment of Safety and Tolerability - Assessment of dose limiting toxicity"></FilterOption><FilterOption id="15286" count="43" label="Solid tumor - Assessment of Safety and Tolerability - Assessment of serious adverse events"></FilterOption><FilterOption id="7680" count="42" label="Lymphoma - Assessment of adverse events"></FilterOption><FilterOption id="7908" count="41" label="Leukemia - Assessment of Response Rates (RR) - Assessment of Complete Response"></FilterOption><FilterOption id="7360" count="40" label="Multiple myeloma - Assessment of Progression Free Survival (PFS)"></FilterOption><FilterOption id="8639" count="39" label="Lung tumor - Assessment of Safety and Tolerability"></FilterOption><FilterOption id="8720" count="38" label="Breast tumor - Assessment of Response Rates (RR) - Assessment of Partial Response (PR)"></FilterOption><FilterOption id="8187" count="38" label="Colorectal tumor - Assessment of Response Rates (RR) - Assessment of Objective/Overall Response Rate (ORR)"></FilterOption><FilterOption id="8670" count="38" label="Lung tumor - Assessment of Pharmacokinetic/Pharmacodynamic Parameters - Assessment of maximum tolerated dose (MTD)"></FilterOption><FilterOption id="8744" count="37" label="Breast tumor - Assessment of Disease Progression"></FilterOption><FilterOption id="8430" count="37" label="Colorectal tumor - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events"></FilterOption><FilterOption id="15309" count="37" label="Solid tumor - Assessment of Laboratory/Diagnostic Measures"></FilterOption><FilterOption id="8640" count="36" label="Lung tumor - Assessment of Safety and Tolerability - Adverse events as graded by CTCAE/CTC"></FilterOption><FilterOption id="8996" count="35" label="Breast tumor - Assessment of Safety and Tolerability"></FilterOption><FilterOption id="7049" count="35" label="Prostate tumor - Assessment of Progression Free Survival (PFS)"></FilterOption><FilterOption id="10545" count="35" label="Renal cell carcinoma - Assessment of Progression Free Survival (PFS)"></FilterOption><FilterOption id="2492" count="34" label="Coronary artery disease - Assessment of Cardiovascular Events - Acute/New Myocardial infarction (MI)/MI (Q-wave and non-Q wave)"></FilterOption><FilterOption id="7367" count="34" label="Multiple myeloma - Assessment of Response Rates (RR) - Assessment of Overall/Objective Response Rate (ORR)"></FilterOption><FilterOption id="17220" count="33" label="Anemia - Hematological Assessments - Assessment of hemoglobin status"></FilterOption><FilterOption id="26827" count="32" label="Solid tumor - Imaging/Radiological Assessments - Assessment by Response Evaluation Criteria in Solid Tumors (RECIST) Criteria"></FilterOption><FilterOption id="8714" count="31" label="Breast tumor - Assessment of Disease Free Survival (DFS)"></FilterOption><FilterOption id="22595" count="31" label="End stage renal disease - Assessment of adverse events"></FilterOption><FilterOption id="22545" count="31" label="End stage renal disease - Hematological Assessments - Assessment of hemoglobin levels"></FilterOption><FilterOption id="1358" count="31" label="Non-insulin dependent diabetes - Assessment of Hemoglobin A1c (HbA1c) Levels"></FilterOption><FilterOption id="9122" count="30" label="Breast tumor - Assessment of Pharmacokinetic/Pharmacodynamic Parameters"></FilterOption><FilterOption id="2" count="30" label="Hypertension - Assessment of Blood Pressure (BP) - BP control rate"></FilterOption><FilterOption id="8140" count="30" label="Leukemia - Protocol Specified Other Endpoints - Assessment of Clinical Efficacy"></FilterOption><FilterOption id="8555" count="30" label="Lung tumor - Assessment of Mortality/Death Rates"></FilterOption><FilterOption id="7045" count="30" label="Prostate tumor - Assessment of Overall Survival (OS)"></FilterOption><FilterOption id="10243" count="30" label="Thrombosis - Assessment of Thrombotic/Thromboembolic Events - Assessment of venous thrombosis/thromboembolism"></FilterOption><FilterOption id="2292" count="29" label="Alzheimers disease - Cognitive, Global and Functional Assessments - Alzheimer's disease assessment scale - cognition (ADAS-cog)"></FilterOption><FilterOption id="9212" count="29" label="HIV infection - Assessment of Viral Load"></FilterOption><FilterOption id="7879" count="29" label="Leukemia - Assessment of Overall Survival (OS)"></FilterOption><FilterOption id="8078" count="29" label="Leukemia - Assessment of adverse events"></FilterOption><FilterOption id="7891" count="28" label="Leukemia - Assessment of Progression Free Survival (PFS)"></FilterOption><FilterOption id="7564" count="28" label="Lymphoma - Assessment of Response Rates (RR) - Assessment of Partial Response (PR)"></FilterOption><FilterOption id="6940" count="28" label="Melanoma - Assessment of Response Rates (RR) - Assessment of overall/objective response rate"></FilterOption><FilterOption id="26033" count="28" label="Pain - Assessment of adverse events"></FilterOption><FilterOption id="24177" count="28" label="Stroke - Assessment of Mortality/Death Rates"></FilterOption><FilterOption id="7026" count="27" label="Melanoma - Assessment of Safety and Tolerability - Assessment of toxicity profile"></FilterOption><FilterOption id="37159" count="26" label="Breast tumor - Assessment of Laboratory/Diagnostic Measures"></FilterOption><FilterOption id="2619" count="26" label="Coronary artery disease - Assessment of Cardiovascular Events - Assessment of major adverse cardiac events (MACEs)"></FilterOption><FilterOption id="8641" count="26" label="Lung tumor - Assessment of Safety and Tolerability - Assessment of frequency and severity of adverse events"></FilterOption><FilterOption id="8997" count="25" label="Breast tumor - Assessment of Safety and Tolerability - Assessment of serious adverse events"></FilterOption><FilterOption id="9218" count="25" label="HIV infection - Assessment of Immune Response"></FilterOption><FilterOption id="8556" count="25" label="Lung tumor - Assessment of Mortality/Death Rates - Assessment of all cause mortality"></FilterOption><FilterOption id="7027" count="25" label="Melanoma - Assessment of adverse events"></FilterOption><FilterOption id="10895" count="25" label="Ovary tumor - Imaging/Radiological Assessments - Assessment by Response Evaluation Criteria in Solid Tumors (RECIST) Criteria"></FilterOption><FilterOption id="3883" count="25" label="Rheumatoid arthritis - American College of Rheumatology (ACR) 20 Response"></FilterOption><FilterOption id="15907" count="25" label="Ulcerative colitis - Ulcerative Colitis Assessed by Activity Indices - Assessment by Mayo clinic score (MCS)/ disease activity index (DAI)"></FilterOption><FilterOption id="2286" count="24" label="Alzheimers disease - Assessment of Adverse Events"></FilterOption><FilterOption id="2515" count="24" label="Coronary artery disease - Assessment of Thrombotic/Thromboembolic Events - Fatal /Non-fatal stroke"></FilterOption><FilterOption id="7312" count="24" label="Head and neck tumor - Assessment of adverse events"></FilterOption><FilterOption id="7909" count="24" label="Leukemia - Assessment of Response Rates (RR) - Assessment of Overall/Objective Response Rate (ORR)"></FilterOption><FilterOption id="8090" count="24" label="Leukemia - Assessment of Safety and Tolerability - Assessment of dose limiting toxicity"></FilterOption><FilterOption id="6972" count="24" label="Melanoma - Imaging/Radiological Assessments - Assessment by Response Evaluation Criteria in Solid Tumors (RECIST) Criteria"></FilterOption><FilterOption id="15215" count="24" label="Solid tumor - Assessment of Response Rates (RR) - Assessment of Complete Response"></FilterOption><FilterOption id="15214" count="24" label="Solid tumor - Assessment of Response Rates (RR) - Assessment of Partial Response (PR)"></FilterOption><FilterOption id="10247" count="24" label="Thrombosis - Assessment of Thrombotic/Thromboembolic Events - Assessment of pulmonary embolism(PE)"></FilterOption><FilterOption id="7313" count="23" label="Head and neck tumor - Assessment of Safety and Tolerability - Assessment of dose limiting toxicity"></FilterOption><FilterOption id="3809" count="23" label="Hepatitis C virus infection - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events"></FilterOption><FilterOption id="23916" count="23" label="Hypercholesterolemia - Assessment of Low-Density Lipoprotein (LDL)"></FilterOption><FilterOption id="8663" count="23" label="Lung tumor - Assessment of Pharmacokinetic/Pharmacodynamic Parameters"></FilterOption><FilterOption id="6924" count="23" label="Melanoma - Assessment of Progression Free Survival (PFS)"></FilterOption><FilterOption id="11542" count="23" label="Soft tissue sarcoma - Assessment of Progression Free Survival (PFS)"></FilterOption><FilterOption id="2981" count="22" label="Acute coronary syndrome - Assessment of Mortality/Death Rates - Cardiovascular mortality"></FilterOption><FilterOption id="2410" count="22" label="Alzheimers disease - Assessment of Safety and Tolerability"></FilterOption><FilterOption id="8754" count="22" label="Breast tumor - Assessment of Mortality/Death Rates"></FilterOption><FilterOption id="9310" count="22" label="Breast tumor - Imaging/Radiological Assessments"></FilterOption><FilterOption id="22596" count="22" label="End stage renal disease - Assessment of Mortality/Death Rates"></FilterOption></Filter><Filter label="Sponsors/Collaborators" name="trialCompanies" total="100"><FilterOption id="23137" count="478" label="Novartis AG"></FilterOption><FilterOption id="19446" count="405" label="Roche Holding AG"></FilterOption><FilterOption id="18767" count="347" label="Pfizer Inc"></FilterOption><FilterOption id="28355" count="297" label="GlaxoSmithKline plc"></FilterOption><FilterOption id="17810" count="230" label="Eli Lilly &amp; Co"></FilterOption><FilterOption id="14190" count="227" label="AstraZeneca plc"></FilterOption><FilterOption id="15065" count="226" label="Bristol-Myers Squibb Co"></FilterOption><FilterOption id="1009547" count="218" label="Sanofi SA"></FilterOption><FilterOption id="26178" count="189" label="F Hoffmann-La Roche AG"></FilterOption><FilterOption id="14455" count="184" label="Bayer AG"></FilterOption><FilterOption id="1067538" count="150" label="Janssen Research &amp; Development LLC"></FilterOption><FilterOption id="14881" count="144" label="Boehringer Ingelheim International GmbH"></FilterOption><FilterOption id="1039423" count="144" label="Hospital Clinic of Barcelona"></FilterOption><FilterOption id="1144568" count="142" label="Novartis Pharma Services AG"></FilterOption><FilterOption id="15331" count="130" label="Celgene Corp"></FilterOption><FilterOption id="25599" count="121" label="Novartis Pharma AG"></FilterOption><FilterOption id="14109" count="117" label="Amgen Inc"></FilterOption><FilterOption id="1072507" count="109" label="AbbVie Inc"></FilterOption><FilterOption id="1003065" count="107" label="Hospital Vall D'Hebron"></FilterOption><FilterOption id="1091809" count="106" label="Janssen-Cilag International NV (BE)"></FilterOption><FilterOption id="16450" count="100" label="Gilead Sciences Inc"></FilterOption><FilterOption id="19453" count="99" label="Genentech Inc"></FilterOption><FilterOption id="1059823" count="96" label="Merck Sharp &amp; Dohme Corp"></FilterOption><FilterOption id="30062" count="90" label="AstraZeneca AB"></FilterOption><FilterOption id="1013295" count="88" label="Astellas Pharma Inc"></FilterOption><FilterOption id="1079783" count="79" label="FUNDACIÓ INSTITUT DE RECERCA DE L'HOSPITAL DE LA SANTA CREU I SANT PAU"></FilterOption><FilterOption id="1121088" count="77" label="Novartis Farmaceutica SA"></FilterOption><FilterOption id="15133" count="71" label="Bristol-Myers Squibb International Corp"></FilterOption><FilterOption id="29218" count="67" label="AbbVie Deutschland GmbH &amp; Co KG"></FilterOption><FilterOption id="1039086" count="63" label="Germans Trias i Pujol Hospital"></FilterOption><FilterOption id="1003983" count="59" label="Bayer HealthCare AG"></FilterOption><FilterOption id="1040940" count="58" label="Hospital Universitari de Bellvitge"></FilterOption><FilterOption id="1038736" count="58" label="PETHEMA Foundation"></FilterOption><FilterOption id="1119200" count="58" label="Sanofi-Aventis Research and Development"></FilterOption><FilterOption id="20300" count="58" label="Takeda Pharmaceutical Co Ltd"></FilterOption><FilterOption id="19214" count="55" label="Regeneron Pharmaceuticals Inc"></FilterOption><FilterOption id="18614" count="54" label="Novo Nordisk A/S"></FilterOption><FilterOption id="1017818" count="53" label="Instituto de Salud Carlos III"></FilterOption><FilterOption id="22546" count="51" label="Boehringer Ingelheim GmbH"></FilterOption><FilterOption id="1068202" count="48" label="Parc de Salut Mar"></FilterOption><FilterOption id="1005244" count="47" label="Biogen Inc"></FilterOption><FilterOption id="15414" count="46" label="Chugai Pharmaceutical Co Ltd"></FilterOption><FilterOption id="13601" count="45" label="Abbott Laboratories"></FilterOption><FilterOption id="23119" count="45" label="European Organisation for Research and Treatment of Cancer (EORTC)"></FilterOption><FilterOption id="20452" count="45" label="UCB SA"></FilterOption><FilterOption id="1110770" count="43" label="Novartis Farma SpA"></FilterOption><FilterOption id="19620" count="41" label="Eisai Inc"></FilterOption><FilterOption id="17839" count="41" label="Eli Lilly SA"></FilterOption><FilterOption id="18101" count="41" label="Merck KGaA"></FilterOption><FilterOption id="22586" count="40" label="Boehringer Ingelheim Corp"></FilterOption><FilterOption id="17216" count="40" label="Incyte Corp"></FilterOption><FilterOption id="24652" count="40" label="Shire plc"></FilterOption><FilterOption id="1050515" count="38" label="ViiV Healthcare Ltd"></FilterOption><FilterOption id="1087775" count="36" label="Novartis Oncology"></FilterOption><FilterOption id="21991" count="36" label="Takeda Oncology"></FilterOption><FilterOption id="1081359" count="35" label="Corporacion Parc Tauli"></FilterOption><FilterOption id="1145220" count="35" label="GlaxoSmithKline Research &amp; Development Ltd"></FilterOption><FilterOption id="18681" count="34" label="Ono Pharmaceutical Co Ltd"></FilterOption><FilterOption id="20348" count="34" label="Teva Pharmaceutical Industries Ltd"></FilterOption><FilterOption id="23780" count="33" label="Actelion Ltd"></FilterOption><FilterOption id="18008" count="33" label="MedImmune LLC"></FilterOption><FilterOption id="1020322" count="32" label="Daiichi Sankyo Inc"></FilterOption><FilterOption id="1122528" count="32" label="SCS Boehringer Ingelheim Comm.V"></FilterOption><FilterOption id="1039087" count="31" label="Fundacio Lluita Contra La Sida"></FilterOption><FilterOption id="1095980" count="31" label="NOVARTIS FARMACEUTICA, S.A. DE C.V."></FilterOption><FilterOption id="15121" count="29" label="Bristol-Myers Squibb Belgium SA"></FilterOption><FilterOption id="27053" count="29" label="Glaxo Group Research Ltd"></FilterOption><FilterOption id="1042061" count="29" label="Spanish Breast Cancer Research Group"></FilterOption><FilterOption id="1103352" count="28" label="Boehringer Ingelheim Espana Sa"></FilterOption><FilterOption id="22563" count="28" label="Boehringer Ingelheim Ltd"></FilterOption><FilterOption id="17259" count="28" label="Ipsen"></FilterOption><FilterOption id="17332" count="28" label="Johnson &amp; Johnson"></FilterOption><FilterOption id="16299" count="28" label="Sanofi Genzyme"></FilterOption><FilterOption id="25902" count="27" label="Array BioPharma Inc"></FilterOption><FilterOption id="1110884" count="27" label="Biogen Idec Research Ltd"></FilterOption><FilterOption id="1003570" count="27" label="Janssen R&amp;D (Ireland)"></FilterOption><FilterOption id="20519" count="26" label="National Cancer Institute"></FilterOption><FilterOption id="14913" count="25" label="Eisai Ltd"></FilterOption><FilterOption id="19461" count="25" label="Hoffmann-La Roche Inc"></FilterOption><FilterOption id="22554" count="24" label="Boehringer Ingelheim BV"></FilterOption><FilterOption id="27847" count="24" label="Boston Scientific Corp"></FilterOption><FilterOption id="29481" count="23" label="Johnson &amp; Johnson Pharmaceutical Research &amp; Development LLC"></FilterOption><FilterOption id="19063" count="23" label="Pharmacyclics Inc"></FilterOption><FilterOption id="1037956" count="22" label="Astellas Pharma Global Development Inc"></FilterOption><FilterOption id="1053612" count="22" label="Fundacion Clinic per a la Recerca Biomédica"></FilterOption><FilterOption id="25554" count="22" label="Seattle Genetics Inc"></FilterOption><FilterOption id="1045513" count="22" label="Spanish Lung Cancer Group"></FilterOption><FilterOption id="22598" count="22" label="Unilfarma Lda"></FilterOption><FilterOption id="1035512" count="21" label="EMD Serono Inc"></FilterOption><FilterOption id="24166" count="21" label="GlaxoSmithKline Biologicals"></FilterOption><FilterOption id="28611" count="20" label="Actelion Pharmaceuticals Ltd"></FilterOption><FilterOption id="27108" count="20" label="Glaxo SA"></FilterOption><FilterOption id="1101929" count="20" label="IQVIA Holdings Inc"></FilterOption><FilterOption id="14112" count="20" label="Wyeth"></FilterOption><FilterOption id="13979" count="19" label="Alexion Pharmaceuticals Inc"></FilterOption><FilterOption id="22555" count="19" label="Boehringer Ingelheim Ellas AE"></FilterOption><FilterOption id="1056053" count="19" label="Celgene International Sarl"></FilterOption><FilterOption id="17900" count="19" label="H Lundbeck A/S"></FilterOption><FilterOption id="1042371" count="19" label="Spanish Oncology Genito-Urinary Group"></FilterOption><FilterOption id="22549" count="18" label="Boehringer Ingelheim Austria GmbH"></FilterOption></Filter><Filter label="Last Changed Date By Day" name="trialDateChangeLastByDay" total="100"><FilterOption count="226" label="2019-01-24"></FilterOption><FilterOption count="138" label="2019-01-25"></FilterOption><FilterOption count="132" label="2019-01-26"></FilterOption><FilterOption count="108" label="2018-10-15"></FilterOption><FilterOption count="106" label="2018-10-14"></FilterOption><FilterOption count="96" label="2019-06-27"></FilterOption><FilterOption count="96" label="2019-06-28"></FilterOption><FilterOption count="94" label="2019-03-07"></FilterOption><FilterOption count="92" label="2018-10-12"></FilterOption><FilterOption count="91" label="2018-10-13"></FilterOption><FilterOption count="88" label="2019-06-20"></FilterOption><FilterOption count="88" label="2019-07-03"></FilterOption><FilterOption count="87" label="2019-06-07"></FilterOption><FilterOption count="86" label="2019-07-02"></FilterOption><FilterOption count="84" label="2019-07-01"></FilterOption><FilterOption count="83" label="2019-06-26"></FilterOption><FilterOption count="80" label="2019-06-14"></FilterOption><FilterOption count="77" label="2019-06-21"></FilterOption><FilterOption count="74" label="2019-06-25"></FilterOption><FilterOption count="72" label="2019-06-12"></FilterOption><FilterOption count="67" label="2019-06-06"></FilterOption><FilterOption count="67" label="2019-06-17"></FilterOption><FilterOption count="64" label="2019-06-19"></FilterOption><FilterOption count="57" label="2019-06-18"></FilterOption><FilterOption count="55" label="2019-06-13"></FilterOption><FilterOption count="50" label="2018-10-16"></FilterOption><FilterOption count="49" label="2019-06-10"></FilterOption><FilterOption count="46" label="2019-05-31"></FilterOption><FilterOption count="42" label="2013-12-02"></FilterOption><FilterOption count="42" label="2018-07-07"></FilterOption><FilterOption count="42" label="2019-05-24"></FilterOption><FilterOption count="39" label="2019-05-17"></FilterOption><FilterOption count="38" label="2019-06-11"></FilterOption><FilterOption count="36" label="2018-06-09"></FilterOption><FilterOption count="36" label="2019-05-22"></FilterOption><FilterOption count="35" label="2019-05-23"></FilterOption><FilterOption count="32" label="2019-06-22"></FilterOption><FilterOption count="31" label="2019-06-24"></FilterOption><FilterOption count="30" label="2018-06-23"></FilterOption><FilterOption count="30" label="2019-05-27"></FilterOption><FilterOption count="29" label="2019-06-04"></FilterOption><FilterOption count="28" label="2019-05-30"></FilterOption><FilterOption count="28" label="2019-06-05"></FilterOption><FilterOption count="27" label="2019-04-05"></FilterOption><FilterOption count="26" label="2019-02-07"></FilterOption><FilterOption count="26" label="2019-05-10"></FilterOption><FilterOption count="25" label="2018-11-27"></FilterOption><FilterOption count="25" label="2019-03-20"></FilterOption><FilterOption count="25" label="2019-04-17"></FilterOption><FilterOption count="25" label="2019-06-03"></FilterOption><FilterOption count="24" label="2018-04-28"></FilterOption><FilterOption count="23" label="2018-11-16"></FilterOption><FilterOption count="23" label="2018-12-05"></FilterOption><FilterOption count="23" label="2018-12-12"></FilterOption><FilterOption count="23" label="2019-02-04"></FilterOption><FilterOption count="23" label="2019-03-21"></FilterOption><FilterOption count="23" label="2019-05-07"></FilterOption><FilterOption count="23" label="2019-06-08"></FilterOption><FilterOption count="22" label="2018-05-26"></FilterOption><FilterOption count="22" label="2018-11-22"></FilterOption><FilterOption count="22" label="2018-12-14"></FilterOption><FilterOption count="22" label="2019-04-11"></FilterOption><FilterOption count="22" label="2019-06-29"></FilterOption><FilterOption count="21" label="2018-11-28"></FilterOption><FilterOption count="21" label="2019-05-21"></FilterOption><FilterOption count="20" label="2018-07-14"></FilterOption><FilterOption count="20" label="2019-02-21"></FilterOption><FilterOption count="20" label="2019-04-22"></FilterOption><FilterOption count="20" label="2019-05-02"></FilterOption><FilterOption count="20" label="2019-05-13"></FilterOption><FilterOption count="20" label="2019-05-14"></FilterOption><FilterOption count="19" label="2018-06-30"></FilterOption><FilterOption count="19" label="2018-12-06"></FilterOption><FilterOption count="19" label="2018-12-13"></FilterOption><FilterOption count="19" label="2019-03-29"></FilterOption><FilterOption count="19" label="2019-04-15"></FilterOption><FilterOption count="18" label="2018-05-19"></FilterOption><FilterOption count="18" label="2018-11-17"></FilterOption><FilterOption count="18" label="2018-12-10"></FilterOption><FilterOption count="18" label="2018-12-18"></FilterOption><FilterOption count="18" label="2019-04-23"></FilterOption><FilterOption count="17" label="2018-11-13"></FilterOption><FilterOption count="17" label="2018-11-20"></FilterOption><FilterOption count="17" label="2018-11-23"></FilterOption><FilterOption count="17" label="2019-03-01"></FilterOption><FilterOption count="17" label="2019-06-15"></FilterOption><FilterOption count="16" label="2018-01-24"></FilterOption><FilterOption count="16" label="2018-11-29"></FilterOption><FilterOption count="16" label="2018-12-20"></FilterOption><FilterOption count="16" label="2019-02-20"></FilterOption><FilterOption count="16" label="2019-02-22"></FilterOption><FilterOption count="16" label="2019-03-18"></FilterOption><FilterOption count="16" label="2019-03-19"></FilterOption><FilterOption count="16" label="2019-03-22"></FilterOption><FilterOption count="16" label="2019-04-25"></FilterOption><FilterOption count="16" label="2019-05-09"></FilterOption><FilterOption count="15" label="2018-01-23"></FilterOption><FilterOption count="15" label="2018-05-29"></FilterOption><FilterOption count="15" label="2018-12-11"></FilterOption><FilterOption count="15" label="2019-03-27"></FilterOption></Filter><Filter label="Trial Date End By Month" name="trialDateEndByMonth" total="100"><FilterOption count="151" label="201912"></FilterOption><FilterOption count="87" label="202012"></FilterOption><FilterOption count="71" label="202003"></FilterOption><FilterOption count="68" label="202112"></FilterOption><FilterOption count="67" label="201812"></FilterOption><FilterOption count="63" label="202006"></FilterOption><FilterOption count="61" label="201906"></FilterOption><FilterOption count="61" label="201909"></FilterOption><FilterOption count="57" label="201806"></FilterOption><FilterOption count="56" label="201512"></FilterOption><FilterOption count="53" label="201612"></FilterOption><FilterOption count="53" label="201910"></FilterOption><FilterOption count="49" label="201712"></FilterOption><FilterOption count="48" label="201907"></FilterOption><FilterOption count="45" label="201112"></FilterOption><FilterOption count="45" label="201905"></FilterOption><FilterOption count="45" label="201911"></FilterOption><FilterOption count="45" label="202001"></FilterOption><FilterOption count="45" label="202007"></FilterOption><FilterOption count="45" label="202009"></FilterOption><FilterOption count="44" label="201803"></FilterOption><FilterOption count="44" label="202106"></FilterOption><FilterOption count="42" label="201705"></FilterOption><FilterOption count="42" label="201706"></FilterOption><FilterOption count="42" label="201801"></FilterOption><FilterOption count="42" label="202005"></FilterOption><FilterOption count="41" label="201412"></FilterOption><FilterOption count="41" label="201707"></FilterOption><FilterOption count="41" label="201901"></FilterOption><FilterOption count="41" label="201908"></FilterOption><FilterOption count="41" label="202002"></FilterOption><FilterOption count="40" label="201409"></FilterOption><FilterOption count="40" label="201503"></FilterOption><FilterOption count="40" label="201605"></FilterOption><FilterOption count="40" label="201701"></FilterOption><FilterOption count="40" label="201710"></FilterOption><FilterOption count="40" label="201810"></FilterOption><FilterOption count="40" label="201811"></FilterOption><FilterOption count="40" label="202011"></FilterOption><FilterOption count="39" label="201310"></FilterOption><FilterOption count="39" label="201805"></FilterOption><FilterOption count="39" label="201809"></FilterOption><FilterOption count="39" label="202008"></FilterOption><FilterOption count="39" label="202010"></FilterOption><FilterOption count="38" label="201504"></FilterOption><FilterOption count="38" label="201709"></FilterOption><FilterOption count="38" label="201902"></FilterOption><FilterOption count="38" label="201903"></FilterOption><FilterOption count="38" label="202004"></FilterOption><FilterOption count="38" label="202103"></FilterOption><FilterOption count="37" label="201603"></FilterOption><FilterOption count="37" label="201708"></FilterOption><FilterOption count="37" label="202101"></FilterOption><FilterOption count="36" label="201312"></FilterOption><FilterOption count="36" label="201506"></FilterOption><FilterOption count="35" label="201305"></FilterOption><FilterOption count="35" label="201401"></FilterOption><FilterOption count="35" label="201601"></FilterOption><FilterOption count="35" label="201604"></FilterOption><FilterOption count="35" label="201611"></FilterOption><FilterOption count="35" label="202104"></FilterOption><FilterOption count="34" label="201406"></FilterOption><FilterOption count="34" label="201407"></FilterOption><FilterOption count="34" label="201511"></FilterOption><FilterOption count="34" label="201607"></FilterOption><FilterOption count="34" label="201704"></FilterOption><FilterOption count="34" label="201804"></FilterOption><FilterOption count="34" label="202102"></FilterOption><FilterOption count="33" label="201507"></FilterOption><FilterOption count="33" label="201609"></FilterOption><FilterOption count="33" label="201904"></FilterOption><FilterOption count="33" label="202109"></FilterOption><FilterOption count="32" label="201306"></FilterOption><FilterOption count="32" label="201402"></FilterOption><FilterOption count="32" label="201508"></FilterOption><FilterOption count="31" label="201209"></FilterOption><FilterOption count="31" label="201304"></FilterOption><FilterOption count="31" label="201307"></FilterOption><FilterOption count="31" label="201404"></FilterOption><FilterOption count="31" label="201405"></FilterOption><FilterOption count="31" label="201606"></FilterOption><FilterOption count="31" label="201711"></FilterOption><FilterOption count="31" label="201808"></FilterOption><FilterOption count="31" label="202105"></FilterOption><FilterOption count="31" label="202108"></FilterOption><FilterOption count="30" label="201210"></FilterOption><FilterOption count="30" label="201212"></FilterOption><FilterOption count="30" label="201411"></FilterOption><FilterOption count="30" label="201501"></FilterOption><FilterOption count="30" label="201702"></FilterOption><FilterOption count="30" label="202212"></FilterOption><FilterOption count="29" label="201302"></FilterOption><FilterOption count="29" label="201303"></FilterOption><FilterOption count="29" label="201410"></FilterOption><FilterOption count="29" label="201502"></FilterOption><FilterOption count="29" label="201510"></FilterOption><FilterOption count="29" label="202107"></FilterOption><FilterOption count="28" label="201106"></FilterOption><FilterOption count="28" label="201206"></FilterOption><FilterOption count="28" label="201602"></FilterOption></Filter><Filter label="Trial Date Start By Month" name="trialDateStartByMonth" total="100"><FilterOption count="65" label="201706"></FilterOption><FilterOption count="63" label="201703"></FilterOption><FilterOption count="60" label="201506"></FilterOption><FilterOption count="60" label="201711"></FilterOption><FilterOption count="58" label="201806"></FilterOption><FilterOption count="57" label="201210"></FilterOption><FilterOption count="56" label="201611"></FilterOption><FilterOption count="55" label="201805"></FilterOption><FilterOption count="54" label="201410"></FilterOption><FilterOption count="54" label="201509"></FilterOption><FilterOption count="54" label="201511"></FilterOption><FilterOption count="54" label="201610"></FilterOption><FilterOption count="53" label="201501"></FilterOption><FilterOption count="53" label="201512"></FilterOption><FilterOption count="53" label="201606"></FilterOption><FilterOption count="53" label="201701"></FilterOption><FilterOption count="53" label="201712"></FilterOption><FilterOption count="52" label="201810"></FilterOption><FilterOption count="51" label="201309"></FilterOption><FilterOption count="51" label="201804"></FilterOption><FilterOption count="50" label="201310"></FilterOption><FilterOption count="50" label="201312"></FilterOption><FilterOption count="50" label="201401"></FilterOption><FilterOption count="50" label="201612"></FilterOption><FilterOption count="49" label="201412"></FilterOption><FilterOption count="49" label="201507"></FilterOption><FilterOption count="48" label="201304"></FilterOption><FilterOption count="48" label="201707"></FilterOption><FilterOption count="47" label="201411"></FilterOption><FilterOption count="47" label="201604"></FilterOption><FilterOption count="46" label="201103"></FilterOption><FilterOption count="45" label="201201"></FilterOption><FilterOption count="45" label="201311"></FilterOption><FilterOption count="45" label="201503"></FilterOption><FilterOption count="45" label="201705"></FilterOption><FilterOption count="45" label="201812"></FilterOption><FilterOption count="44" label="201212"></FilterOption><FilterOption count="44" label="201407"></FilterOption><FilterOption count="44" label="201609"></FilterOption><FilterOption count="44" label="201704"></FilterOption><FilterOption count="43" label="201110"></FilterOption><FilterOption count="43" label="201204"></FilterOption><FilterOption count="43" label="201303"></FilterOption><FilterOption count="43" label="201403"></FilterOption><FilterOption count="43" label="201802"></FilterOption><FilterOption count="42" label="201112"></FilterOption><FilterOption count="42" label="201203"></FilterOption><FilterOption count="42" label="201504"></FilterOption><FilterOption count="42" label="201601"></FilterOption><FilterOption count="42" label="201605"></FilterOption><FilterOption count="42" label="201803"></FilterOption><FilterOption count="41" label="200812"></FilterOption><FilterOption count="41" label="201207"></FilterOption><FilterOption count="41" label="201301"></FilterOption><FilterOption count="41" label="201607"></FilterOption><FilterOption count="40" label="201510"></FilterOption><FilterOption count="40" label="201602"></FilterOption><FilterOption count="40" label="201801"></FilterOption><FilterOption count="39" label="200903"></FilterOption><FilterOption count="39" label="201111"></FilterOption><FilterOption count="39" label="201406"></FilterOption><FilterOption count="39" label="201603"></FilterOption><FilterOption count="39" label="201811"></FilterOption><FilterOption count="38" label="201012"></FilterOption><FilterOption count="38" label="201107"></FilterOption><FilterOption count="38" label="201109"></FilterOption><FilterOption count="38" label="201211"></FilterOption><FilterOption count="37" label="201202"></FilterOption><FilterOption count="37" label="201205"></FilterOption><FilterOption count="37" label="201305"></FilterOption><FilterOption count="37" label="201807"></FilterOption><FilterOption count="37" label="201903"></FilterOption><FilterOption count="36" label="200711"></FilterOption><FilterOption count="36" label="200904"></FilterOption><FilterOption count="36" label="200912"></FilterOption><FilterOption count="36" label="201102"></FilterOption><FilterOption count="36" label="201306"></FilterOption><FilterOption count="36" label="201402"></FilterOption><FilterOption count="36" label="201702"></FilterOption><FilterOption count="36" label="201710"></FilterOption><FilterOption count="36" label="201902"></FilterOption><FilterOption count="35" label="200804"></FilterOption><FilterOption count="35" label="201011"></FilterOption><FilterOption count="35" label="201104"></FilterOption><FilterOption count="35" label="201105"></FilterOption><FilterOption count="35" label="201206"></FilterOption><FilterOption count="35" label="201505"></FilterOption><FilterOption count="35" label="201709"></FilterOption><FilterOption count="35" label="201808"></FilterOption><FilterOption count="35" label="201905"></FilterOption><FilterOption count="34" label="201001"></FilterOption><FilterOption count="34" label="201010"></FilterOption><FilterOption count="34" label="201106"></FilterOption><FilterOption count="34" label="201307"></FilterOption><FilterOption count="34" label="201405"></FilterOption><FilterOption count="34" label="201502"></FilterOption><FilterOption count="33" label="200801"></FilterOption><FilterOption count="33" label="200909"></FilterOption><FilterOption count="33" label="201006"></FilterOption><FilterOption count="33" label="201608"></FilterOption></Filter><Filter label="Trial Phase" name="trialPhase" total="15"><FilterOption id="C3" count="2490" label="Phase 3 Clinical"></FilterOption><FilterOption id="C2" count="1369" label="Phase 2 Clinical"></FilterOption><FilterOption id="C4" count="716" label="Phase 4 Clinical"></FilterOption><FilterOption id="PNA" count="482" label="Phase Not Applicable"></FilterOption><FilterOption id="C12" count="313" label="Phase 1/Phase 2 Clinical"></FilterOption><FilterOption id="C1" count="283" label="Phase 1 Clinical"></FilterOption><FilterOption id="C3B" count="209" label="Phase 3b Clinical"></FilterOption><FilterOption id="C2B" count="168" label="Phase 2b Clinical"></FilterOption><FilterOption id="NS" count="146" label="Phase not specified"></FilterOption><FilterOption id="C23" count="139" label="Phase 2/Phase 3 Clinical"></FilterOption><FilterOption id="C1B" count="115" label="Phase 1b Clinical"></FilterOption><FilterOption id="C2A" count="87" label="Phase 2a Clinical"></FilterOption><FilterOption id="C3A" count="17" label="Phase 3a Clinical"></FilterOption><FilterOption id="C0" count="8" label="Phase 0 Clinical"></FilterOption><FilterOption id="C1A" count="8" label="Phase 1a Clinical"></FilterOption></Filter><Filter label="Inclusion Criteria Index" name="trialInclusionCriteriaIndex" total="100"><FilterOption id="3976" count="323" label="Lung tumor - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 0"></FilterOption><FilterOption id="3977" count="323" label="Lung tumor - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 1"></FilterOption><FilterOption id="3900" count="296" label="Lung tumor - Subjects with Non Small Cell Lung Cancer (NSCLC)"></FilterOption><FilterOption id="3957" count="288" label="Lung tumor - Subjects Confirmed of Lung Cancer by Specific Modes - Subjects with cytologically/histologically confirmed diagnosis of lung cancer"></FilterOption><FilterOption id="4840" count="284" label="Breast tumor - Subjects with Advanced/Metastatic Cancer"></FilterOption><FilterOption id="4880" count="265" label="Breast tumor - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 1"></FilterOption><FilterOption id="4879" count="264" label="Breast tumor - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 0"></FilterOption><FilterOption id="3936" count="263" label="Lung tumor - Subjects with Protocol Specified Stages of Lung Cancer(TNM staging) - Subjects with stage IV lung cancer"></FilterOption><FilterOption id="3940" count="228" label="Lung tumor - Subjects with Advanced/Metastatic Cancer"></FilterOption><FilterOption id="13096" count="206" label="Solid tumor - Subjects with Advanced/Metastatic Cancer"></FilterOption><FilterOption id="3938" count="203" label="Lung tumor - Subjects with Protocol Specified Stages of Lung Cancer(TNM staging) - Subjects with advanced stage lung cancer"></FilterOption><FilterOption id="3914" count="193" label="Lung tumor - Subjects with Measurable Disease - Subjects with measurable disease as per RECIST criteria"></FilterOption><FilterOption id="584" count="191" label="Non-insulin dependent diabetes - Subjects with Diabetes Mellitus - Subjects with type 2 diabetes mellitus"></FilterOption><FilterOption id="5418" count="185" label="HIV infection - Subjects with HIV Infection - Subjects with HIV-1 infection"></FilterOption><FilterOption id="3537" count="163" label="Lymphoma - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 0"></FilterOption><FilterOption id="3538" count="163" label="Lymphoma - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 1"></FilterOption><FilterOption id="13129" count="162" label="Solid tumor - Subjects with Treatment Refractory Disease"></FilterOption><FilterOption id="5317" count="161" label="HIV infection - Subjects with Protocol Specified HIV Viral Load"></FilterOption><FilterOption id="4483" count="160" label="Colorectal tumor - Subjects with Advanced/Metastatic Cancer"></FilterOption><FilterOption id="13111" count="157" label="Solid tumor - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 1"></FilterOption><FilterOption id="13110" count="156" label="Solid tumor - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 0"></FilterOption><FilterOption id="22417" count="150" label="Breast tumor - Subjects with Locally Advanced Cancer/Tumor"></FilterOption><FilterOption id="4074" count="150" label="Lung tumor - Subjects with Protocol Specified Compliance Status - Subjects able to comply with the study protocol procedures/ requirements"></FilterOption><FilterOption id="4032" count="150" label="Lung tumor - Subjects with Protocol Specified Renal Function - Subjects with normal/acceptable renal function"></FilterOption><FilterOption id="4814" count="148" label="Breast tumor - Subjects with HER-2 Negative Breast Cancer"></FilterOption><FilterOption id="4024" count="146" label="Lung tumor - Subjects with Normal/Acceptable Organ Function - Subjects with normal/acceptable liver function"></FilterOption><FilterOption id="22381" count="140" label="Lung tumor - Protocol Specified Other Inclusion Criteria - Protocol specified inclusion criteria for females"></FilterOption><FilterOption id="4528" count="137" label="Colorectal tumor - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 1"></FilterOption><FilterOption id="4527" count="136" label="Colorectal tumor - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 0"></FilterOption><FilterOption id="3935" count="136" label="Lung tumor - Subjects with Protocol Specified Stages of Lung Cancer(TNM staging) - Subjects with stage IIIB lung cancer"></FilterOption><FilterOption id="4922" count="127" label="Breast tumor - Subjects with Progressive/Treatment Refractory Disease"></FilterOption><FilterOption id="3933" count="125" label="Lung tumor - Subjects with Protocol Specified Stages of Lung Cancer(TNM staging) - Subjects with stage III lung cancer"></FilterOption><FilterOption id="4857" count="124" label="Breast tumor - Subjects with Measurable Disease - Subjects with measurable disease as per RECIST criteria"></FilterOption><FilterOption id="3539" count="123" label="Lymphoma - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 2"></FilterOption><FilterOption id="4894" count="122" label="Breast tumor - Subjects with History of Anti Cancer Therapy - Subjects with history of anti-cancer chemotherapy"></FilterOption><FilterOption id="4073" count="122" label="Lung tumor - Protocol Specified Other Inclusion Criteria"></FilterOption><FilterOption id="3989" count="121" label="Lung tumor - Subjects with History of Anti Cancer Therapy - Subjects with history of anti-cancer chemotherapy"></FilterOption><FilterOption id="4813" count="119" label="Breast tumor - Subjects with HER-2 Positive Breast Cancer"></FilterOption><FilterOption id="5086" count="117" label="Leukemia - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 0"></FilterOption><FilterOption id="901" count="117" label="Non-insulin dependent diabetes - Subjects with specific level of glycemic control - Subjects with Moderate Glycemic Control"></FilterOption><FilterOption id="7091" count="117" label="Prostate tumor - Subjects with Advanced/Metastatic Cancer"></FilterOption><FilterOption id="5087" count="115" label="Leukemia - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 1"></FilterOption><FilterOption id="3971" count="115" label="Lung tumor - Subjects with Protocol Specified Life Expectancy - Subjects with life expectancy of three months or more"></FilterOption><FilterOption id="1751" count="114" label="Hepatitis C virus infection - Subjects with Chronic Hepatitis C Infection"></FilterOption><FilterOption id="3548" count="110" label="Lymphoma - Subjects Diagnosed Based on Histo-Pathological Examination"></FilterOption><FilterOption id="4106" count="108" label="Lung tumor - Subjects with Protocol Specified Reproductive Status - Men with adequate contraception"></FilterOption><FilterOption id="607" count="108" label="Non-insulin dependent diabetes - Subjects with specific level of glycemic control - Subjects with Poor/Inadequate Glycemic Control"></FilterOption><FilterOption id="4509" count="103" label="Colorectal tumor - Subjects with Histologically Confirmed Colorectal Cancer"></FilterOption><FilterOption id="4923" count="100" label="Breast tumor - Subjects with Relapsed/Recurrent Disease"></FilterOption><FilterOption id="3987" count="100" label="Lung tumor - Treatment Naive Subjects"></FilterOption><FilterOption id="4808" count="99" label="Breast tumor - Subjects with Hormone Receptor Positive Breast Cancer - Estrogen receptor positive (ER+) breast cancer"></FilterOption><FilterOption id="4569" count="98" label="Colorectal tumor - Subjects with Normal/Acceptable Organ Function - Subjects with normal/acceptable hematopoetic/marrow function"></FilterOption><FilterOption id="5088" count="98" label="Leukemia - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 2"></FilterOption><FilterOption id="4817" count="93" label="Breast tumor - Postmenopausal Breast Cancer Women"></FilterOption><FilterOption id="4877" count="92" label="Breast tumor - Subjects with Protocol Specified Life Expectancy"></FilterOption><FilterOption id="3614" count="92" label="Lymphoma - Subjects with Progressive/Treatment Refractory Disease"></FilterOption><FilterOption id="4558" count="91" label="Colorectal tumor - Subjects with Treatment Resistant Disease"></FilterOption><FilterOption id="3978" count="91" label="Lung tumor - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 2"></FilterOption><FilterOption id="3997" count="91" label="Lung tumor - Subjects with Treatment Resistant Disease"></FilterOption><FilterOption id="4041" count="90" label="Lung tumor - Subjects with Normal/Acceptable Organ Function - Subjects with normal/acceptable hematological functions"></FilterOption><FilterOption id="4815" count="88" label="Breast tumor - Subjects with Triple Negative Breast Cancer"></FilterOption><FilterOption id="4467" count="88" label="Colorectal tumor - Subjects with Rectal Cancer"></FilterOption><FilterOption id="4856" count="87" label="Breast tumor - Subjects with Measurable Disease"></FilterOption><FilterOption id="32043" count="86" label="Lung tumor - Subjects with Protocol Specified Participation Status - Subjects able/willing to provide written informed consent"></FilterOption><FilterOption id="3642" count="86" label="Lymphoma - Subjects with Normal/Acceptable Organ Function - Subjects with normal/acceptable hematological functions"></FilterOption><FilterOption id="4691" count="86" label="Multiple myeloma - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 0"></FilterOption><FilterOption id="4692" count="86" label="Multiple myeloma - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 1"></FilterOption><FilterOption id="4565" count="83" label="Colorectal tumor - Subjects with Protocol Specified Renal Function - Subjects with normal/acceptable renal function"></FilterOption><FilterOption id="3695" count="83" label="Prostate tumor - Subjects with Stage IV Prostate Cancer"></FilterOption><FilterOption id="4468" count="82" label="Colorectal tumor - Subjects with Colon Cancer"></FilterOption><FilterOption id="4169" count="82" label="Melanoma - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 0"></FilterOption><FilterOption id="4170" count="82" label="Melanoma - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 1"></FilterOption><FilterOption id="13131" count="82" label="Solid tumor - Subjects with Normal/Acceptable Organ Function - Subjects with normal/acceptable hematological functions"></FilterOption><FilterOption id="4955" count="81" label="Breast tumor - Subjects with Protocol Specified Participation Status - Subjects willing/able to provide informed consent/assent"></FilterOption><FilterOption id="4564" count="80" label="Colorectal tumor - Subjects with Normal/Acceptable Organ Function - Subjects with normal/acceptable liver function"></FilterOption><FilterOption id="5344" count="80" label="HIV infection - Subjects on Prior/Concurrent Antiretroviral Therapy"></FilterOption><FilterOption id="4981" count="79" label="Leukemia - Subjects with Acute Myeloid Leukemia (AML)"></FilterOption><FilterOption id="4397" count="78" label="Head and neck tumor - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 0"></FilterOption><FilterOption id="792" count="78" label="Multiple sclerosis - Subjects with Relapsing Remitting Multiple Sclerosis (RRMS)"></FilterOption><FilterOption id="4864" count="77" label="Breast tumor - Subjects with Normal/Acceptable Organ Function - Subjects with acceptable hematological test values"></FilterOption><FilterOption id="4398" count="77" label="Head and neck tumor - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 1"></FilterOption><FilterOption id="22262" count="77" label="Pain - Protocol Specified Other Inclusion Criteria"></FilterOption><FilterOption id="13098" count="77" label="Solid tumor - Subjects with Measurable Disease"></FilterOption><FilterOption id="3609" count="76" label="Lymphoma - Subjects with Relapsed/Recurrent Disease"></FilterOption><FilterOption id="4126" count="76" label="Melanoma - Subjects with Advanced Melanoma"></FilterOption><FilterOption id="6663" count="75" label="Hepatitis C virus infection - Subjects Infected with HCV Genotype 1"></FilterOption><FilterOption id="4139" count="75" label="Melanoma - Subjects with Stage IV Melanoma"></FilterOption><FilterOption id="4767" count="75" label="Multiple myeloma - Subjects with Relapsed/Recurrent Disease"></FilterOption><FilterOption id="8817" count="75" label="Pancreas tumor - Subjects with Advanced/Metastatic Cancer"></FilterOption><FilterOption id="3755" count="75" label="Prostate tumor - Subjects with Castrate Resistant Prostate Cancer"></FilterOption><FilterOption id="4881" count="74" label="Breast tumor - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 2"></FilterOption><FilterOption id="4928" count="73" label="Breast tumor - Subjects with Protocol Specified Compliance Status - Subjects able to comply with the study protocol procedures/ requirements"></FilterOption><FilterOption id="4471" count="73" label="Colorectal tumor - Subjects with Measurable Disease - Subjects with measurable disease as per modified RECIST Criteria"></FilterOption><FilterOption id="3447" count="73" label="Lymphoma - Subjects with B Cell Non Hodgkin's Lymphoma - Subjects with diffuse large B cell lymphoma"></FilterOption><FilterOption id="3448" count="73" label="Lymphoma - Subjects with B Cell Non Hodgkin's Lymphoma - Subjects with follicular lymphoma"></FilterOption><FilterOption id="8263" count="73" label="Ovary tumor - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 0"></FilterOption><FilterOption id="4893" count="72" label="Breast tumor - Subjects with History of Anti Cancer Therapy"></FilterOption><FilterOption id="4827" count="72" label="Breast tumor - TNM Stage III Breast Cancer"></FilterOption><FilterOption id="13132" count="72" label="Solid tumor - Subjects with Normal/Acceptable Organ Function - Subjects with normal/acceptable liver function"></FilterOption><FilterOption id="7913" count="72" label="Stomach tumor - Subjects with Advanced/Metastatic Cancer"></FilterOption></Filter><Filter label="Trial Interventions Control Alone Name Display" name="trialInterventionsControlAloneNameDisplay" total="100"><FilterOption id="2953" count="44" label="docetaxel"></FilterOption><FilterOption id="3803" count="33" label="paclitaxel"></FilterOption><FilterOption id="3199" count="25" label="gemcitabine"></FilterOption><FilterOption id="13928" count="22" label="enoxaparin sodium"></FilterOption><FilterOption id="12205" count="21" label="capecitabine"></FilterOption><FilterOption id="7413" count="18" label="darbepoetin alfa"></FilterOption><FilterOption id="3313" count="17" label="fulvestrant"></FilterOption><FilterOption id="44375" count="17" label="warfarin"></FilterOption><FilterOption id="11961" count="16" label="erlotinib"></FilterOption><FilterOption id="37370" count="14" label="azacitidine"></FilterOption><FilterOption id="70667" count="14" label="pembrolizumab"></FilterOption><FilterOption id="29831" count="14" label="sorafenib"></FilterOption><FilterOption id="14163" count="13" label="adalimumab"></FilterOption><FilterOption id="6736" count="13" label="rituximab"></FilterOption><FilterOption id="4529" count="13" label="temozolomide"></FilterOption><FilterOption id="4577" count="13" label="topotecan"></FilterOption><FilterOption id="2784" count="12" label="letrozole"></FilterOption><FilterOption id="8165" count="12" label="tiotropium bromide"></FilterOption><FilterOption id="11460" count="11" label="imatinib"></FilterOption><FilterOption id="12973" count="11" label="sunitinib"></FilterOption><FilterOption id="44401" count="11" label="vancomycin"></FilterOption><FilterOption id="6408" count="11" label="vinorelbine"></FilterOption><FilterOption id="6050" count="10" label="metformin hydrochloride"></FilterOption><FilterOption id="7934" count="9" label="doxorubicin (liposomal, STEALTH), Alza"></FilterOption><FilterOption id="10252" count="9" label="insulin glargine"></FilterOption><FilterOption id="22395" count="9" label="ranibizumab"></FilterOption><FilterOption id="2807" count="8" label="atorvastatin"></FilterOption><FilterOption id="4567" count="8" label="etanercept"></FilterOption><FilterOption id="3360" count="8" label="interferon beta-1a, Biogen"></FilterOption><FilterOption id="3616" count="8" label="meropenem"></FilterOption><FilterOption id="3536" count="8" label="pemetrexed disodium"></FilterOption><FilterOption id="4510" count="8" label="tacrolimus"></FilterOption><FilterOption id="14493" count="8" label="tenofovir disoproxil fumarate"></FilterOption><FilterOption id="53547" count="7" label="aflibercept (intravitreal, wet AMD, macular edema, diabetic retinopathy), Regeneron/Bayer"></FilterOption><FilterOption id="3321" count="7" label="anastrozole"></FilterOption><FilterOption id="3081" count="7" label="exemestane"></FilterOption><FilterOption id="14336" count="7" label="fluticasone propionate + salmeterol (asthma and COPD), GlaxoSmithKline"></FilterOption><FilterOption id="54804" count="7" label="nivolumab"></FilterOption><FilterOption id="13239" count="6" label="decitabine"></FilterOption><FilterOption id="53981" count="6" label="enzalutamide"></FilterOption><FilterOption id="28773" count="6" label="eribulin mesylate"></FilterOption><FilterOption id="13340" count="6" label="everolimus"></FilterOption><FilterOption id="6140" count="6" label="formoterol"></FilterOption><FilterOption id="2871" count="6" label="irinotecan"></FilterOption><FilterOption id="10388" count="5" label="cetuximab"></FilterOption><FilterOption id="5999" count="5" label="ciclosporin, Novartis"></FilterOption><FilterOption id="67892" count="5" label="epoetin alfa (Procrit/Eprex), Johnson &amp; Johnson"></FilterOption><FilterOption id="3159" count="5" label="fluticasone propionate"></FilterOption><FilterOption id="32355" count="5" label="indacaterol"></FilterOption><FilterOption id="5267" count="5" label="leuprorelin acetate"></FilterOption><FilterOption id="12978" count="5" label="moxifloxacin"></FilterOption><FilterOption id="3738" count="5" label="olanzapine"></FilterOption><FilterOption id="13460" count="5" label="oseltamivir"></FilterOption><FilterOption id="8713" count="5" label="sildenafil citrate"></FilterOption><FilterOption id="50038" count="5" label="tenofovir disoproxil fumarate + emtricitabine + efavirenz, Gilead/BMS/Merck &amp; Co"></FilterOption><FilterOption id="42858" count="5" label="ustekinumab"></FilterOption><FilterOption id="2773" count="5" label="valsartan"></FilterOption><FilterOption id="72699" count="4" label="atezolizumab"></FilterOption><FilterOption id="8047" count="4" label="bevacizumab"></FilterOption><FilterOption id="44697" count="4" label="carbamazepine (extended-release), Novartis"></FilterOption><FilterOption id="2836" count="4" label="clopidogrel"></FilterOption><FilterOption id="55798" count="4" label="crizotinib"></FilterOption><FilterOption id="53200" count="4" label="daratumumab"></FilterOption><FilterOption id="2992" count="4" label="donepezil hydrochloride"></FilterOption><FilterOption id="58762" count="4" label="empagliflozin"></FilterOption><FilterOption id="44289" count="4" label="enalapril"></FilterOption><FilterOption id="8710" count="4" label="glatiramer acetate"></FilterOption><FilterOption id="55237" count="4" label="ibrutinib"></FilterOption><FilterOption id="6850" count="4" label="infliximab"></FilterOption><FilterOption id="10411" count="4" label="insulin aspart"></FilterOption><FilterOption id="36630" count="4" label="ipilimumab"></FilterOption><FilterOption id="11036" count="4" label="linezolid"></FilterOption><FilterOption id="5148" count="4" label="liraglutide"></FilterOption><FilterOption id="3735" count="4" label="octreotide acetate (long-acting formulation), Novartis"></FilterOption><FilterOption id="43738" count="4" label="pazopanib"></FilterOption><FilterOption id="54624" count="4" label="regorafenib"></FilterOption><FilterOption id="49219" count="4" label="tenofovir disoproxil fumarate + emtricitabine (fixed dose), Gilead Sciences"></FilterOption><FilterOption id="6747" count="3" label="adefovir dipivoxil"></FilterOption><FilterOption id="2509" count="3" label="anagrelide"></FilterOption><FilterOption id="7781" count="3" label="aripiprazole"></FilterOption><FilterOption id="3311" count="3" label="bicalutamide"></FilterOption><FilterOption id="44383" count="3" label="carboplatin"></FilterOption><FilterOption id="6955" count="3" label="cidofovir"></FilterOption><FilterOption id="3350" count="3" label="Fluarix"></FilterOption><FilterOption id="17558" count="3" label="fluoxetine hydrochloride"></FilterOption><FilterOption id="7607" count="3" label="follitropin alfa"></FilterOption><FilterOption id="11603" count="3" label="gefitinib"></FilterOption><FilterOption id="3353" count="3" label="insulin lispro"></FilterOption><FilterOption id="14681" count="3" label="lopinavir + ritonavir"></FilterOption><FilterOption id="3669" count="3" label="mycophenolate mofetil"></FilterOption><FilterOption id="42299" count="3" label="ofatumumab"></FilterOption><FilterOption id="8747" count="3" label="palivizumab"></FilterOption><FilterOption id="9702" count="3" label="recombinant interferon beta-1a, Merck Serono"></FilterOption><FilterOption id="12420" count="3" label="rosuvastatin"></FilterOption><FilterOption id="44313" count="3" label="simvastatin"></FilterOption><FilterOption id="6386" count="3" label="trastuzumab"></FilterOption><FilterOption id="15130" count="3" label="vinflunine"></FilterOption><FilterOption id="99926" count="2" label="18F-GTP1"></FilterOption><FilterOption id="6242" count="2" label="abacavir"></FilterOption><FilterOption id="31012" count="2" label="aclidinium bromide"></FilterOption></Filter><Filter label="Trial Actions Primary Interventions Control" name="trialActionsPrimaryInterventionsControl" total="100"><FilterOption id="372" count="96" label="Thymidylate synthase inhibitor"></FilterOption><FilterOption id="5085" count="60" label="B-lymphocyte antigen CD20 inhibitor"></FilterOption><FilterOption id="1016" count="57" label="HIV-1 reverse transcriptase inhibitor"></FilterOption><FilterOption id="1832" count="55" label="Nucleoside reverse transcriptase inhibitor"></FilterOption><FilterOption id="3808" count="51" label="Kit tyrosine kinase inhibitor"></FilterOption><FilterOption id="135" count="49" label="DHFR inhibitor"></FilterOption><FilterOption id="740" count="49" label="Epidermal growth factor receptor antagonist"></FilterOption><FilterOption id="374" count="49" label="Transferase inhibitor"></FilterOption><FilterOption id="181" count="47" label="GAR transformylase inhibitor"></FilterOption><FilterOption id="142" count="47" label="Topoisomerase II inhibitor"></FilterOption><FilterOption id="3846" count="47" label="VEGF-1 receptor antagonist"></FilterOption><FilterOption id="3848" count="47" label="VEGF-2 receptor antagonist"></FilterOption><FilterOption id="138" count="46" label="DNA polymerase inhibitor"></FilterOption><FilterOption id="3756" count="40" label="Erbb2 tyrosine kinase receptor inhibitor"></FilterOption><FilterOption id="204" count="38" label="HIV protease inhibitor"></FilterOption><FilterOption id="12521" count="38" label="VEGF ligand inhibitor"></FilterOption><FilterOption id="3850" count="38" label="VEGF-3 receptor antagonist"></FilterOption><FilterOption id="8805" count="37" label="AMP activated protein kinase stimulator"></FilterOption><FilterOption id="23014" count="37" label="Insulin ligand"></FilterOption><FilterOption id="400" count="37" label="Insulin receptor agonist"></FilterOption><FilterOption id="40" count="35" label="Beta 2 adrenoceptor agonist"></FilterOption><FilterOption id="76" count="34" label="Aromatase inhibitor"></FilterOption><FilterOption id="768" count="34" label="HIV-1 protease inhibitor"></FilterOption><FilterOption id="721" count="34" label="TNF binding agent"></FilterOption><FilterOption id="48492" count="33" label="PDGF receptor beta antagonist"></FilterOption><FilterOption id="141" count="33" label="Topoisomerase I inhibitor"></FilterOption><FilterOption id="3816" count="32" label="RET tyrosine kinase receptor family inhibitor"></FilterOption><FilterOption id="948" count="30" label="PDGF receptor antagonist"></FilterOption><FilterOption id="3806" count="29" label="Flt3 tyrosine kinase inhibitor"></FilterOption><FilterOption id="4010" count="28" label="Calcineurin inhibitor"></FilterOption><FilterOption id="7424" count="28" label="Cytochrome P450 3A4 inhibitor"></FilterOption><FilterOption id="1741" count="28" label="Low molecular weight heparin"></FilterOption><FilterOption id="67136" count="28" label="Programmed cell death protein 1 inhibitor"></FilterOption><FilterOption id="381" count="27" label="TNF alpha ligand inhibitor"></FilterOption><FilterOption id="629" count="26" label="Inosine monophosphate dehydrogenase inhibitor"></FilterOption><FilterOption id="262" count="26" label="Muscarinic M3 receptor antagonist"></FilterOption><FilterOption id="111" count="25" label="Factor IIa antagonist"></FilterOption><FilterOption id="1722" count="25" label="VEGF receptor antagonist"></FilterOption><FilterOption id="113" count="24" label="Factor IX antagonist"></FilterOption><FilterOption id="114" count="24" label="Factor VII antagonist"></FilterOption><FilterOption id="119" count="24" label="Factor X antagonist"></FilterOption><FilterOption id="10583" count="24" label="Vitamin K epoxide reductase inhibitor"></FilterOption><FilterOption id="286" count="23" label="Estrogen receptor antagonist"></FilterOption><FilterOption id="4548" count="23" label="Raf B protein kinase inhibitor"></FilterOption><FilterOption id="12162" count="22" label="Erythropoietin ligand"></FilterOption><FilterOption id="4917" count="22" label="Proteasome inhibitor"></FilterOption><FilterOption id="3754" count="21" label="EGFR family tyrosine kinase receptor inhibitor"></FilterOption><FilterOption id="214" count="21" label="Interferon alpha 2 ligand"></FilterOption><FilterOption id="259" count="20" label="Muscarinic receptor antagonist"></FilterOption><FilterOption id="1833" count="20" label="Non-nucleoside reverse transcriptase inhibitor"></FilterOption><FilterOption id="11778" count="20" label="PurH purine biosynthesis protein inhibitor"></FilterOption><FilterOption id="6512" count="19" label="DNA methyltransferase inhibitor"></FilterOption><FilterOption id="261" count="19" label="Muscarinic M1 receptor antagonist"></FilterOption><FilterOption id="48489" count="19" label="PDGF receptor alpha antagonist"></FilterOption><FilterOption id="76469" count="18" label="26S proteasome complex inhibitor"></FilterOption><FilterOption id="4550" count="18" label="Raf 1 protein kinase inhibitor"></FilterOption><FilterOption id="10240" count="17" label="mTOR inhibitor"></FilterOption><FilterOption id="4913" count="17" label="P2Y12 purinoceptor antagonist"></FilterOption><FilterOption id="57003" count="17" label="Peptidoglycan recognition protein inhibitor"></FilterOption><FilterOption id="71851" count="16" label="HIV GAG POL polyprotein inhibitor"></FilterOption><FilterOption id="12395" count="16" label="HIV GAG protein inhibitor"></FilterOption><FilterOption id="7588" count="16" label="HIV-1 integrase inhibitor"></FilterOption><FilterOption id="205" count="16" label="HMG CoA reductase inhibitor"></FilterOption><FilterOption id="3524" count="15" label="Abl tyrosine kinase inhibitor"></FilterOption><FilterOption id="431" count="15" label="DNA gyrase inhibitor"></FilterOption><FilterOption id="13571" count="14" label="Bcr protein inhibitor"></FilterOption><FilterOption id="3154" count="14" label="CSF-1 antagonist"></FilterOption><FilterOption id="2506" count="14" label="PARP modulator"></FilterOption><FilterOption id="66340" count="14" label="Penicillin binding protein inhibitor"></FilterOption><FilterOption id="4542" count="14" label="Raf protein kinase inhibitor"></FilterOption><FilterOption id="814" count="14" label="Tubulin modulator"></FilterOption><FilterOption id="481" count="13" label="Interferon beta ligand"></FilterOption><FilterOption id="7025" count="13" label="Signal transduction inhibitor"></FilterOption><FilterOption id="76090" count="12" label="mTOR complex 1 inhibitor"></FilterOption><FilterOption id="9320" count="12" label="Topoisomerase IV inhibitor"></FilterOption><FilterOption id="60" count="11" label="Androgen receptor antagonist"></FilterOption><FilterOption id="64" count="11" label="Angiotensin II receptor antagonist"></FilterOption><FilterOption id="7472" count="11" label="Cytochrome P450 17 inhibitor"></FilterOption><FilterOption id="2585" count="11" label="Glucagon-like peptide 1 receptor agonist"></FilterOption><FilterOption id="18" count="10" label="ACE inhibitor"></FilterOption><FilterOption id="385" count="10" label="Protein tyrosine kinase inhibitor"></FilterOption><FilterOption id="346" count="10" label="Ribonucleotide reductase inhibitor"></FilterOption><FilterOption id="13" count="9" label="5-HT 2 receptor antagonist"></FilterOption><FilterOption id="7418" count="9" label="Cytochrome P450 3 inhibitor"></FilterOption><FilterOption id="6515" count="9" label="Cytosine DNA methyltransferase inhibitor"></FilterOption><FilterOption id="82444" count="9" label="DNA helicase inhibitor"></FilterOption><FilterOption id="51708" count="9" label="DNA polymerase alpha inhibitor"></FilterOption><FilterOption id="6830" count="9" label="DNA primase inhibitor"></FilterOption><FilterOption id="150" count="9" label="Dopamine D2 receptor antagonist"></FilterOption><FilterOption id="14007" count="9" label="Programmed cell death ligand 1 inhibitor"></FilterOption><FilterOption id="551" count="9" label="RNA DNA polymerase inhibitor"></FilterOption><FilterOption id="1092" count="8" label="GNRH receptor agonist"></FilterOption><FilterOption id="778" count="8" label="PDE 5 inhibitor"></FilterOption><FilterOption id="511" count="8" label="TNF antagonist"></FilterOption><FilterOption id="8222" count="8" label="Type II TNF receptor modulator"></FilterOption><FilterOption id="5482" count="7" label="Cytotoxic T-lymphocyte protein-4 inhibitor"></FilterOption><FilterOption id="3682" count="7" label="FGF1 receptor antagonist"></FilterOption><FilterOption id="3688" count="7" label="FGF3 receptor antagonist"></FilterOption><FilterOption id="3584" count="7" label="Lck tyrosine kinase inhibitor"></FilterOption><FilterOption id="516" count="7" label="Muscarinic M2 receptor antagonist"></FilterOption></Filter><Filter label="Trial Indications Adverse" name="trialIndicationsAdverse" total="100"><FilterOption id="102" count="1045" label="Diarrhea"></FilterOption><FilterOption id="226" count="969" label="Nausea"></FilterOption><FilterOption id="829" count="854" label="Fatigue"></FilterOption><FilterOption id="148" count="636" label="Headache"></FilterOption><FilterOption id="110" count="612" label="Emesis"></FilterOption><FilterOption id="1991" count="597" label="Neutropenia"></FilterOption><FilterOption id="17" count="576" label="Anemia"></FilterOption><FilterOption id="3038" count="410" label="Appetite loss"></FilterOption><FilterOption id="3020" count="400" label="Skin rash"></FilterOption><FilterOption id="324" count="391" label="Thrombocytopenia"></FilterOption><FilterOption id="1833" count="368" label="Fever"></FilterOption><FilterOption id="404" count="346" label="Constipation"></FilterOption><FilterOption id="2274" count="342" label="Rhinopharyngitis"></FilterOption><FilterOption id="178" count="296" label="Hypertension"></FilterOption><FilterOption id="3062" count="271" label="Death"></FilterOption><FilterOption id="360" count="257" label="Pneumonia"></FilterOption><FilterOption id="516" count="253" label="Upper respiratory tract infection"></FilterOption><FilterOption id="82" count="241" label="Cough"></FilterOption><FilterOption id="746" count="238" label="Infectious disease"></FilterOption><FilterOption id="3472" count="234" label="Abdominal pain"></FilterOption><FilterOption id="2439" count="228" label="Arthralgia"></FilterOption><FilterOption id="2400" count="222" label="Dyspnea"></FilterOption><FilterOption id="680" count="194" label="Leukopenia"></FilterOption><FilterOption id="3795" count="189" label="Febrile neutropenia"></FilterOption><FilterOption id="402" count="188" label="Edema"></FilterOption><FilterOption id="3221" count="187" label="Back pain"></FilterOption><FilterOption id="3454" count="184" label="Dizziness"></FilterOption><FilterOption id="1009" count="175" label="Urinary tract infection"></FilterOption><FilterOption id="1016" count="164" label="Stomatitis"></FilterOption><FilterOption id="279" count="161" label="Pruritus"></FilterOption><FilterOption id="13" count="160" label="Alopecia"></FilterOption><FilterOption id="20" count="150" label="Pain"></FilterOption><FilterOption id="552" count="132" label="Bleeding"></FilterOption><FilterOption id="1821" count="132" label="Hyperglycemia"></FilterOption><FilterOption id="750" count="123" label="Insomnia"></FilterOption><FilterOption id="1039" count="123" label="Myalgia"></FilterOption><FilterOption id="129" count="114" label="Gastrointestinal disease"></FilterOption><FilterOption id="1992" count="99" label="Lymphocytopenia"></FilterOption><FilterOption id="259" count="98" label="Peripheral neuropathy"></FilterOption><FilterOption id="181" count="91" label="Hypokalemia"></FilterOption><FilterOption id="50" count="89" label="Bronchitis"></FilterOption><FilterOption id="2576" count="88" label="Dysgeusia"></FilterOption><FilterOption id="445" count="80" label="Hypoglycemia"></FilterOption><FilterOption id="2955" count="79" label="Weight loss"></FilterOption><FilterOption id="3073" count="77" label="Drowsiness"></FilterOption><FilterOption id="1078" count="77" label="Lung embolism"></FilterOption><FilterOption id="191" count="76" label="Influenza virus infection"></FilterOption><FilterOption id="224" count="76" label="Myocardial infarction"></FilterOption><FilterOption id="114" count="71" label="Sepsis"></FilterOption><FilterOption id="1063" count="71" label="Xerostomia"></FilterOption><FilterOption id="432" count="67" label="Dyspepsia"></FilterOption><FilterOption id="408" count="65" label="Hypotension"></FilterOption><FilterOption id="505" count="64" label="Hypersensitivity"></FilterOption><FilterOption id="93" count="63" label="Depression"></FilterOption><FilterOption id="1835" count="60" label="Epistaxis"></FilterOption><FilterOption id="182" count="57" label="Hypothyroidism"></FilterOption><FilterOption id="3050" count="56" label="Chill"></FilterOption><FilterOption id="1280" count="54" label="Hypophosphatemia"></FilterOption><FilterOption id="69" count="54" label="Renal failure"></FilterOption><FilterOption id="25" count="53" label="Anxiety disorder"></FilterOption><FilterOption id="2024" count="52" label="Erythema"></FilterOption><FilterOption id="277" count="52" label="Proteinuria"></FilterOption><FilterOption id="2434" count="51" label="Vertigo"></FilterOption><FilterOption id="55" count="49" label="Cardiac failure"></FilterOption><FilterOption id="1263" count="48" label="Mucositis"></FilterOption><FilterOption id="3868" count="47" label="Xerosis"></FilterOption><FilterOption id="1256" count="46" label="Hyponatremia"></FilterOption><FilterOption id="1072" count="45" label="Colitis"></FilterOption><FilterOption id="94" count="45" label="Dermatitis"></FilterOption><FilterOption id="2440" count="45" label="Musculoskeletal pain"></FilterOption><FilterOption id="2954" count="44" label="Weight gain"></FilterOption><FilterOption id="1542" count="42" label="Atrial fibrillation"></FilterOption><FilterOption id="358" count="42" label="Muscle spasm"></FilterOption><FilterOption id="574" count="41" label="Deep vein thrombosis"></FilterOption><FilterOption id="678" count="41" label="Neuropathy"></FilterOption><FilterOption id="2195" count="39" label="Gastroenteritis"></FilterOption><FilterOption id="668" count="39" label="Muscle weakness"></FilterOption><FilterOption id="95" count="38" label="Dermatological disease"></FilterOption><FilterOption id="325" count="38" label="Thromboembolism"></FilterOption><FilterOption id="172" count="36" label="Hyperbilirubinemia"></FilterOption><FilterOption id="65" count="36" label="Stroke"></FilterOption><FilterOption id="2529" count="35" label="Hot flashes"></FilterOption><FilterOption id="250" count="35" label="Pancreatitis"></FilterOption><FilterOption id="286" count="35" label="Renal disease"></FilterOption><FilterOption id="626" count="34" label="Heart disease"></FilterOption><FilterOption id="1559" count="33" label="Congestive heart failure"></FilterOption><FilterOption id="392" count="32" label="Varicella zoster virus infection"></FilterOption><FilterOption id="174" count="31" label="Hypercholesterolemia"></FilterOption><FilterOption id="2733" count="31" label="Hypomagnesemia"></FilterOption><FilterOption id="201" count="31" label="Liver disease"></FilterOption><FilterOption id="154" count="30" label="Hepatitis"></FilterOption><FilterOption id="57" count="29" label="Cardiovascular disease"></FilterOption><FilterOption id="188" count="29" label="Inflammatory disease"></FilterOption><FilterOption id="453" count="29" label="Pharyngitis"></FilterOption><FilterOption id="509" count="29" label="Respiratory tract infection"></FilterOption><FilterOption id="2145" count="28" label="Paronychia"></FilterOption><FilterOption id="1876" count="26" label="Syncope"></FilterOption><FilterOption id="2291" count="25" label="Hematuria"></FilterOption><FilterOption id="2738" count="25" label="Hyperkalemia"></FilterOption><FilterOption id="1061" count="25" label="Sinusitis"></FilterOption></Filter></Filters><SearchResults><Trial Id="9997"><Indications><Indication>Candida infection</Indication></Indications><ActionsPrimaryInterventionsControl><Action>1,3 beta glucan synthase inhibitor</Action><Action>Lanosterol-14 demethylase inhibitor</Action></ActionsPrimaryInterventionsControl><ActionsPrimaryInterventionsPrimary><Action>Lanosterol-14 demethylase inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsControl><Action>Ergosterol synthesis inhibitor</Action><Action>Fungicide</Action><Action>Systemic dermatological antifungal product</Action></ActionsSecondaryInterventionsControl><ActionsSecondaryInterventionsPrimary><Action>Ergosterol synthesis inhibitor</Action><Action>Fungicide</Action><Action>Synergist</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Capsule formulation</Technology><Technology>Film coating</Technology><Technology>Formulation powder</Technology><Technology>Freeze drying</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Oral formulation</Technology><Technology>Oral liquid formulation</Technology><Technology>Oral suspension formulation</Technology><Technology>Prodrug</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesCollaborator><Company>Basilea Pharmaceutica International Ltd</Company></CompaniesCollaborator><CompaniesSponsor><Company>Astellas Pharma Global Development Inc</Company><Company>Astellas Pharma Inc</Company></CompaniesSponsor><Countries><Country>Germany</Country><Country>Spain</Country><Country>Philippines</Country><Country>Thailand</Country><Country>Singapore</Country><Country>Hungary</Country><Country>Lebanon</Country><Country>Israel</Country><Country>India</Country><Country>South Africa</Country><Country>Australia</Country><Country>Argentina</Country><Country>China</Country><Country>South Korea</Country><Country>Belgium</Country><Country>UK</Country><Country>France</Country><Country>Egypt</Country><Country>US</Country><Country>Brazil</Country><Country>Switzerland</Country><Country>New Zealand</Country><Country>Canada</Country><Country>Turkey</Country><Country>Mexico</Country><Country>Malaysia</Country><Country>Chile</Country><Country>Russian Federation</Country><Country>Italy</Country></Countries><DateChangeLast>2019-02-19T00:00:00Z</DateChangeLast><DateEnd>2015-03-03T00:00:00Z</DateEnd><DateStart>2007-03-08T00:00:00Z</DateStart><Identifiers><Identifier>2006-003951-18</Identifier><Identifier>9766-CL-0105</Identifier><Identifier>ACTIVE</Identifier><Identifier>CTRI/2012/01/002351</Identifier><Identifier>NCT00413218</Identifier><Identifier>NCT00444366</Identifier><Identifier>WSA-CS-008</Identifier></Identifiers><InterventionsControlDisplay><Intervention>caspofungin alone</Intervention><Intervention>voriconazole alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>isavuconazonium chloride/sulfate (intravenous), Basilea/Astellas alone</Intervention><Intervention>isavuconazonium chloride/sulfate (oral), Basilea/Astellas alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>450</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The primary objective of this phase III, double-blind, randomized, ACTIVE study was to compare the safety and efficacy of isavuconazole (ASP-9766, ISA) versus caspofungin ( Cancidas , CAS) followed by voriconazole ( VFend , VRC) in the treatment of candidemia and other invasive Candida infections. Based on the DRC assessments of positive clinical and mycological responses, as well as no need for alternative systemic antifungal therapy (SAT), the primary endpoint, success rate of overall response</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Candida infection - Assessment by Global Assessment Scales</EndpointIndex><EndpointIndex>Candida infection - Assessment of Clinical Response</EndpointIndex><EndpointIndex>Candida infection - Assessment of Microbiological Response</EndpointIndex><EndpointIndex>Candida infection - Assessment of Mortality/Death Rates</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>ACTIVE: Isavuconazole (BAL-8557) in the Treatment of Candidemia and Other Invasive Candida Infections</TitleDisplay><PatientSegmentTerms><PatientSegment>Candida infection - Subjects with Invasive Candidiasis - Subjects with candidemia</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2015-03-03T00:00:00Z</PrimaryCompletionDate><TrialDuration>95 Months</TrialDuration><NumberOfSites>301</NumberOfSites><ContactNames><Name>Clinical Trial Support</Name><Name>David Lye Chian Boon</Name><Name>Ernest Wang Chee Meng</Name><Name>Medical Director</Name><Name>ND</Name><Name>Wijaya Limin</Name><Name>contact@nl.astellas.com</Name></ContactNames></Trial><Trial Id="99945"><Indications><Indication>Neuropathic pain</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Vanilloid VR1 agonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Analgesic</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Patch formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Transdermal formulation</Technology></Technologies><CompaniesCollaborator><Company>Astellas Pharma Inc</Company></CompaniesCollaborator><CompaniesSponsor><Company>Astellas Pharma Europe Ltd</Company></CompaniesSponsor><Countries><Country>Switzerland</Country><Country>Austria</Country><Country>UK</Country><Country>Italy</Country><Country>Greece</Country><Country>Spain</Country><Country>Portugal</Country></Countries><DateChangeLast>2018-05-19T00:00:00Z</DateChangeLast><DateEnd>2014-08-31T00:00:00Z</DateEnd><DateStart>2012-02-29T00:00:00Z</DateStart><Identifiers><Identifier>ASCEND</Identifier><Identifier>CCRN 840 (Peripheral Neuropathic Pain)</Identifier><Identifier>NCT01737294</Identifier><Identifier>QTZ-EC-0003</Identifier><Identifier>UKCRN 12588</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>capsaicin dermal patch, NeurogesX/Astellas/Acorda/Grunenthal alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>429</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>This non-interventional study was to evaluate the efficacy, tolerability, health related quality of life and use of health resources associated with Qutenza treatment when Qutenza is used in standard clinical practice [ 1433705 ]. The patients primary diagnosis of peripheral neuropathic pain (PNP) would be classified into subtypes: post-herpetic neuralgia (PHN); HIV-associated neuropathy (HIV-AN); neuropathic back pain; cancer-related neuropathic pain; post-operative and post-traumatic neuropathic</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Observational</Term><Term>Cohort</Term><Term>Prospective</Term></TermsDesign><EndpointIndex><EndpointIndex>Pain - Assessment of Therapy Related Outcomes</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>ASCEND: Observation of the use of Qutenza in Standard Clinical Practice</TitleDisplay><PatientSegmentTerms><PatientSegment>Pain - Subjects with Neuropathic Pain</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2014-08-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>30 Months</TrialDuration><NumberOfSites>50</NumberOfSites><ContactNames><Name>Company Medical Expert</Name></ContactNames></Trial><Trial Id="99922"><Indications><Indication>Familial amyloid neuropathy</Indication><Indication>Myocardial disease</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Amyloid protein deposition inhibitor</Action><Action>TTR gene inhibitor</Action><Action>Transthyretin inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Antisense oligonucleotide inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Oligonucleotide antisense</Technology><Technology>Subcutaneous formulation</Technology></Technologies><CompaniesCollaborator><Company>GlaxoSmithKline plc</Company></CompaniesCollaborator><CompaniesSponsor><Company>Ionis Pharmaceuticals Inc</Company></CompaniesSponsor><Countries><Country>France</Country><Country>Brazil</Country><Country>US</Country><Country>Italy</Country><Country>Portugal</Country><Country>Bulgaria</Country><Country>New Zealand</Country><Country>Spain</Country><Country>UK</Country><Country>Germany</Country><Country>Argentina</Country></Countries><DateChangeLast>2019-06-26T00:00:00Z</DateChangeLast><DateEnd>2017-11-07T00:00:00Z</DateEnd><DateStart>2013-03-15T00:00:00Z</DateStart><Identifiers><Identifier>2012-001831-30</Identifier><Identifier>ISIS 420915-CS2</Identifier><Identifier>NCT01737398</Identifier><Identifier>NEURO-TTR</Identifier></Identifiers><IndicationsAdverse><Indication>Anemia</Indication><Indication>Chill</Indication><Indication>Emesis</Indication><Indication>Fever</Indication><Indication>Glomerulonephritis</Indication><Indication>Intracranial hemorrhage</Indication><Indication>Nausea</Indication><Indication>Renal insufficiency</Indication><Indication>Thrombocytopenia</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>inotersen alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>173</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The purpose of this phase III, pivotal, 15-month, double-blind, placebo-controlled, international study was to evaluate the efficacy and safety of IONIS-TTRRx (inotersen) given for 65 weeks in patients with familial amyloid polyneuropathy (FAP) [ 1530405 ], [ 1600925 ], [ 1609790 ], [ 1766279 ], [ 1927401 ], [ 1943708 ], [ 1970866 ], [ 1977255 ], [ 1977874 ], [ 1978744 ], [ 1995708 ], [ 2016937 ], [ 2026008 ], [ 2040714 ], [ 2053248 ], [ 2065868 ], [ 2061819 ]. The purpose of this study was to</Teaser><TrialCategories><Category>Gene therapy</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term><Term>Pharmacodynamics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Other neurological disease - Assessment of Pharmacokinetic/Pharmacodynamic Parameters</EndpointIndex><EndpointIndex>Other neurological disease - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Other neurological disease - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>NEURO-TTR: Efficacy and Safety of Inotersen in Familial Amyloid Polyneuropathy</TitleDisplay><PatientSegmentTerms><PatientSegment>Other neurological disease - Subjects with gene variants - TTR_HUMAN_Mutation</PatientSegment><PatientSegment>Other neurological disease - Subjects with specific disease - Subjects with Neuropathy</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Amyloid </BiomarkerName><BiomarkerName> Blood platelets </BiomarkerName><BiomarkerName> Body Mass Index </BiomarkerName><BiomarkerName> Creatinine </BiomarkerName><BiomarkerName> Retinol-binding protein 4 </BiomarkerName><BiomarkerName> Transthyretin</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2017-03-03T00:00:00Z</PrimaryCompletionDate><TrialDuration>55 Months</TrialDuration><NumberOfSites>30</NumberOfSites><ContactNames><Name>Dr. Josep Gámez</Name><Name>John L. Berk</Name><Name>Matt R. Buck</Name></ContactNames></Trial><Trial Id="99864"><Indications><Indication>Non-insulin dependent diabetes</Indication></Indications><ActionsPrimaryInterventionsControl><Action>Dipeptidyl peptidase IV inhibitor</Action></ActionsPrimaryInterventionsControl><ActionsPrimaryInterventionsPrimary><Action>Dipeptidyl peptidase IV inhibitor</Action><Action>Sodium glucose transporter-2 inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsControl><Action>DPP IV inhibitor antidiabetic product</Action><Action>Hypoglycemic agent</Action><Action>Vulnerary agent</Action></ActionsSecondaryInterventionsControl><ActionsSecondaryInterventionsPrimary><Action>DPP IV inhibitor antidiabetic product</Action><Action>Hypoglycemic agent</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Daily dosing</Technology><Technology>Drug combination</Technology><Technology>Film coating</Technology><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesCollaborator><Company>Eli Lilly &amp; Co</Company></CompaniesCollaborator><CompaniesSponsor><Company>Boehringer Ingelheim International GmbH</Company></CompaniesSponsor><Countries><Country>Norway</Country><Country>India</Country><Country>US</Country><Country>Australia</Country><Country>Russian Federation</Country><Country>Canada</Country><Country>France</Country><Country>Philippines</Country><Country>El Salvador</Country><Country>Taiwan</Country><Country>Italy</Country><Country>South Korea</Country><Country>Brazil</Country><Country>Bulgaria</Country><Country>New Zealand</Country><Country>North Korea</Country><Country>Spain</Country></Countries><DateChangeLast>2017-10-27T00:00:00Z</DateChangeLast><DateEnd>2015-03-31T00:00:00Z</DateEnd><DateStart>2013-01-31T00:00:00Z</DateStart><Identifiers><Identifier>1275.9</Identifier><Identifier>2012-002270-31</Identifier><Identifier>NCT01734785</Identifier></Identifiers><IndicationsAdverse><Indication>Genital tract infection</Indication><Indication>Hypersensitivity</Indication><Indication>Hypoglycemia</Indication><Indication>Urinary tract infection</Indication></IndicationsAdverse><InterventionsControlDisplay><Intervention>linagliptin alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>empagliflozin + linagliptin (oral, type 2 diabetes), Boehringer/Eli Lilly alone</Intervention><Intervention>empagliflozin alone</Intervention><Intervention>group 1 alone</Intervention><Intervention>group 2 alone</Intervention><Intervention>linagliptin + placebo alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>607</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The purpose of this phase III, randomized, double-blind, parallel-group, 24-week study was to evaluate efficacy and safety of empagliflozin + linagliptin (Glyxambi) 10 mg qd + 5 mg and 25 mg qd + 5 mg po compared to placebo, all administered as fixed dose combinations, in patients with type 2 diabetes mellitus and insufficient glycemic control after 16 weeks treatment with linagliptin 5 mg qd on metformin background therapy.This trial was to compare the use of the two different doses of empagliflozin</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Anthropometric Assessments - Assessment of body weight</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Assessment of Hemoglobin A1c (HbA1c) Levels</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Glycemic Control Analysis - Assessment of fasting blood glucose</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Safety And Efficacy Of The Combination Of Empagliflozin And Linagliptin Compared To Linagliptin Alone Over 24 Weeks In Patients With Type 2 Diabetes</TitleDisplay><PatientSegmentTerms><PatientSegment>Non-insulin dependent diabetes - Subjects Inadequately Controlled with Oral Hypoglycemic Agents</PatientSegment><PatientSegment>Non-insulin dependent diabetes - Subjects on Monotherapy - Subjects only on metformin</PatientSegment><PatientSegment>Non-insulin dependent diabetes - Subjects with Moderate Glycemic Control</PatientSegment><PatientSegment>Non-insulin dependent diabetes - Subjects with Poor/Inadequate Glycemic Control</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Body Mass Index </BiomarkerName><BiomarkerName> Calcium </BiomarkerName><BiomarkerName> Diastolic blood pressure </BiomarkerName><BiomarkerName> Estimated glomerular filtration rate </BiomarkerName><BiomarkerName> Glucose </BiomarkerName><BiomarkerName> Hemoglobin A, glycosylated </BiomarkerName><BiomarkerName> Magnesium </BiomarkerName><BiomarkerName> Phosphate </BiomarkerName><BiomarkerName> Potassium </BiomarkerName><BiomarkerName> Sodium </BiomarkerName><BiomarkerName> Systolic blood pressure </BiomarkerName><BiomarkerName> Total body mass </BiomarkerName><BiomarkerName> Uric acid </BiomarkerName><BiomarkerName> Waist circumference</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2015-03-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>26 Months</TrialDuration><NumberOfSites>104</NumberOfSites><ContactNames><Name>Boehringer Ingelheim</Name><Name>QRPE PSC CT Information Disclosure</Name></ContactNames></Trial><Trial Id="99814"><Indications><Indication>Aggression</Indication><Indication>Agitation</Indication><Indication>Alzheimers disease</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Amyloid protein deposition inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Neuroprotectant</Action><Action>Psychomodulator</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesCollaborator><Company>Elan Pharmaceuticals Inc</Company></CompaniesCollaborator><CompaniesSponsor><Company>Transition Therapeutics Ireland Ltd</Company></CompaniesSponsor><Countries><Country>France</Country><Country>Spain</Country><Country>Canada</Country><Country>US</Country><Country>UK</Country></Countries><DateChangeLast>2018-06-08T00:00:00Z</DateChangeLast><DateEnd>2015-05-31T00:00:00Z</DateEnd><DateStart>2012-11-30T00:00:00Z</DateStart><Identifiers><Identifier>2012-004299-20</Identifier><Identifier>ELND005-AG201</Identifier><Identifier>HARMONY-AD</Identifier><Identifier>NCT01735630</Identifier><Identifier>UKCRN 13705</Identifier></Identifiers><IndicationsAdverse><Indication>Agitation</Indication><Indication>Diarrhea</Indication><Indication>Urinary tract infection</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>ELND-005 alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>350</PatientCountEnrollment><Phase>Phase 2/Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The primary purpose of this 12-week, two-arm, randomized, double-blind, placebo-controlled study was to determine whether ELND-005 would be effective in treating symptoms of agitation and aggression in patients with Alzheimer's disease (AD) [ 1647150 ], [ 1672734 ]. The main objective of this trial was to evaluate the efficacy of ELND-005 treatment compared with placebo in reducing the severity of agitation and aggression at 12 weeks; to evaluate the safety and tolerability of the ELND-005 dosing</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term><Term>Pharmacodynamics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Alzheimers disease - Assessment of Adverse Events</EndpointIndex><EndpointIndex>Alzheimers disease - Assessment of Neuropsychological Function - Assessment by Mini-Mental State Examination (MMSE)</EndpointIndex><EndpointIndex>Alzheimers disease - Assessment of Psychiatric Symptoms - Assessment by Neuropsychiatric Inventory (NPI)</EndpointIndex><EndpointIndex>Alzheimers disease - Cognitive, Global and Functional Assessments - Alzheimer's Disease Co-operative Study - Clinical Global Impression of Change (ADCS CGIC) score</EndpointIndex><EndpointIndex>Alzheimers disease - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Activities of Daily Living scale (ADL)</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>HARMONY-AD: Efficacy and Safety Study of ELND-005 as a Treatment for Agitation and Aggression in Alzheimer's Disease</TitleDisplay><PatientSegmentTerms><PatientSegment>Alzheimers disease - Subjects with Moderate Alzheimer's Disease</PatientSegment><PatientSegment>Alzheimers disease - Subjects with Probable Diagnosis of Alzheimer's Disease</PatientSegment><PatientSegment>Alzheimers disease - Subjects with Severe Alzheimer's Disease</PatientSegment><PatientSegment>Alzheimers disease - Subjects with Treatment Resistant Disease</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2015-05-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>30 Months</TrialDuration><NumberOfSites>74</NumberOfSites><ContactNames><Name>Europe: Lisa Parsons</Name><Name>Global Project Management</Name><Name>US and Canada: Call Center</Name></ContactNames></Trial><Trial Id="99811"><Indications><Indication>Molybdenum cofactor deficiency</Indication></Indications><CompaniesSponsor><Company>Alexion Pharmaceuticals Inc</Company></CompaniesSponsor><Countries><Country>Poland</Country><Country>Netherlands</Country><Country>Japan</Country><Country>Saudi Arabia</Country><Country>Spain</Country><Country>Germany</Country><Country>US</Country><Country>Israel</Country><Country>UK</Country><Country>Italy</Country><Country>Malaysia</Country><Country>Tunisia</Country><Country>Canada</Country><Country>Turkey</Country></Countries><DateChangeLast>2018-06-09T00:00:00Z</DateChangeLast><DateEnd>2016-06-30T00:00:00Z</DateEnd><DateStart>2013-08-31T00:00:00Z</DateStart><Identifiers><Identifier>ALX-MCD-502</Identifier><Identifier>NCT01735188</Identifier></Identifiers><PatientCountEnrollment>65</PatientCountEnrollment><Phase>Phase not specified</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The primary objective of the study was to characterize the natural history of MoCD type A in terms of survival. The secondary objectives were: Evaluate blood and urine for biochemical markers. Evaluate head circumference, seizure activity and neurological outcomes. To evaluate brain MRI. To compare blood and urine analysis, head circumference, seizure activity and neurological outcomes to MRI findings.</Teaser><TrialCategories><Category>Pathophysiology</Category></TrialCategories><EndpointIndex><EndpointIndex>Other metabolic disease - Assessment of Biomarkers - Assessment of S-sulfo-cysteine (SSC)</EndpointIndex><EndpointIndex>Other metabolic disease - Assessment of Biomarkers - Assessment of urine and blood biomarkers</EndpointIndex><EndpointIndex>Other metabolic disease - Assessment of Biomarkers - Assessment of xanthine</EndpointIndex><EndpointIndex>Other metabolic disease - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Other metabolic disease - Assessment of Renal Function - Assessment of uric acid</EndpointIndex><EndpointIndex>Other metabolic disease - Imaging/Radiological Assessments</EndpointIndex></EndpointIndex><TitleDisplay>A Natural History Study of Molybdenum Cofactor and Isolated Sulfite Oxidase Deficiencies</TitleDisplay><PatientSegmentTerms><PatientSegment>Other metabolic disease - Subjects with comorbid conditions - Subjects co-morbid with Molybdenum cofactor deficiency</PatientSegment><PatientSegment>Other metabolic disease - Subjects with comorbid conditions - Subjects with isolated sulfite oxdiase deficiency</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Head circumference </BiomarkerName><BiomarkerName> S-Sulphocysteine </BiomarkerName><BiomarkerName> Sulfite oxidase, mitochondrial </BiomarkerName><BiomarkerName> Uric acid </BiomarkerName><BiomarkerName> Xanthine</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2015-11-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>34 Months</TrialDuration><NumberOfSites>32</NumberOfSites></Trial><Trial Id="99776"><Indications><Indication>Multiple myeloma</Indication></Indications><ActionsPrimaryInterventionsControl><Action>26S proteasome complex inhibitor</Action><Action>Proteasome inhibitor</Action></ActionsPrimaryInterventionsControl><ActionsPrimaryInterventionsPrimary><Action>26S proteasome complex inhibitor</Action><Action>Proteasome inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsControl><Action>Anticancer</Action><Action>Apoptosis stimulator</Action></ActionsSecondaryInterventionsControl><ActionsSecondaryInterventionsPrimary><Action>Angiogenesis inhibitor</Action><Action>Anticancer</Action><Action>Antiviral</Action><Action>Apoptosis stimulator</Action><Action>Immunomodulator</Action><Action>TNF alpha synthesis inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Capsule formulation</Technology><Technology>Formulation powder</Technology><Technology>Freeze drying</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Subcutaneous formulation</Technology></Technologies><CompaniesSponsor><Company>Celgene Corp</Company></CompaniesSponsor><Countries><Country>Netherlands</Country><Country>Australia</Country><Country>Israel</Country><Country>Italy</Country><Country>Denmark</Country><Country>Argentina</Country><Country>Ireland</Country><Country>UK</Country><Country>Puerto Rico</Country><Country>Austria</Country><Country>Japan</Country><Country>Sweden</Country><Country>Poland</Country><Country>Russian Federation</Country><Country>Spain</Country><Country>Turkey</Country><Country>Norway</Country><Country>South Korea</Country><Country>Portugal</Country><Country>Finland</Country><Country>France</Country><Country>US</Country><Country>Greece</Country><Country>Canada</Country><Country>Germany</Country><Country>Taiwan</Country></Countries><DateChangeLast>2019-05-28T00:00:00Z</DateChangeLast><DateEnd>2022-05-01T00:00:00Z</DateEnd><DateStart>2013-01-07T00:00:00Z</DateStart><Identifiers><Identifier>2014-000268-17</Identifier><Identifier>CC-4047-MM-007</Identifier><Identifier>DRKS00008025</Identifier><Identifier>MM-007</Identifier><Identifier>NCT01734928</Identifier><Identifier>OPTIMISMM</Identifier><Identifier>UKCRN 18756</Identifier></Identifiers><IndicationsAdverse><Indication>Deep vein thrombosis</Indication><Indication>Infectious disease</Indication><Indication>Lung embolism</Indication><Indication>Neutropenia</Indication><Indication>Thrombocytopenia</Indication></IndicationsAdverse><InterventionsControlDisplay><Intervention>Variable regimens including Velcade + dexamethasone , bortezomib , dexamethasone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>Variable regimens including bortezomib , dexamethasone , pomalidomide , pomalidomide + Velcade + dexamethasone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>559</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>No longer recruiting</RecruitmentStatus><Teaser>The purpose of this phase III, randomized, open-label, international clinical study was to compare the efficacy and safety of the combination of pomalidomide , bortezomib (Velcade) and low dose dexamethasone (POM + BTZ + LD-DEX) to the combination of bortezomib and low dose dexamethasone (BTZ + LD-DEX) in patients with relapsed/refractory multiple myeloma [ 1666142 ], [ 1984669 ], [ 2003039 ], [ 2033153 ], [ 2040804 ], [ 2155172 ]. This study would also assess how safe the combination of pomalidomide</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term><Term>Pharmacodynamics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Multiple myeloma - Assessment of Overall Survival (OS)</EndpointIndex><EndpointIndex>Multiple myeloma - Assessment of Progression Free Survival (PFS)</EndpointIndex><EndpointIndex>Multiple myeloma - Assessment of Response Rates (RR) - Assessment of Complete Response</EndpointIndex><EndpointIndex>Multiple myeloma - Assessment of Response Rates (RR) - Assessment of Overall/Objective Response Rate (ORR)</EndpointIndex><EndpointIndex>Multiple myeloma - Assessment of Response Rates (RR) - Assessment of Partial Response (PR)</EndpointIndex><EndpointIndex>Multiple myeloma - Assessment of Response Rates (RR) - Assessment of tumor response rate (Duration of response)</EndpointIndex><EndpointIndex>Multiple myeloma - Assessment of Safety and Tolerability - Assessment of other adverse events</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>OPTIMISMM: Safety and Efficacy of Pomalidomide, Bortezomib and Low-Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma</TitleDisplay><PatientSegmentTerms><PatientSegment>Multiple myeloma - Subjects with Relapsed/Recurrent Multiple Myeloma</PatientSegment><PatientSegment>Multiple myeloma - Subjects with Treatment Resistant Disease - Subjects with chemotherapy resistant disease</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Beta-2-microglobulin </BiomarkerName><BiomarkerName> Calcium </BiomarkerName><BiomarkerName> Free light chains </BiomarkerName><BiomarkerName> Hemoglobin </BiomarkerName><BiomarkerName> Immunoglobulins </BiomarkerName><BiomarkerName> Myeloma protein </BiomarkerName><BiomarkerName> Urinary protein</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2022-05-01T00:00:00Z</PrimaryCompletionDate><TrialDuration>111 Months</TrialDuration><NumberOfSites>217</NumberOfSites><ContactNames><Name>Amine Bensmaine, MD</Name><Name>ClinicalTrialDisclosure</Name><Name>Dr NCRN Coordinating Centre</Name><Name>Luo Ling Ling</Name><Name>Paul Richardson, M.D</Name><Name>RJ Corman</Name></ContactNames></Trial><Trial Id="99719"><Indications><Indication>Allergic conjunctivitis</Indication><Indication>Allergic rhinitis</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Allergen</Action><Action>Immunomodulator</Action><Action>Therapeutic vaccine</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Subcutaneous formulation</Technology></Technologies><CompaniesSponsor><Company>Laboratorios Leti SL</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2017-08-12T00:00:00Z</DateChangeLast><DateEnd>2013-03-31T00:00:00Z</DateEnd><DateStart>2012-11-30T00:00:00Z</DateStart><Identifiers><Identifier>2012-001699-12</Identifier><Identifier>6078-PG-PSC-193</Identifier><Identifier>NCT01734265</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Parietaria Judaica-containing vaccine (sc, allergic rhinitis/rhinoconjunctivitis), Laboratorios Leti alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>54</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The primary objective of this study was to evaluate the safety and tolerance of a rush build up administration of Depigoid forte pollen and the first maintenance dose administered 4 weeks later.</Teaser><TrialCategories><Category>Vaccine</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Non-Randomized</Term><Term>Open Label</Term><Term>No Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Allergic rhinitis - Assessment of Inflammatory &amp; Oxidative Stress Markers - Assessment of immunoglobulin levels</EndpointIndex><EndpointIndex>Allergic rhinitis - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Allergic rhinitis - Assessment of adverse events</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term></TermsPatientSelection><TitleDisplay>Safety Clinical Trial With Depigopid 50% Grasses/50% Olea Europaea (2000 DPP/ml) or Depigoid 50% Grasses/50% Parietaria Judaica (2000 DPP/ml)</TitleDisplay><PatientSegmentTerms><PatientSegment>Allergic rhinitis - Subjects with Seasonal Allergic Rhinitis</PatientSegment><PatientSegment>Allergic rhinitis - Subjects with comorbid conditions</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2013-03-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>4 Months</TrialDuration><NumberOfSites>4</NumberOfSites><ContactNames><Name>Aranzazu  Minano</Name><Name>Joaquín Quiralte, Dr</Name><Name>Luis Angel Navarro, Dr</Name><Name>Maria  Gomez</Name><Name>Pedro Guardia, Dr</Name><Name>Santiago Nevot, Dr</Name></ContactNames></Trial><Trial Id="99619"><Indications><Indication>Metastatic breast cancer</Indication><Indication>Metastatic colorectal cancer</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>VEGF ligand inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Angiogenesis inhibitor</Action><Action>Anti-inflammatory</Action><Action>Anticancer</Action><Action>Anticancer monoclonal antibody</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Immunoglobulin-G</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Monoclonal antibody humanized</Technology><Technology>Protein recombinant</Technology><Technology>Solution</Technology></Technologies><CompaniesCollaborator><Company>Roche Holding AG</Company></CompaniesCollaborator><CompaniesSponsor><Company>Spanish Breast Cancer Research Group</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2017-02-15T00:00:00Z</DateChangeLast><DateEnd>2015-12-31T00:00:00Z</DateEnd><DateStart>2012-11-30T00:00:00Z</DateStart><Identifiers><Identifier>BRECOL</Identifier><Identifier>GEI-BEV-2011-02</Identifier><Identifier>GEICAM/2011-04</Identifier><Identifier>NCT01733628</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>bevacizumab alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>137</PatientCountEnrollment><Phase>Phase not specified</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>This is a multicenter, post-authorization observational with prospective follow-up (EPA-SP) study. A total of 137 metastatic breast cancer patients or metastatic colorectal cancer. The hypertension will be evaluated as a predictor of efficacy of bevacizumab associated with chemotherapy, in terms of progression-free survival (main endpoint).</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Observational</Term><Term>Prospective</Term></TermsDesign><EndpointIndex><EndpointIndex>Breast tumor - Assessment of Biomarkers</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Biopsy/Cytology/Histology</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Vital Signs</EndpointIndex><EndpointIndex>Breast tumor - Pharmacogenetic/Pharmacogenomics Analysis</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Biomarkers</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Oncogenes/Oncoproteins</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Organ Function</EndpointIndex><EndpointIndex>Colorectal tumor - Protocol Specified Other Endpoints - Pharmacogenomic Evaluation</EndpointIndex><EndpointIndex>Hypertension - Assessment of Ambulatory Blood Pressure (ABP)</EndpointIndex><EndpointIndex>Hypertension - Assessment of Blood Pressure (BP)</EndpointIndex><EndpointIndex>Hypertension - Assessment of Inflammatory &amp; Oxidative Stress Markers - Interleukin-6 (IL-6)</EndpointIndex><EndpointIndex>Hypertension - Assessment of Vascular Endothelial Function</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>BRECOL: Evaluation of Hypertension as a Predictor of Efficacy Bevacizumab in Metastatic Breast Cancer and Metastatic Colorectal Cancer</TitleDisplay><PatientSegmentTerms><PatientSegment>Breast tumor - Subjects with Advanced/Metastatic Breast Cancer/Stage IV Breast Cancer</PatientSegment><PatientSegment>Breast tumor - Treatment Naive Subjects</PatientSegment><PatientSegment>Colorectal tumor - Subjects with TNM stage IV/Metastatic/Advanced Colorectal Cancer</PatientSegment><PatientSegment>Colorectal tumor - Treatment Naive Subjects</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Angiotensin converting enzyme </BiomarkerName><BiomarkerName> Angiotensinogen </BiomarkerName><BiomarkerName> Beta2-adrenergic receptor </BiomarkerName><BiomarkerName> Beta3-adrenergic receptor </BiomarkerName><BiomarkerName> Blood pressure </BiomarkerName><BiomarkerName> GNAS complex locus </BiomarkerName><BiomarkerName> Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-3 </BiomarkerName><BiomarkerName> Interleukin-6 </BiomarkerName><BiomarkerName> Placenta growth factor </BiomarkerName><BiomarkerName> VEGF/SEMA ratio </BiomarkerName><BiomarkerName> Vascular endothelial growth factor receptor-1 </BiomarkerName><BiomarkerName> Vascular endothelial growth factors </BiomarkerName><BiomarkerName> von Willebrand factor</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2013-12-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>37 Months</TrialDuration><NumberOfSites>4</NumberOfSites><ContactNames><Name>Alvaro Rodríguez Lescure</Name><Name>Alvaro Lescure</Name><Name>Antonio Antón, PhD., MD.</Name><Name>Antonio Anton</Name><Name>Eva Carrasco Carrascal</Name><Name>Eva Carrascal</Name><Name>Jose Chacon</Name><Name>José I. Chacón, PhD., MD.</Name><Name>José Ignacio Chacón, PhD., MD.</Name><Name>Lourdes Calvo</Name><Name>Miguel Segui</Name><Name>Ruth Campo de la Fuente</Name><Name>Ruth Fuente</Name></ContactNames></Trial><Trial Id="99593"><Indications><Indication>Juvenile rheumatoid arthritis</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>IL-6 receptor antagonist</Action><Action>IL-6 receptor modulator</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Analgesic</Action><Action>Anti-inflammatory</Action><Action>Anticancer monoclonal antibody</Action><Action>Antihypertensive</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Immunoglobulin-G</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Monoclonal antibody humanized</Technology><Technology>Protein recombinant</Technology><Technology>Solution</Technology></Technologies><CompaniesCollaborator><Company>Productos Roche, S.A. de C.V.</Company></CompaniesCollaborator><CompaniesSponsor><Company>Roche Holding AG</Company></CompaniesSponsor><Countries><Country>Canada</Country><Country>Spain</Country><Country>Sweden</Country><Country>Russian Federation</Country><Country>UK</Country><Country>Germany</Country><Country>Mexico</Country><Country>Argentina</Country><Country>Israel</Country><Country>US</Country><Country>Italy</Country></Countries><DateChangeLast>2019-06-06T00:00:00Z</DateChangeLast><DateEnd>2019-09-07T00:00:00Z</DateEnd><DateStart>2013-06-10T00:00:00Z</DateStart><Identifiers><Identifier>2012-000444-10</Identifier><Identifier>MCRN214 (WA28029)</Identifier><Identifier>NCT01734382</Identifier><Identifier>UKCRN 13561</Identifier><Identifier>WA28029</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>tocilizumab (intravenous), Roche/Chugai alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>40</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>No longer recruiting</RecruitmentStatus><Teaser>This open-label, phase IV study will evaluate the efficacy, safety, pharmacokinetics, pharmacodynamics and immunogenicity of RoActemra/Actemra ( tocilizumab ) in reduced dose frequency in patients with adequately controlled systemic juvenile idiopathic arthritis who have experienced a laboratory abnormality on twice-weekly tocilizumab dosing. The primary objectives are: Efficacy: To explore the efficacy of tocilizumab in reduced dosing frequency regimens using Juvenile Arthritis Disease Activity</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Non-Randomized</Term><Term>Open Label</Term><Term>No Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term><Term>Pharmacodynamics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Rheumatoid arthritis - Assessment of Laboratory/Diagnostic Measures - Assessment of anti-drug antibodies</EndpointIndex><EndpointIndex>Rheumatoid arthritis - Assessment of Pharmacokinetic/Pharmacodynamic Parameters</EndpointIndex><EndpointIndex>Rheumatoid arthritis - Assessment of adverse events</EndpointIndex><EndpointIndex>Rheumatoid arthritis - Assessment of disease flare</EndpointIndex><EndpointIndex>Rheumatoid arthritis - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Rheumatoid arthritis - Patient Reported Outcomes/Quality of Life Assessments - Patient Global Assessment of Disease Activity</EndpointIndex><EndpointIndex>Rheumatoid arthritis - Physician Global Assessment of Disease Activity</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Preschool Children (2-5 yrs)</Term><Term>Children (6-12 yrs)</Term><Term>Adolescents (13-17 yrs)</Term></TermsPatientSelection><TitleDisplay>A Study of Decreased Dose Frequency in Patients With Systemic Juvenile Arthritis Who Experience Laboratory Abnormalities During Treatment With RoActemra/Actemra (Tocilizumab)</TitleDisplay><PatientSegmentTerms><PatientSegment>Rheumatoid arthritis - Juvenile Rheumatoid Arthritis (JRA)</PatientSegment><PatientSegment>Rheumatoid arthritis - Treatment Naive Subjects</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>C-reactive protein </BiomarkerName><BiomarkerName> Erythrocyte sedimentation rate </BiomarkerName><BiomarkerName> Interleukin-6</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2019-09-07T00:00:00Z</PrimaryCompletionDate><TrialDuration>74 Months</TrialDuration><NumberOfSites>29</NumberOfSites><ContactNames><Name>Carla Owen</Name><Name>Clinical Trials</Name><Name>Eileen Baildam</Name><Name>Karina Santamaria</Name><Name>Monica Lopez Navarro</Name><Name>Trial Information Support Line-TISL</Name></ContactNames></Trial></SearchResults></ns2:com.thomsonreuters.ls.service.contract.soap.trials.v2.TrialResultsOutput>